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AbstractHepatocellular carcinoma (HCC) is a common malignancy of the liver that isone of the most frequent causes of cancerGrelated death in the world. Surgicalresection and liver transplantation are the only curative options for HCC, and tumorinvasion and metastasis render many patients ineligible for these treatments.Identification of the mechanisms that contribute to invasive and metastatic diseasemay enlighten therapeutic strategies for those not eligible for surgical treatments. Inthis dissertation, I describe two sets of experiments to elucidate mechanismsunderlying HCC dissemination, involving the activities of KrüppelGlike factor 6 and aparticular p53 point mutation, R172H.Gene expression profiling of migratory HCC subpopulations demonstratedreduced expression of KrüppelGlike factor 6 (KLF6) in invasive HCC cells.Knockdown of KLF6 in HCC cells increased cell transformation and migration.SingleGcopy deletion of Klf6 in a HCC mouse model results in increased tumorformation, increased metastasis to the lungs, and decreased survival, indicating thatKLF6 suppresses both tumor formation and metastasis in HCC.To elucidate the mechanism of KLF6Gmediated tumor and metastasissuppression, we performed gene expression profiling and ChIPGsequencing toidentify direct transcriptional targets of KLF6 in HCC cells. This analysis revealednovel transcriptional targets of KLF6 in HCC including CDC42EP3 and VAV3, both ofwhich are positive regulators of Rho family GTPases. Concordantly, KLF6knockdown cells demonstrate increased activity of the Rho family GTPases RAC1
vi
and CDC42, and RAC1 is required for migration induced following KLF6 knockdown.Moreover, VAV3 and CDC42EP3 are also required for enhanced cell migration inHCC cells with KLF6 knockdown. Together, this work describes a novel signalingaxis through which KLF6Gmediated repression of VAV3 and CDC42EP3 inhibitsRAC1Gmediated HCC cell migration in culture, and potentially HCC metastasis in vivo.
TP53 gene mutations are commonly found in HCC and are associated withpoor prognosis. Prior studies have suggested that p53 mutants can display gainGofGfunction properties in other tumor types. Therefore, I sought to determine if aparticular hotspot p53 mutation, p53R172H, provided enhanced, gainGofGfunctionproperties compared to p53 loss in HCC. In vitro, soft agar colony formation and cellmigration is reduced upon knockdown of p53R172H, indicating that this mutation isrequired for transformationGassociated phenotypes in these cells. However,p53R172HGexpressing mice did not have enhanced tumor formation or metastasiscompared to p53Gnull mice. These data suggest that p53R172H and p53 deletion arefunctionally equivalent in vivo, and that p53R172H is not a gainGofGfunction mutant inHCC. Inhibition of the related transcription factors p63 and p73 has been suggestedas a potential mechanism by which mutant p53 exerts its gainGofGfunction effects.Analysis of p63 and p73 target genes demonstrated that they are similarlysuppressed in p53Gnull and p53R172HGexpressing HCC cell lines, suggesting apotential explanation for the phenotypes I observed in vivo and in vitro.Together, the studies described in this dissertation increase ourunderstanding of the mechanisms underlying HCC progression and metastasis.
vii
Specifically, we find and characterize KLF6 as a novel suppressor of HCC metastasis,and determine the contribution of a common p53 point mutation in HCC. This workcontributes to ongoing efforts to improve treatment options for HCC patients.
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1CHAPTER I
Introduction
2
Hepatocellular carcinoma (HCC) is a common malignancy of the liver and isone of the most frequent causes of cancer<related death worldwide. Annually,800,000 people are diagnosed with liver cancer, contributing to its status as the 2ndleading cause of cancer<related death (Ferlay et al. 2013). The major type of livercancer is HCC, accounting for 75<80% of liver cancer cases (El<Serag 2011). Despiteawareness of many risk factors for HCC, the disease is increasing in incidence bothin the United States and worldwide (Davila et al. 2004; Altekruse et al. 2012).Proportionally, liver cancers are more frequent in developing nations, where theincidence risk is more than twice that of a more developed region. Largely, thisdisparity is due to hepatitis B viral infections, which are significantly less prevalentin developed nations due to vaccination programs (Di Bisceglie 2009).Despite having a comparably lower risk of HCC in the United States, HCC isstill a significant cause of cancer<related death (Jemal et al. 2011). In the U.S.,approximately 25,000 new cases of HCC are diagnosed annually. The ratio of men towomen diagnosed with HCC in the U.S. is 3:1 (Siegel et al. 2013): a bias which alsoexists in global statistics. While HCC is not an exceedingly common cancer in theU.S., it is still a significant source of cancer<related death due to poor overallsurvival. Overall five<year survival for HCC is 16.1%, but this varies greatly by thestage of the cancer at diagnosis. If the tumor is localized at diagnosis, five<yearsurvival is 29.1%. This stands in contrast to HCCs with either regional or distantspread, which have five<year survival rates of 10.2% and 3.0%, respectively (Hayatet al. 2007).
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One of the reasons for the dismal survival rates of HCC patients is a limitednumber of effective treatments. Since HCCs tend to occur in patients with abackground of liver disease, many traditional treatments for cancer, such ascytotoxic chemotherapies, generate higher drug toxicity and are not well tolerated(Edeline et al. 2009). In advanced liver disease, there are few opportunities fortumor resection. While patients can be cured by liver transplantation, the paucity ofsuitable donor livers requires that certain patient eligibility criteria be satisfied.Unfortunately, these criteria exclude many patients, particularly those with invasiveor metastatic disease (El<Serag 2011).Determining the molecular mechanisms that drive cancer has shaped thetargeted treatment strategies used in other cancer types. Since many of themechanisms driving HCC are still unknown, characterization of genes involved inHCC development and progression are essential for discovering new treatmentstrategies. Studying the mechanisms that lead to invasive or advanced stage HCC areparticularly important, since patients at these stages currently have few treatmentoptions.
HCC Etiology and DiagnosisVirtually all (70<90%) HCC cases develop in the background of chronic liverinflammation and cirrhosis (El<Serag 2011). An inflammatory microenvironment isone of the hallmarks of cancer (Hanahan and Weinberg 2011) contributing tohepatocarcinogenesis through delivery of cytokines and chemokines, increased
4
hepatocyte turnover, interactions with immune cells, or advantageous interactionswith fibrotic stroma (Weber et al. 2011). Common contributors to liverinflammation and eventual cirrhosis include chronic hepatitis B and C infections,and excessive alcohol consumption. Obesity, metabolic syndrome, and smoking arealso contributors to liver inflammation and can lead to cell transformation, asdepicted in Figure 1.1 (El<Serag and Rudolph 2007).In East Asia and Africa, regions of high HCC incidence, over 60% of HCCs canbe attributed to hepatitis B viral (HBV) infection (Bosch et al. 2004). This stands incontrast to HCC patients in the U.S., of which only 20% are positive for the hepatitisB surface antigen (HBsAg) (Di Bisceglie et al. 2003). Examination of HCC frequenciesin HBsAg carriers has found that the relative risk of HCC is 223 times greater thannon<carriers (Beasley et al. 1981), providing strong evidence that HBV infectioncontributes to HCC development. The ability to clear HBV infection increases withage, as viral clearance occurs in 90<95% of adults. However, 25<50% of infectedchildren, and 90% of infants will develop a chronic infection (Alter and Mast 1994).Prevention of HBV transmission in youth is critical to reducing HBV<induced HCC.
5
Figure 1.1. Development of hepatocellular carcinoma. Several sources of liverinjury may result in chronic state of hepatocyte cell death and compensatoryproliferation. Chronic liver disease can lead to cirrhosis, which results in theformation of scar tissue. Amidst scar tissue, liver cells become abnormal, andaccumulate gene expression changes that can result in progression to carcinoma.(Adapted from (Farazi and DePinho 2006)).
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Transmission of HBV can be reduced through a strong hepatitis B vaccinationprogram (Di Bisceglie 2009). As an example, 10% of children in Taiwan werepositive for HBsAg in the early 1980s. Following the implementation of a universalinfant HBV vaccination program, HBsAG rates decreased to 1.3%. Years later, theincidence of childhood HCC decreased by almost 50%, indicating that vaccination isan effective solution for HCC prevention (Chang et al. 1997). Despite the existence ofan effective prevention strategy, over half of HCCs worldwide are still triggered, atleast in part, by HBV infection.HBV can induce the development of HCC through several mechanisms.Firstly, the development of inflammation and increased hepatocyte regeneration inresponse to HBV infection may provide an environment conducive to celltransformation and tumor growth (Di Bisceglie 2009). In addition to theinflammation caused by chronic viral infection, HBV may accelerate tumor initiationthrough insertional mutagenesis (Murakami et al. 2005). The HBV genome containscis<regulatory elements that can result in transcriptional activation of nearby genes.For example, a common site of HBV insertion is near the TERT locus, which canresult in telomerase activation (Fujimoto et al. 2012). Lastly, the HBx protein, codedby the HBV genome, is itself an oncogene. Through binding to other transcriptionfactors, HBx activates transcription of both viral and cellular genes. HBx can initiatesignaling cascades through activation of kinases such as MAPKs and JNKs (Bouchardand Schneider 2004), and also inactivates the tumor suppressor p53 via directbinding (Wang et al. 1994).
7
Hepatitis C virus (HCV) infections also contribute to HCC formation, and areresponsible for part of the increase in HCC incidence seen in the United States(Davila et al. 2004; Welzel et al. 2013). Unlike HBV, relatively few individuals withacute hepatitis C will clear the infection, and 85<90% develop chronic disease. Ofindividuals with chronic HCV infection, 50<60% of them will develop liver disease,and up to 20% will develop cirrhosis (Alter and Mast 1994). Of HCV<inducedcirrhosis cases, 1<6% per year will develop HCC (Buhler and Bartenschlager 2012).Recent developments in antiviral therapies for hepatitis C can reduce virus belowdetection levels for two years or more (Lawitz and Gane 2013), so the HCV<inducedHCC rate may decrease as these therapies become more commonplace. However,there is no currently available vaccine for hepatitis C (Liang 2013), so worldwideinfection rates remain high.HCV is thought to induce HCC formation through increased cytokinesignaling and hepatocyte turnover resulting from chronic liver inflammation andfibrosis (Levrero 2006; Tan et al. 2008). The HCV genome does not integrate intohost DNA, so insertional mutagenesis is not a trigger for hepatocyte transformation(Buhler and Bartenschlager 2012). However, HCV<coded proteins, like the HCV coreprotein, may contribute to cell transformation through interaction with host RNAhelicase, DDX3, though its impact on HCC is not known (Owsianka and Patel 1999).Additionally, HCV protein NS5B binds to host Retinoblastoma (Rb) protein. NS5B isthought to downregulate Rb to facilitate viral replication (McGivern et al. 2009).However, no studies have confirmed that these proteins impact hepatocytes in vivo
8
or affect progression to HCC, so the role of viral oncogenes in HCV<induced HCC isunclear.Another contributor to HCC formation, Aflatoxin B1 (AFB1), is a fungalmetabolite that contaminates food products, particularly in tropical regions such asSoutheast Asia and Sub<Saharan Africa where the climates are most suitable forgrowth of the fungi that produce it (Hamid et al. 2013). This toxin is known toinduce hepatitis and increase risk of HCC in those who continually ingest it (Alpertand Davidson 1969; Newberne and Butler 1969). AFB1 frequently causes amutation at p53R249S, which is thought to facilitate hepatocarcinogenesis (Bressac etal. 1991; Ozturk 1991; Stern et al. 2001). Unsurprisingly, regions with the highestrates of AFB1 exposure overlap strongly with regions that have the highest rates ofHCC (McGlynn and London 2005; Hamid et al. 2013). Food contamination by fungusis rare in developed nations, and is not a major contributor to HCC in these regions.In regions where HBV infection and aflatoxin exposure are uncommon, amore frequent contributor to HCC is alcohol abuse. Excessive alcohol consumptionis known to contribute to hepatic steatosis. A third of such cases will developfibrosis, which may subsequently lead to HCC (Bellentani et al. 1997). Diabetes andmetabolic syndrome are also HCC risk factors more common to Western nations. Inthese contexts, fatty liver disease is the likely source of increased risk (Davila et al.2005; Lai et al. 2006).Like many other cancers, cigarette smoking significantly increases anindividual’s risk of hepatocellular carcinoma (Jee et al. 2004). Other less frequent
9
contributors to HCC include autoimmune hepatitis, porphyria, hereditaryhemochromatosis, α1<antitrypsin deficiency, and Wilson’s disease (El<Serag 2011).HCCs occurring in a non<damaged liver background account for 10<15% of allcases (Trevisani et al. 2010). These tumors are in patients without viral hepatitisinfection, and livers absent of cirrhosis. Typically, these tumors are a single noduleand are well<encapsulated even at sizes greater than 5cm (Cetta et al. 2001).Early studies attempting to determine genetic components to familial HCCwere confounded by the transmission of HBV infection between family members.Recently, family members without viral hepatitis infection were found to share HCCrisk, suggesting a genetic predisposition may in fact exist (Turati et al. 2012). Theprecise genes responsible for this link remain unknown.Two conventional staging systems are used to classify HCC clinically. One is amodified form of the Tumor<Node<Metastasis (TNM) staging system, which is usedto classify many cancers (Vauthey et al. 2002). Another common method forclassifying HCC is the Barcelona Clinic Liver Cancer (BCLC) system. BCLC combinesfeatures of the tumor(s), such as size, number, and presence of vascular invasion,with the addition of liver function tests. The combination is used to classify tumorstage and patient prognosis (Llovet et al. 1999).Early HCCs are characterized by their small size, typically less than 2cm, andtheir well<differentiated cytology. These tumors often display fatty change, butotherwise do not display structural atypia (Takayama et al. 1998; Kondo 2009).
10
With HCC progression, in addition to a larger cell size, hepatocytes become clearlyabnormal and vascularity of the tumor increases (Kojiro 1998).
Molecular Biology of HCC progressionAnalyses of gene expression changes in different tumor types have improvedclassification of patient tumors by providing additional metrics besideshistopathology. Copy number analysis of HCCs has revealed that overall, 32% oftumors have focal amplification of chromosomes, while 40% of tumors havehomozygous deletions. Tumors with homozygous deletions are associated with thelater tumor grades III or IV, and other traits of aggressiveness, such as increasedmicrovascular invasion (Guichard et al. 2012). In combination with copy numberanalysis, sequence analysis has pointed to five pathways that are frequentlydisrupted in HCC. Commonly disrupted systems include the p53 pathway, chromatinremodeling enzymes, PI3K/RAS signaling, ER stress, and the Wnt/β<cateninpathway (Aravalli et al. 2008; Fujimoto et al. 2012). However, a clear molecularprogression of HCC has not been identified, potentially due to heterogeneity of thedisease.One particular deletion frequently seen by cytogenetic studies in HCC is therecurrent deletion of chromosome 1p. This deletion is common in well<differentiated HCCs, indicating that it may be an early contributor to HCC formation(Chen et al. 1996; Parada et al. 1998). Loss of heterozygosity (LOH) at chromosome
11
16p is associated with advanced stage or metastatic tumors (Buendia 2000), butwhich genes are important in either of these regions is unknown.Allelic deletions at chromosome 17p13 are one of the most common in HCC,and are associated with advanced disease (Buendia 2000). Contained within thisregion is the tumor suppressor p53. LOH of this region has been seen in 25<60% ofHCCs, depending on the study (Kusano et al. 1999; Wong et al. 1999b; Buendia2000). Point mutations in the p53 sequence are also frequent in HCC (Oda et al.1992). In HCCs with wild<type p53, inactivation of p14ARF is common, indicating thatmultiple mechanisms may converge to inactivate the p53 pathway (Tannapfel et al.2001). Loss of p53 alone does not induce HCC formation in mice, but HCC mousemodels that include p53 loss generate more aggressive disease that metastasizes tothe lung (Lewis et al. 2005). These data indicate that p53 inactivation is a majorcontributor to HCC progression.The expression of p14ARF/p16INK4A tumor suppressors are often impaired inhuman HCC. Investigation into this shared promoter region revealed that 60<70% ofHCC tissues had hypermethylation of this promoter (Matsuda et al. 1999; Wong etal. 1999a), and deletion of this locus occurs in approximately 10% of cases (Liew etal. 1999). In a p53<null HCC mouse model, additional deletion of Ink4a/Arf increasestumor formation and lung metastasis (Chen et al. 2007), suggesting that decreasedlevels of these proteins are important for human HCC development and progression.The most commonly mutated pathway in HCC is the Wnt/β<catenin pathway.Activating mutations in β<catenin occur in 32.8% of tumors, while inactivating
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mutations in Axin1 or Adenomatous Polyposis coli (APC) occur in 15.2% and 1.6%of tumors, respectively. These mutations are mutually exclusive, resulting in almosthalf of all HCCs with deregulated Wnt/β<catenin pathway (Guichard et al. 2012).Liver<specific deletion of APC in mice generates HCC, while expression of activatedβ<catenin in mice increases proliferation and hepatomegaly (Cadoret et al. 2001;Colnot et al. 2004). These mouse models indicate that these common mutations aredrivers, and not just consequences, of hepatocarcinogenesis.While Wnt pathway alterations are likely sources of oncogenic activity inmany tumors, amplification of MYC is also common in HCC. MYC amplification isdetected in approximately 30% of HCCs (Peng et al. 1993; Kawate et al. 1999; Chanet al. 2004). MYC amplification significantly correlates with mutant p53, and is alsomore frequent in tumors with a higher histologic grade (Kawate et al. 1999). Whilethese data suggest a potential role for MYC in driving tumorigenesis andprogression of HCC, others have found no correlation between MYC amplificationand MYC protein expression, confounding the correlations with MYC amplificationand HCC (Chan et al. 2004). Yet, mouse models that drive MYC expression in theliver generate HCC, indicating that MYC is sufficient to induce hepatocarcinogenesis(Sandgren et al. 1989; Shachaf et al. 2004; Zender et al. 2006).Increased PI3K/RAS signaling is common to HCC, even under circumstanceswhere mutations are not detected in pathway components. Direct activation of thesepathways through mutation is rare in HCC, where activating KRAS and PIK3CAmutations occur in only 2% of tumors (Guichard et al. 2012). One source of
13
amplified signaling is thought to be the inflammatory liver microenvironment. In thecirrhotic liver, hepatic stellate cells have been shown to produce TGFβ and PDGF,which activate MAPK and PI3K signaling in hepatocytes (Parsons et al. 2007).Activation of these pathways likely contributes to tumor initiation in the liver inresponse to liver damage.While HCC is currently diagnosed using clinical and pathological features,some researchers have pushed to diagnose and characterize HCC by molecularprofile. One particular profile of 65 genes is a more accurate prognostic indicatorthan clinical characteristics alone (Kim et al. 2012). Another study used theexpression of only seven proteins to accurately diagnose hepatocellular carcinomaversus normal liver. These critical factors were FOS, ESR1, JUNB, EGFR, SOCS3,FOLH1 and IGF1 (Zhang et al. 2011).Studies indicate that a combination of current practices and moleculardiagnostics could simplify and benefit HCC diagnosis and prognosis. One groupcombined markers of normal hepatocytes and markers identified from previousHCC prognostic studies in order to assess liver function and tumor stagesimultaneously. The markers, assessed by immunohistochemistry, included p53,Ki67, Cyclin D1, β<catenin, CD31, and α<fetoprotein (AFP), among others. Theoutcomes of these 13 markers can be applied to a model in order to calculate a riskscore of the tumor. The score from this risk analysis was found to be a predictor ofoverall and recurrence<free survival (Srivastava et al. 2012).
14
Many HCCs display increased expression of insulin<like growth factor II(IGF2), which is negatively correlated with survival (Iizuka et al. 2004). Theexpression of IGF2 by HCC cells has been found to be critical for HCC metastasis tothe lung (Chen et al. 2009). It is no surprise then, that IGF2 is included in lists ofprognostic genes for HCC patient outcomes (Kim et al. 2012). IGF2 is evendetectable in the serum of some HCC patients (Rehem and El<Shikh 2011) and maybe useful to differentiate between liver dysfunction and HCC.Despite developments in numerous potential diagnostic and prognostic HCCmarkers, AFP is the only one currently in clinical use. AFP is normally onlyexpressed during liver development and not in healthy adults, but its expressionincreases in cirrhosis and HCC (Taketa 1990). Since AFP is expressed in advancedliver disease, imaging tests are required to validate an HCC diagnosis (Llovet et al.1999). Higher levels of AFP are correlated to a decreased survival time in HCCpatients (Izumi et al. 1992). While AFP is a marker of poor prognosis in HCC, it is nota driver of tumor formation or progression in HCC (Baig et al. 2009). As more islearned about the molecular drivers and markers of HCC, diagnostic and prognosticmethods will likely improve.
HCC TherapeuticsDespite the existence of several treatments for HCC, the only curative optionsare tumor resection or liver transplant. Some focal tumors may be cured bypercutaneous ethanol injection, but liver resection of the tumor area is preferred for
15
early HCCs (Fortune et al. 2013). For patients with very early, focal HCC, 5<yearsurvival is approximately 90% (El<Serag 2011). However, the average 5<yearsurvival for all HCC patients who undergo resection is only 45<50% (Poon et al.2000; Lang et al. 2007). Liver resection is not an option for most HCC patients, sincethose with poor liver function, vascular invasion or extrahepatic spread are typicallyexcluded. Feasibility of tumor resection is also impacted by large tumor size,multiple tumors, or challenging location (Vauthey et al. 2002). Occasionally,resection is performed on tumors with the presence of vascular invasion, but inthese instances, 5<year survival post<resection is only 6% due to tumor recurrence(Lang et al. 2007).Despite careful selection of surgical candidates, many patients still haverecurrence of disease following resection (Poon et al. 1999). Of recurrences afterresection, 40% occur only in the liver, 33% occur in both the liver and extrahepaticsites, 25% are only in extrahepatic sites, and 2% are of unknown location (Lang etal. 2007). These data indicate that in addition to recurrence at the primary site,tumor cell dissemination to other sites is frequent. Mutational fingerprinting ofprimary HCCs and secondary HCCs would have to be performed in order todetermine if the same primary tumor is recurring, or if there is de novo tumorformation. However, the formation of tumors outside the liver post<resectionindicates that disseminated cells prior to resection are a major reason forrecurrence.
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The potential for disease recurrence is one reason why liver transplant is thepreferred treatment method, since both the tumor and the tumorigenicenvironment of the diseased liver are removed (Kakodkar and Soin 2012). Thetypical requirements for liver transplant are collectively referred to as the MilanCriteria, which restrict patients by tumor size and number of lesions. Using thesecriteria, 5<year survival is 73.3% post liver transplant, versus 53.6% for patientsoutside the criteria (Mazzaferro et al. 2009). Patients with liver disease arepreferentially selected for liver transplants based on a Model for End<Stage LiverDisease (MELD) score, so that the patients with the greatest need are treated first(Sharma et al. 2004).Even for HCC patients who undergo liver transplantation, almost 20% ofthem have recurrence of disease in the five years post<transplantation. The mostcommon site of recurrence is the liver, however the lung and bone are also frequentsites (Roayaie et al. 2004). These data suggest that tumor cell dissemination hadalready occurred pre<transplant. Relapsed patients require other treatment options,though none are curative at this time.Several institutions have begun to perform liver transplants on patientswhose tumors are outside of the Milan Criteria. Approximately 25% of thesepatients have comparable overall survival after transplant to those who do fallwithin the Milan Criteria (Mazzaferro et al. 2009), indicating that these standards donot accurately predict tumor behavior for all patients. Molecular biomarkers of HCC
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prognosis may be better predictors of survival outcome post<resection ortransplantation (Boyault et al. 2007; Dvorchik et al. 2008; Ji et al. 2009a).Patients who do not qualify for surgery or have relapsed disease are oftentreated with radiofrequency ablation or percutaneous ethanol injection. Thesetreatments lead to necrosis of tumor cells and can decrease tumor size (Orlando etal. 2009; Germani et al. 2010). HCCs at an intermediate stage can be treated withtransarterial chemoembolization (TACE). In TACE, beads containing doxorubicin areinjected, which occlude the feeding arteries of the tumor, and result in tumor celldeath. TACE has been shown to extend the survival of patients that are not eligiblefor surgery (Bruix et al. 1998; Llovet and Bruix 2003).For advanced patients, treatments are limited to traditional chemotherapyand molecularly<targeted therapy. Chemotherapeutics have had limited efficacy inHCC patients due to high toxicity (Palmer et al. 2004). Only one molecularly targetedtherapy, Sorafenib, has been approved for use in HCC thus far. Sorafenib is the onlyapproved systemic treatment for HCC patients that has demonstrated a survivalbenefit (Gauthier and Ho 2013). Sorafenib was designed to inhibit RAF1, but alsoinhibits VEGFR1<3, PDGFRβ, FGF1, cKIT, FLT3, and RET (Wilhelm et al. 2004;Carlomagno et al. 2006). In a phase III trial for Sorafenib in HCC patients, survivalwas significantly extended by a period of three months over those in the placeboarm of the study (p<0.001) (Llovet et al. 2008). Additionally, disease was stabilizedin a larger proportion of patients taking Sorafenib versus those given placebo(Llovet et al. 2008). While this therapy is beneficial, virtually all HCCs acquire
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resistance to Sorafenib (Lencioni et al. 2010) and further study of HCC is required toguide beneficial treatment strategies.
Mouse Models of HCCMouse models of HCC take multiple forms. Some are induced with chemicalexposure, while others mimic the viral etiologies of the disease. Further, multipleHCC models have been developed using specific oncogenic drivers. Each has beenused to parse the molecular changes involved in the formation of HCC.One chemically induced HCC model utilizes injections of diethylnitrosamine(DEN) to induce liver damage. Treatment with this chemical results in DNA damageand the generation of reactive oxygen species, which leads to HCC formation in 80<100% of male mice (Verna et al. 1996). Unfortunately, DEN can target additionalorgans in the mouse, including other parts of the gastrointestinal tract, the skin, andhematopoetic cells, where it can also contribute to tumorigenesis (Heindryckx et al.2009). Despite this downside, DEN treatment generates HCCs that are geneticallysimilar to human HCCs with poor survival (Lee et al. 2004).Another toxin<induced model mimics human HCC induced by aflatoxin B1(AFB) ingestion. Consumption of contaminated food has been associated with theformation of hepatocellular carcinoma in both laboratory animals and humans(Alpert and Davidson 1969; Newberne and Butler 1969). While adult mice areresistant to HCC formation when treated with AFB1, when infant mice are injectedwith three doses of AFB1, 70% form HCC in approximately one year (Vesselinovitch
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et al. 1972; McGlynn et al. 2003). Resistance to AFB1<induced HCC in adult mice isdue to the high levels of an enzyme that targets the DNA<binding metabolites ofAFB1 (Quinn et al. 1990). These mice are valuable for assessing common mutationsthat occur in response to this toxin in the absence of typical HCC confounders, likehepatitis infection. Additionally, male mice have an increased susceptibility to tumorformation in response to AFB1 treatment, which reflects the male bias of HCC inhuman disease (Vesselinovitch et al. 1972). These mice may be valuable fordetermining the causes for increased HCC formation in men.As described previously, HBV infection is one of the major causes of HCC. Todetermine if HBx, an oncogene in the HBV genome, was sufficient to induce HCC onits own, transgenic mice were engineered to express the HBx gene (Kim et al. 1991).These mice quickly develop dysplastic hepatocytes, which progress to adenomas by8<10 months of age. Interestingly, these adenomas progress to carcinoma, butpreferentially do so in male mice: 90% of male mice develop HCC, while only 60% offemale mice do. Additionally, tumor formation in females has a longer latency thanmale mice (Kim et al. 1991). Notably, this model demonstrates that the HBxoncogene within HBV is sufficient to induce hepatocarcinogenesis, independent ofthe inflammation produced by chronic viral infection. Additionally, this modelmimics the male bias for HCC formation seen in humans, and may be valuable fordetermining the mechanisms for this difference.Another model of HBV<induced HCC uses transgenic mice that express theHBV surface antigen downstream of the Albumin promoter. These mice develop
20
inflammatory liver disease, and eventually develop HCC (Chisari et al. 1989;Nakamoto et al. 1998). Importantly, this mouse model indicates that theinflammation resulting from HBV infection is sufficient to induce HCC, even withoutviral genome incorporation or HBx activity.Another mouse model recapitulates many features of HCCs induced by HBVand HCV without the use of viral components. Previously, it was demonstrated thatlymphotoxin signaling was increased in both lymphocytes and hepatocytes ofpatients with hepatitis or HCC (Haybaeck et al. 2009). Transgenic mice weregenerated that specifically express lymphotoxin in liver cells, called AlbLTαβ. Thesemice develop tumors that strongly resemble human HCC induced by chronic viralhepatitis infection. This model has been used to tease apart NF<kb signalingpathways involved in HCC (Ruddell et al. 2009).Expression of potent oncogenes in the liver can also drive HCC formation.Since alterations to the Wnt/β<Catenin pathway and cJMYC amplification arecommon in human HCC, these pathway alterations have been modeled in mice todetermine their roles in HCC formation and progression.Transgenic mice expressing cJMyc under the Albumin promoter develop focalhepatic tumors at approximately 15 months of age (Sandgren et al. 1989).Genetically, these tumors are similar to human HCCs with a good prognosticoutcome (Lee et al. 2004). Due to the low penetrance and long latency of tumorformation, these mice were crossed to a transgenic mouse expressing Tgfα underthe metallothionein1 promoter to co<express TGFα and c<MYC in hepatocytes and
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accelerate tumorigenesis (Jhappan et al. 1990). These oncogenes cooperate toproduce HCC in 70% of animals by 16 weeks of age. Mice form either single ormultifocal tumors that histologically resemble human HCC (Murakami et al. 1993).Their expression patterns bear similarity to human HCC with poor prognosis (Lee etal. 2004). While transgenic c<MYC expression alone resulted in eventual tumorformation in some mice, more robust tumor formation occurs when cJMyc iscontrolled under a liver<specific tetracycline<responsive system. Hepatocyte<specificc<MYC expression induces HCCs that display oncogene addiction to c<MYC, as itswithdrawal results in tumor regression (Shachaf et al. 2004). Potentially, thetetracycline<responsive cJMycmouse model results in higher c<MYC expression thanthe Albumin promoter<driven model, which may account for its enhanced tumorformation.Several mouse models have been used to recapitulate Wnt/β<cateninpathway alterations seen in human HCCs. Liver<specific deletion of the Apc gene inmice leads to nuclear accumulation of β<Catenin and the induction of knowndownstream target genes. Approximately 70% of these mice develop HCC, whichhistologically mimics human disease. Interestingly, these tumors show a wide rangeof aggressiveness, as they possess well, moderate, and poorly differentiated regions(Colnot et al. 2004). Mice expressing a liver<specific, activated form of β<Cateninexhibit hepatomegaly. Hepatocytes have increased proliferative rates in this model,though they do not progress to HCC (Cadoret et al. 2001).
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Another HCC model utilizes the RCAS<TVA system to somatically deliver aretrovirus containing the polyoma middle<T oncogene (PyMT) to hepatocytes. PyMTexpression in these cells induces the formation of HCCs that display histologicalcharacteristics reminiscent of human HCC in 50<70% of injected animals (Lewis etal. 2005; Chen et al. 2007). PyMT induces the activity of the RAS and PI3K pathwaysto drive tumor formation (Schaffhausen and Roberts 2009). These pathways arecommonly activated in human HCC (Parsons et al. 2007; Guichard et al. 2012) so useof PyMT provides signaling effects that are relevant to HCC biology. This modelforms HCC more rapidly than several other models, as tumors are sometimesdetectable as early as four months of age (Lewis et al. 2005). Additionally, thesetumors may display metastasis to the lung depending on the tumor suppressorbackground, so genes modulating HCC progression and metastasis may be studied(Lewis et al. 2005; Chen et al. 2007; Chen et al. 2009).In addition to viral delivery of oncogenes, hydrodynamic injection has beenshown to effectively deliver naked plasmid DNA to hepatocytes. Along with deliveryof DNA, the procedure induces some liver inflammation, which may contribute totumor formation (Sebestyen et al. 2006). As an example, the HBx oncogene wasdelivered to hepatocytes using this method. The inflammation generated resulted incycling of affected hepatocytes, which allowed for continued transmission of theHBx gene. HBx was combined with an shRNA to p53 for hydrodynamic delivery inorder to mimic gene changes common in HCC (Keng et al. 2011). This method is afast and effective way to deliver DNA to hepatocytes, and the inflammation induced
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may mimic some of what is seen in the human condition, though this state istransitory in the mouse and not sustained in a chronic state like in human disease.Several studies have found that hepatocytes are particularly sensitive tomodulation of the Hippo pathway, as YAP activity is pro<tumorigenic in the liver(Zender et al. 2006). Germline deletions of YAP<repressors Mst1 and 2 formhepatomegaly and spontaneous HCC due to increased YAP activity (Zhou et al.2009). Additionally, single<copy germline or liver<specific deletion of Nf2, anupstream regulator of the Hippo pathway, results in HCC development (McClatcheyet al. 1997; Zhang et al. 2010). Due to these examples, repressors of YAP in theHippo pathway are considered to be potent tumor suppressors in HCC.Hepatocytes are highly susceptible to transformation upon deletion of othertumor suppressors as well. Mice with liver<specific deletion of Nemo (Luedde et al.2007), Dicer (Sekine et al. 2009), and Tak1 (Bettermann et al. 2010) all form HCC.Another tumor suppressor characterized in HCC is a transcription factor, Krüppel<like factor 6 (KLF6).
KrüppelJlike factor 6The KLF6 cDNA was originally cloned from a placental cDNA library using acore promoter binding element probe, leading to its original name, core promoter<binding protein (CPBP) (Koritschoner et al. 1997). Almost simultaneously, KLF6 wasisolated from a yeast one<hybrid screen using a binding sequence from the HIV<1core promoter (Suzuki et al. 1998), as well as from injured rat hepatic stellate cells
24
(Ratziu et al. 1998). By sequence analysis with other known transcription factors, itwas determined that KLF6 contained three zinc finger domains in its C<terminus(Koritschoner et al. 1997).The structure of KLF6 is conserved across many species (Gehrau et al. 2005).In zebrafish, the closest homolog to KLF6 is the gene copeb. Upon knockdown ofCopeb in embryos, zebrafish development is impaired. Further investigationrevealed that liver, pancreas, and intestine are smaller upon Copeb knockdown,suggesting it has an important role in gastrointestinal development (Zhao et al.2010). To date, murine germline knockout of any Klf gene is lethal, Klf6 included.
Klf6J/J mice die by embryonic day 12.5 (Matsumoto et al. 2006). At day 10.5, Klf6J/Jembryos had no discernable livers, and had a depleted and less organized yolk saccompared to Klf6+/J, or Klf6+/+ embryos. Closer analysis of the yolk sacs revealed thatthe vasculature was not well developed, indicating that KLF6 plays a role in eitherhematopoiesis or vasculogenesis (Matsumoto et al. 2006). While the impact onorgan developmet and size is similar between the zebrafish and mice, vascularityand differentiation of zebrafish liver were not impaired, suggesting the impact onorgan size may have been due to parenchymal cell cycle defects (Zhao et al. 2010).In human cell lines and tissues, KLF6 is localized to both the cytoplasm andnucleus with varying intensity (Slavin et al. 2004). This is due to alternative splicingof the KLF6 gene, particularly full<length Klf6, and a small isoform called Klf6JSv1.The localization of KLF6 is regulated by the presence of a nuclear localization signal
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(NLS) in the zinc finger domain as well as a nuclear export signal (NES) in the N<terminal region. The NES is common to all KLF6 splice variants, but the NLS is onlypresent in full<length KLF6 and the longest splice variant, SV3 (Figure 1.2). Thepresence of the NLS is required for nuclear localization and protein stability.Interestingly, KLF6<SV1 lacks the zinc finger domains, and the NLS, leading to itslocalization to the cytoplasm (Rodriguez et al. 2010). Thus, KLF6<SV1 can act as adominant negative to full<length KLF6 by directly binding to it and sequestering itfrom the nucleus. While in the cytoplasm, full<length KLF6 is then preferentiallydegraded by the proteasome (Vetter et al. 2012).Alternative splicing of KLF6 is modulated by several mechanisms. IncreasedPI3K/AKT signaling downstream of RAS increases expression of the dominantnegative variant, SV1 (Yea et al. 2008). Additionally, hepatocyte growth factor (HGF)signaling through PI3K/AKT has been shown to favor SV1 splicing (Munoz et al.2012). Cell proliferation stimulated by HGF was shown to be due, at least in part, toan increase in SV1 levels (Munoz et al. 2012). Splicing of Klf6 is decreased by TGFβsignaling, resulting in an increase in full<length KLF6 (Botella et al. 2009). Lastly, asingle<nucleotide polymorphism (SNP), called IVSdA, was discovered that results inan altered splicing at the Klf6 locus. In individuals with this SNP, SV1 is expressed athigher levels than in individuals without the SNP (Narla et al. 2005).
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Figure 1.2. The Klf6 locus is alternatively spliced to generate four known
variants. Full<length KLF6 features an N<terminus (black boxes) that contains bothan NES and NLS. Its C<terminus contains three zinc finger binding domains,represented by white boxes. KLF6<SV3 retains the same N<terminal region as fulllength KLF6, but lacks one zinc finger binding domain. KLF6<SV2 also lacks one DNAbinding domain, but additionally lacks the NLS sequence. Lastly, KLF6<SV1 lacks allzinc finger domains, and instead has a novel C<terminus generated by a frame shift,represented by the gray box. SV1 also lacks the NLS sequence.(Adapted from (Rodriguez et al. 2010).)
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KLF6 Transcriptional ActivityKLF6 is known to behave as both a transcriptional activator and a repressorand has many characterized target genes. It is a direct transcriptional repressor of
Pttg1 (Lee et al. 2010), and Mdm2 (Tarocchi et al. 2011). It has been shown to be atranscriptional activator of p21 (Narla et al. 2001; Narla et al. 2007), Tgfβ1 (Kim etal. 1998), inducible nitric oxide synthase (Warke et al. 2003), urokinaseplasminogen activator (Kojima et al. 2000), Atf3 (Huang et al. 2008), and E<Cadherin(DiFeo et al. 2006). All of these target genes are known to impact human cancer.Intrguingly, KLF6 activates the transcription of genes shown to restrain tumorformation and progression, while it represses the transcription of genes shown topromote tumor formation and progression.KLF6 may impact gene expression through cooperation with othertranscription factors to which it can directly bind, including KLF4. Together, KLF6and KLF4 transcriptionally activate keratin 4 in esophageal epithelium (Okano et al.2000). KLF6 interacts with Sp transcription factors as well. For example, KLF6represses MMP9 in endothelial cells through cooperation with Sp2 (Das et al. 2006).KLF6 was shown to interact with Sp1 to activate transcription of the apoptosismediator, DAPK2 (Britschgi et al. 2008). Interestingly, Smad3 indirectly interactswith KLF6 via Sp1. This coordinate interaction has been shown to enhance KLF6transcriptional activity (Botella et al. 2009).KLF6 and Sp1 were also found to induce expression of IGF1R, but in a p53<dependent manner. In p53<null cells, KLF6<induced transcription from the IGF1R
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promoter was reduced when compared to cells that retained wild<type p53. In thesecells, KLF6 and p53 physically interact, suggesting KLF6 may be cooperating withp53 to drive gene expression (Rubinstein et al. 2004). In cell lines with functionalp53, drug<induced stress reduces KLF6 message levels. Yet, cells with non<functional p53 display increased KLF6 message levels in response to stress agents,implying KLF6 has a role in response to cell stress independent of p53 (Gehrau et al.2011). p53 is likely only one of many important components of cell context that canimpact KLF6 behavior. Interestingly, this impact may be due to direct interactionbetween the two proteins. More studies on KLF6 binding partners are required toclarify regulation of this important transcription factor. This is especially the casesince many known KLF6 target genes have been implicated in tumorigenesis ortumor progression. Unsurprisingly, studies have found that KLF6 is frequentlyderegulated in human cancer.
KLF6 in NeoplasmsKLF6 is frequently misexpressed in human cancers, including those of theprostate, lung and breast. This misexpression may occur through a variety ofmechanisms, including allelic loss, mutation, or alternative splicing. Chromosome10p, where KLF6 is located, is deleted in 55% of prostate cancers. Of prostatetumors with KLF6 allelic loss, 71% additionally exhibited mutations in an otherwise
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intact KLF6 allele. Due to its frequent loss or mutation, KLF6 was described as atumor suppressor in prostate cancer (Narla et al. 2001).KLF6<SV1 is expressed at a higher level in prostate cancers compared tonormal tissue. This is especially true for patients that contain the SNP IVSdA, whichincreases alternative splicing at the KLF6 locus. With IVSdA, increased KLF6<SV1levels antagonize the function of full<length KLF6. Unfortunately, patients with thisSNP have an increased risk of prostate cancer (Narla et al. 2005).This correlation aside, KLF6 has been shown to directly regulate theformation and progression of prostate cancer. In prostate cancer cells, expression ofKLF6 induces apoptosis through transcriptional activation of the pro<apoptoticfactor ATF3 (Huang et al. 2008). KLF6<SV1 is highly expressed in metastaticprostate cancer, and is a predictor of poor survival. Forced expression of SV1increases growth and invasion of prostate cancer cell lines (Narla et al. 2008). Wheninjected into a mouse, these cells show increased dissemination. However, deliveryof a siRNA targeting SV1 demonstrated impaired growth of these orthotopic tumorswhen compared to a control siRNA. Potentially, this variant could be targeted as atherapeutic strategy (Narla et al. 2008).In non<small cell lung cancer (NSCLC), chromosome 10p15, where KLF6 islocated, is frequently deleted (Girard et al. 2000). 84% of NSCLC samples havedecreased KLF6 mRNA when compared to normal lung tissue. LOH analysis of the
KLF6 locus showed that 34% of these tumors had LOH, and 66% of samples hadheterozygosity at the KLF6 locus. In lung cancer cell lines, expression of KLF6
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inhibited soft agar colony formation, demonstrating that its expression reduces thetransformation status of these cells. Additionally, overexpressing cells displayedhigher levels of apoptotic markers, suggesting that loss of KLF6 may enhancetransformation and survival of NSCLC (Ito et al. 2004).In addition to regulating apoptosis in cancer cells, KLF6 has also been shownto inhibit pro<growth mechanisms. In cell lines, KLF6 was shown to directly bind tothe oncogene c<JUN, and inhibit its transcriptional activity by facilitating itsdegradation by the proteasome (Slavin et al. 2004). In cells with decreased KLF6activity, it is possible that the activity of the c<JUN oncogene is higher, which couldfacilitate tumor formation or progression in these cells. Another potentialmechanism for KLF6 loss to impact tumor formation is its ability to bind directly toCyclin D1. With this binding, KLF6 inhibits the interaction of Cyclin D1 with CDK4,and thus reduces their phosphorylation of RB, leading to cell cycle inhibition(Benzeno et al. 2004). In a colon cancer cell line, increased KLF6 expression reducesproliferation and promotes growth arrest through this mechanism (Benzeno et al.2004). This describes another potential mechanism by which KLF6 loss mayfacilitate tumor formation.KLF6 expression and localization was also examined in normal andcancerous breast tissues. While normal breast tissue displays a mix betweencytoplasmic and nuclear staining, tumor tissues mainly displayed cytoplasmicstaining (Gehrau et al. 2010). Of the tumor tissues that had nuclear localization ofKLF6, there was a significant correlation with HER2<ERBB2 overexpression. Of stage
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I tumors with ERBB2 overexpression, 86% of them exhibited nuclear KLF6,providing a strong association between nuclear KLF6 in breast carcinomas andHER2<ERBB2 positivity. These tumors were also likely to have metastasized to thelymph nodes (Gehrau et al. 2010). While other studies have demonstrated anincrease in tumor formation in response to a decrease in KLF6 transcriptionalactivity, this study finds that the inverse is true for a subset of breast cancers.Potentially, nuclear KLF6 in these cells is accessing a different set of transcriptionaltargets that allow for KLF6 transcriptional activity to contribute to malignancyinstead of repressing it, as has been demonstrated in other tissues.In a different sampling of breast cancers, tumors with high expression ofKLF6<SV1 were associated with an increased risk of forming distant metastasis(Hatami et al. 2013). Ectopic expression of KLF6<SV1 induced a reversible epithelialto mesenchymal transition in breast cancer cells, through the increased expressionof TWIST1 in response to SV1 expression. Subcutaneous and orthotopic mousemodels demonstrated that increased SV1 levels resulted in greater tumor celldissemination (Hatami et al. 2013).
KLF6 Status in Hepatocellular CarcinomaAs in many other human cancers, KLF6 expression is also frequently reducedin HCC. However, there is some discrepancy as to the nature of this reduced activity.Studies have connected allelic loss, mutation, or epigenetic alterations to decreasedKLF6 activity. The data regarding KLF6 mutation frequency is questionable, since
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there are conflicting reports. This conflicting data may be due to the analysis ofHCCs of different etiology. However, the consensus of these studies is that KLF6expression is commonly reduced in human HCC as compared to normal liver.In one of the first studies of KLF6 in HCC, analysis of microsatellite markersdetermined that 39% of tumors had single<copy loss at the KLF6 locus whencompared to normal tissue. Also, 15% of tumors had missense mutations in exon 2of KLF6 that were not present in matched tissue, but only half of these mutationsoccurred in a tumor with allelic imbalance (Kremer<Tal et al. 2004). Similarly,another HCC study detected single<copy loss in 52% of tumors, and exon 2 pointmutations in 24% of tumors (Wang et al. 2010).Yet, follow<up studies have not detected mutations at similar frequencies. Inone study of 71 HCCs, no mutations in KLF6 were found (Boyault et al. 2005). In2006, two additional studies sought to clarify the presence or absence of KLF6mutations in HCC. In 21 dysplastic nodules and 85 HCC samples, no mutations inexon 2 of KLF6 were detected. Allelic loss was not found in any of the dysplasticsamples, but was present in 7% of HCCs (Song et al. 2006). In a set of 23 HCCs, onlyone case was found to have a missense mutation in exon 2. Despite no mutations inthe coding sequence, 34.7% of tumors had decreased KLF6 transcript levels ascompared to respective normal tissue (Pan et al. 2006). These studies demonstratethat mutation in KLF6 is a rare event in HCC, or may be strongly dependent onpatient selection. Yet, reductions in KLF6 expression can occur in the absence ofgenetic mutation.
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In a set of HCCs from HBV<infected patients, KLF6 was reduced in 57% oftumors compared to control liver. Additionally, this study found that reduced levelsof KLF6 are associated with tumors larger than 5cm. In a separate cohort of HCCsfrom HCV<infected patients, KLF6 was decreased in dysplastic nodules, and furtherdecreased in advanced HCC. Here, a reduction in KLF6 levels correlated withadvanced tumor stage (Kremer<Tal et al. 2007). This data suggests that reducedlevels of KLF6 may be an early event in hepatocarcinogenesis, but is selected for inlater stages as well. Interestingly, frequency or timing of KLF6 deregulation may bedependent on HCC etiology.In livers with hepatitis C infection displaying a spectrum of disease,decreased levels of KLF6 were associated with more advanced HCC, with the lowestKLF6 levels occurring in very advanced HCCs. In addition to inverse correlation withHCC stage, patients with tumors that had less than 10% of normal KLF6 expressionhad worse survival and higher tumor recurrence than patients whose tumors hadbetween 10 and 20% of normal KLF6 expression (Tarocchi et al. 2011). Thesecorrelations indicate a possible role for decreased KLF6 in HCC progression. Othershave found decreased KLF6 in HCC, but in those studies the decrease in KLF6expression did not correlate with histological grade or stage (Wang et al. 2010).While the consensus of the literature demonstrates that KLF6 levels arecommonly reduced in HCC compared to normal liver, this is not universally the case.In an analysis comparing normal liver, cirrhotic liver, macronodules, andhepatocellular carcinoma, KLF6 expression was decreased in all macronodule
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samples as compared to normal liver. However in this study, both cirrohotic liversand HCCs had higher levels of KLF6 expression than the normal livers. Uponsequence analysis, mutations in exon 2 were not found (Bureau et al. 2008).Several of these studies reveal contradictory information regarding theexpression level, mutation, or deletion status of KLF6 in patient samples. This may,in part, be due to the etiological variation in hepatocellular carcinoma patients. It ispossible that the form of KLF6 dysfunction is linked to the particular oncogenicstimulus that gives rise to HCC. Yet, with the exception of one study (Bureau et al.2008), KLF6 levels are decreased in hepatocellular carcinoma compared to normalliver, strongly suggesting a tumor suppressor role for KLF6 in HCC. Some of thesestudies also show that KLF6 is decreased further in late HCCs versus early HCCs,alluding to a potential role in HCC progression.In addition to deletion, mutation, and gene expression alterations, increasedalternative splicing of the KLF6 locus is another mechanism of reducing full<lengthKLF6 activity. Alternative splicing events of KLF6 have been detected in humanprostate cancer (Narla et al. 2005). In HCC, 18% of HBV<derived HCCs had a higherratio of KLF6<SV1 to full<length KLF6, and no HCV<derived HCCs were found to havean increased splicing ratio (Kremer<Tal et al. 2007). These data indicate thatincreased splicing of KLF6<SV1 is a less common event in HCC compared todownregulation of total KLF6.Despite this study suggesting KLF6<SV1 expression in HCC was a rare event,analysis of the ratio of KLF6<SV1 to full length KLF6 in aggressive HCV<induced
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HCCs shows that the splicing ratio is higher in HCC versus normal tissue, increaseslinearly with HCC progression, and is also increased in tumors with vascularinvasion (Vetter et al. 2012). Like the mutational analysis of KLF6, there iscontradictory information regarding the importance of KLF6<SV1 in human HCC.These data suggest that increased splicing of KLF6<SV1 may occur more frequentlyin later stages than in earlier tumors.Post<transcriptional regulation of the KLF6 message has recently beendescribed in HCC cells. Decay of KLF6 mRNA was significantly increased in humanHCC lines compared to immortalized hepatocytes. The 3’ untranslated region (UTR)of KLF6 was subsequently shown to be a negative regulator of mRNA stability usinga reporter assay (Diab et al. 2013). This outcome suggests that factors expressed inHCC cells may negatively regulate KLF6 levels through binding to the 3’UTR. Thiseffect is not as strong in normal hepatocytes, and could be one reason why manyHCCs have decreased KLF6 levels without the presence of a mutation or allelic loss.At least two microRNAs, miR<122 and miR<181a, are known to negatively regulateKLF6 levels. While not studied in liver cells, miR<181a was found to negativelyregulate levels of KLF6 in gastric cancer cells (Zhang et al. 2012a). Mice withdeletion of miR<122 display higher KLF6 levels (Tsai et al. 2012). Intriguingly, lossof miR<122 expression in liver cells increases migration and invasion, and correlateswith poor HCC prognosis (Coulouarn et al. 2009). These effects upon miR<122deletion would correlate with an increase in KLF6 expression. This result isinconsistent with other cancer models that have shown that reduced KLF6 levels
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lead to increased tumorigenesis and dissemination. Since microRNAs have multipletargets, potentially miR<122 is targeting multiple transcripts in HCC cells that areconfounding the correlation between KLF6 and HCC progression.By Western blot, KLF6 in HCC cells typically appears as multiple species.What was previously thought to represent different splice variants of KLF6 has nowbeen found to be differentially phosphorylated KLF6. A mutant form of KLF6 thatcould not be phosphorylated lacked the ability to transcribe p21 (Lang et al. 2013),indicating phosphorylation is required for its activity. N<terminal phosphorylationof the KLF6 transactivation domain is present on about 50% of total KLF6 protein inthe fibroblast<like COS7 cells (Slavin et al. 2004). One kinase known tophosphorylate KLF6 is GSK3β (Lang et al. 2013), but there are likely others as well.Regulation of phosphorylation status is yet another mechanism of regulating KLF6activity.
KLF6 Activity in Hepatocellular CarcinomaKLF6 was discovered, in part, because of its importance to liver biology. Oneof the groups that cloned KLF6 identified it in hepatic stellate cells from rats withhepatic fibrosis. KLF6 expression was increased in response to liver injury in thesecells, and was localized exclusively to the nucleus, where it increased transcriptionalexpression of collagen α1, an important component of fibrotic reactions in the liver(Ratziu et al. 1998).
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In the human HCC cell line HepG2, forced expression of KLF6 reducesproliferation (Kremer<Tal et al. 2004; Kremer<Tal et al. 2007). However, forcedexpression of KLF6 mutants fail to reduce proliferation, suggesting the effect isspecific to KLF6 activity (Kremer<Tal et al. 2004). These mutants were derived fromhuman HCCs, and their inability to regulate proliferation indicates that their normaltranscriptional activation is impaired.Similarly, Klf6 was either conditionally deleted, or KLF6<SV1 wasoverexpressed in primary hepatocytes. In both cases, the rate of proliferation andthe ploidy of cells increased. KLF6 expression even regulates proliferation in non<transformed cells, providing evidence that KLF6 functions as a tumor suppressor inhepatocytes (Vetter et al. 2012).Yet, there is some discrepancy over the role of KLF6 in regulatingproliferation. While previously it was shown that KLF6 overexpression reducedproliferation in HepG2 cells, another group demonstrated that KLF6 knockdown bysiRNA also decreased proliferation in these cells. Additionally, there was no impactof KLF6 knockdown on growth of immortalized hepatocytes (Sirach et al. 2007),which disagrees with data describing the increased proliferation of primaryhepatocytes when Klf6 is deleted (Vetter et al. 2012). The use of cell lines hasresulted in contradictory information regarding the role of KLF6 in HCC, which maybe heavily dependent on unknown contextual factors. The use of mouse models cancontrol for some context<dependent factors to potentially clarify the role of KLF6 inHCC.
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Klf6 heterozygous mice survive to adulthood with 40<60% of wild<type KLF6levels, and have increased liver mass compared to wild<type littermates (Narla et al.2007). After DEN treatment, liver size was increased in Klf6+/J mice by 1.5%. Overnine months, these mice have an increase in HCC incidence from 40 to 71%.Additionally, tumor number, and tumor size were increased. Interestingly, sinceKLF6 is a transcriptional repressor of Mdm2, the levels of Mdm2 are increased inmice with reduced KLF6. Higher Mdm2 levels lead to decreased p53 expression in
Klf6+/J HCCs. Concordantly, the expression signatures of these tumors were similarto HCCs with a deregulated p53 pathway, which is associated with poor survivalafter tumor resection in human disease. (Tarocchi et al. 2011).An additional study of KLF6 involvement in hepatocarcinogenesis combinedtwo approaches, liver<specific Klf6 deletion and increased transgenic expression ofhuman KLF6<SV1. Liver tumor formation was induced by DEN injection. This studyfound that Klf6 deletion and KLF6<SV1 both increase HCC tumor formation andtumor size following DEN treatment (Vetter et al. 2012). Together with the germlinemouse study, these data demonstrate that a decrease in KLF6 activity increases HCCformation. Interestingly, tumorigenic effects were compounded when Klf6conditional deletion and transgenic KLF6<SV1 expression were combined, whichsuggests that KLF6<SV1 can drive hepatocarcinogenesis, independent of its ability torepress full<length KLF6 (Vetter et al. 2012). Potentially, SV1 may also sequesterother transcription factors from the nucleus, thus further deregulating geneexpression in HCC.
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Previous data has clearly shown that full<length KLF6 expression iscommonly decreased in human cancer, including HCC. Importantly, cell line andmouse modeling studies have characterized KLF6 as a regulator of proliferation andcell death, consistent with its status as a tumor suppressor. While studies havefound KLF6<SV1 expression increases dissemination and metastasis in prostate andbreast cancers, this has not yet been demonstrated in HCC. Several transcriptionaltargets of KLF6 have been described, but to date, gene expression profiling has notbeen performed on HCC cells with different KLF6 levels. Therefore, determiningKLF6 target genes is important for understanding mechanisms important to theformation and progression of HCC.
p53 The tumor suppressor p53 is one of the most frequently lost or mutatedgenes in human cancer, occurring in over 50% of tumors (Hollstein et al. 1994).When active, p53 transcribes DNA as a tetramer (Friedman et al. 1993; Kitayner etal. 2006). While wild<type p53 typically has a short half<life, it is stabilized by cellstressors, such as DNA damage (Vousden and Lu 2002). Once stabilized, p53tetramers transcribe a host of transcriptional targets that can trigger many cellprocesses, including cell cycle arrest, apoptosis, or senescence, as seen in Figure 1.3(Liu et al. 2013a).The mutant form of p53 is not degraded at the same pace as wild<type p53and thus has a significantly longer half<life (Hinds et al. 1990). Frequently, tumor
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cells are found to have elevated levels of nuclear p53, which is almost always due toaccumulated mutant p53 (Bartek et al. 1991). The greatest number of p53mutationsoccur in the DNA binding domain, which ablates normal p53 transcriptional activity(Hollstein et al. 1991).Despite p53’s numerous roles in the cell, mice that possess germlinedeletions of p53 are surprisingly developmentally normal, indicating that p53 is notrequired for normal mouse development. However, over time these micespontaneously form cancer with high penetrance, indicating p53 is a tumorsuppressor (Donehower et al. 1992). While p53 is not required for normal celldevelopment, it is required to effectively mediate responses to cell stress. Withoutthis response, cells are more susceptible to transformation. Concordantly,individuals born with somatic mutations in the p53 gene suffer from Li<Fraumenisyndrome (Srivastava et al. 1990), and are susceptible to tumor formation. Knock<inmouse models of p53 mutants that mimic those seen in Li<Fraumeni syndrome alsoform spontaneous tumors (Lang et al. 2004; Olive et al. 2004).
41
Figure 1.3. p53 incorporates cellular stress signals and transcribes a myriad
of target genes to regulate multiple cell processes. Upon cell stress, p53 isstabilized and no longer targeted for degradation by Mdm2. p53 forms a tetramer toactivate transcription, including its negative regulator, Mdm2.(Adapted from (Liu et al. 2013a))
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p53 in HCCOverall, p53 mutations occur in 33% of HCCs. Of these p53<mutated HCCs,80% of them contain single point mutations, mostly distributed across the DNAbinding domain (Oda et al. 1992). HCCs that are poorly differentiated are enrichedfor p53 mutations versus those that are well or moderately differentiated,suggesting that aberrations in the p53 gene are a later event in HCC development. OfHCCs with chromosomal loss at the p53 locus, 62% have a point mutation on theremaining allele (Oda et al. 1992), which is consistent with its role as a tumorsuppressor.Despite the overall high frequency of p53 mutations in HCC, the frequencyvaries depending on HCC etiology. When HBV positive HCCs were examined therewas no significant association between HBV positivity and p53 mutation. Yet, therewas a correlation between p53 mutations and HCV positivity, which occurred in38.5% of cases (Long et al. 2013).Another HCC etiology associated with p53 mutation is the ingestion of AFB1.AFB1 has been shown to induce mutations at codon 249 in p53, and so many HCCsin regions with aflatoxin exposure carry a p53R249S mutation (Bressac et al. 1991;Ozturk 1991; Stern et al. 2001). In a cohort of patients without aflatoxin<inducedHCC, the mutation at R249 was shown to be quite rare, and does not occur with agreater frequency in HCC than the general cancer spectrum (Thongbai et al. 2013).This indicates that R249 mutations in HCC are a consequence of AFB1 exposure, andis not otherwise a frequent consequence of HCC progression.
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Importantly, p53mutations are associated with a poorer prognosis in HCC. InHCC tissue sections that were scored for intensity of nuclear accumulation of p53,tumors that had the highest levels of nuclear p53 had the poorest overall survival.High levels of nuclear p53 in tumor tissue are typically indicative of an accumulationof mutant p53 protein (Bartek et al. 1991). Post<resection, overexpression of p53was a better predictor of poor overall survival than either tumor size or vascularinvasion (Qin et al. 2002).In addition to impacting HCC tumorigenesis, p53 plays an important role inHCC progression. In an HCC mouse model with intact p53, there is little to nometastasis. However, upon deletion of p53, the frequency of metastasis increases to40%. The p53<deficient tumors display a more aggressive morphology and have agene signature associated with a poorer prognosis (Lewis et al. 2005). It is clear thatthe loss of wild type p53 function is a frequent and important event in HCC. Yet, it isunclear if p53 mutation may provide an additional advantage to HCC beyond theloss of wild<type p53 tumor suppressor activity.
p53R172H Gain of Function ActivityWhen the first investigations into p53 function occurred, tumor<derived p53cDNA was cloned for experimentation. The delivery of the tumor<derived p53 geneinto cell lines increased transformation<related phenotypes, leading to its initialcharacterization as an oncogene (Eliyahu et al. 1984; Finlay et al. 1988). We now
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know this tumor<derived cDNA coded for a mutated p53 (Hinds et al. 1989), and thetransformation advantage it provided was due to the presence of this mutation.Gain of function mutations in p53 were initially characterized in cell cultures,where cells lacking p53 protein were transfected with common p53 mutants. Uponmutant expression, including hotspot mutation R175H, cell lines displayedincreased soft agar colony formation and tumor formation in nude mice (Dittmer etal. 1993). It became clear that the p53 mutant conveyed tumorigenic properties thatwere independent of wild<type p53 loss.Most mice with germline p53 deletion form tumors within six months of age.Largely, these tumors are malignant lymphomas, but sarcomas are common as well(Donehower et al. 1992). In mice heterozygous for p53, tumor formation is lessfrequent, with a longer latency and of a different spectrum than p53<null mice.Proportionally, p53 heterozygous mice generate more sarcomas, and slightly fewerlymphomas. Interestingly, 12% of tumors in p53 heterozygous mice are carcinomas,since these types of tumors are rare in p53<null mice (Lang et al. 2004).A conditional, single<copy knock<in allele for p53R172H was directly comparedto mice with a germline p53 deletion. In this instance, since no wild<type p53 ispresent, the p53 mutant is not acting as a dominant negative. When null and mutantmice were compared, the overall survival of mice did not change, but the spectra oftumors differed. Mice with a p53 mutation had an increase in the occurrence ofcarcinomas, which occurred throughout the mouse in lung, colon, breast, and livertissue. Interestingly, many of these tumors were invasive or metastatic, which did
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not occur in p53<null animals. Mutant mice displayed increased tumor formationcompared to the p53<null mice, and these tumors were more likely to metastasize,suggesting a gain<of<function role for the R172H mutation (Olive et al. 2004).This p53R172H knock<in allele has been used to characterize p53 gain<of<function globally as well as in tissue<specific contexts. For example, it was found that
p53R172H cooperated with activated KRAS to facilitate pancreatic cancer formationand increase metastasis (Morton et al. 2010). Cooperation between oncogenic KRASand p53R172H also occurs in the skin, where mice with the R172H mutant form moreskin tumors than p53<null mice. These tumors also progress and become metastatic,while the p53<null skin tumors do not (Caulin et al. 2007). When these sameproteins are expressed in the oral epithelium, p53R172H<expressing mice grew moretumors, which progressed to carcinoma. The p53<null animals did generate tumors,but they were fewer, and remained benign (Acin et al. 2011). In a model of breastcancer, p53R172H did not impact the acceleration or metastasis of tumors, but tumorinitiation and the number of tumors per mouse were increased compared to p53<null animals (Lu et al. 2013). Lastly, a model of colon cancer induced by a pro<inflammatory treatment, dextran sulfate sodium, was used to assess p53R172H gain offunction. Mice with p53R172H were more prone to the formation of colon cancer inresponse to the pro<inflammatory drug than p53<null mice (Cooks et al. 2013).Together, these examples demonstrate that p53R172H can produce an array of gain<of<function phenotypes dependent on tissue context.
p53 GainJofJFunction Mechanisms
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One well<characterized mechanism by which p53 can acquire gain<of<function abilities is through the inhibition of the transcription factors p63 and p73(Lang et al. 2004). p63 and p73 are structurally related to p53, particularly in theDNA binding domains (Courtois et al. 2004), and have multiple isoforms and splicevariants which play different biological roles (De Laurenzi et al. 1998; Yang et al.1998; Ueda et al. 1999). Transcriptional targets of p63 and p73 overlap in part withp53 target genes, including p21, Mdm2, 14J3J3σ, and p85 (Jost et al. 1997; Yang et al.1998; Zhu et al. 1998; Westfall et al. 2003), though each factor also has uniquetarget genes (Dietz et al. 2002).Like p53, p63 and p73 form tetramers to bind to DNA. These factors do notheterotetramerize with wild<type p53 (Davison et al. 1999; Di Como et al. 1999), yetmutant p53 can heterotetramerize with p63 and p73, and subsequently inhibit theirnormal transcriptional activity (Di Como et al. 1999; Gaiddon et al. 2001; Strano etal. 2002). In p53<null mouse embryonic fibroblasts (MEFs), subsequent knockdownof p63 or p73 increases focus formation. While p53R172H<expressing MEFs have atwo<fold higher rate of focus formation at baseline, subsequent p63 or p73knockdown had no impact, suggesting that p63 and p73 activity is already inhibitedin p53 mutant cells (Lang et al. 2004).Unlike p53, mice that are deficient for p63 or p73 have strong developmentaldefects (Mills et al. 1999; Yang et al. 1999; Yang et al. 2000). Despite roles thatpartially overlap wild<type p53 function, p63 and p73 are rarely mutated or lost incancer, suggesting they are not classic tumor suppressor genes (Moll and Slade
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2004). However, the inactivation of these transcription factors in the context ofmutant p53 seems to exacerbate the loss of p53 tumor suppressive function (Orenand Rotter 2010).Mutant p53 can also impact the activity of transcription factors other thanp63 and p73. Studies have found that mutant p53 can increase transcription of NF<Ytarget genes via direct binding (Di Agostino et al. 2006). Additionally, mutant p53directly interacts with SP1 (Chicas et al. 2000) and SREBP (Freed<Pastor et al. 2012)leading to increased transcription of their target genes.Aside from altering the activity of other transcription factors, mutant p53 canalso directly bind DNA and alter gene expression. While p53 DNA binding mutantshave lost the ability to bind DNA in a sequence<specific manner, they can stilldirectly bind DNA and impact transcription. Studies have found that mutant p53binds to DNA in a non<B conformation, independent of the sequence (Gohler et al.2005). Genes found to be directly transcribed by mutant p53 include cJMYC (Frazieret al. 1998), IGF1R (Werner et al. 1996), and IGF2 (Lee et al. 2000), which are knowndrivers of tumorigenesis and progression in HCC.Mutant p53 may indirectly impact a large number of genes through the directregulation of microRNA expression. In particular, mutant p53 was found to repressthe expression of miR<130b (Dong et al. 2013) and miR<27a (Wang et al. 2013).Aside from this direct regulation, mutant p53 also inhibits DICER, the microRNAprocessing enzyme, through inhibition of p63, a transcriptional activator of Dicer(Su et al. 2010). Depletion of DICER through this mutant p53<p63 axis has been
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shown to promote invasion in cancer cell lines (Muller et al. 2014). Previously,decreased DICER expression has been associated with increased invasion andmetastasis (Han et al. 2010; Martello et al. 2010).
p53 GainJofJFunction Activity in HCCWhile gain<of<function p53 activity has been characterized for some tissues,the specific impact of p53 mutation is unclear in HCC. A few studies have implicatedp53 gain<of<function mutants in HCC cell lines, but results vary by the mutant andcell context used. For example, overexpression of various p53 mutants in a p53<nullHCC cell line decreased its apoptotic response. This effect was mediated through theinhibition of p53 family members, p63 and p73 (Schilling et al. 2010). Another studycharacterized a common p53 mutant, R249S, which occurs in response to aflatoxinexposure. Unlike the previously described study, forced expression of the mutant in
p53<null HCC cell lines did not confer any proliferation or colony formation benefit.However, p53 knockdown in a cell line with endogenous R249S expressiondecreased proliferation and increased apoptosis compared to a control infection(Gouas et al. 2010). Though complicated, this suggests that this particular p53mutant may not confer gain<of<function benefits over p53 loss in HCC cells. Yet, incells with the endogenous p53 mutant, expression of the mutant is required for itsgrowth and survival phenotypes. This result is in direct contrast with an additionalstudy, which demonstrates impaired cell death in p53<null HCC cells ectopicallyexpressing the R249S mutant (Lee et al. 2000). The source of this discrepancy could
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be due to artifacts of ectopic expression of the mutant form versus endogenousexpression models. Also, unknown differences in cell context may be important formediating the effects of p53 mutant gain<of<function effects.Aside from proliferation or survival effects seen with p53 mutant expression,other experiments suggest gain<of<function status through observations of geneexpression changes. For example, the expression of Stathmin is decreased uponknockdown of mutant p53, but is not altered upon an increase or decrease inexpression of wild<type p53 (Singer et al. 2007). Also, IGF2 expression is increasedupon expression of the R249S mutant in a p53<null cell line (Lee et al. 2000).Interestingly, increased expression of both of these proteins is associated with HCCprogression (Yuan et al. 2006; Chen et al. 2009), so the presence of mutant p53correlates with the increased expression of these poor<prognosis markers.Together, these data paint a confusing picture for p53 gain<of<functionmutations in HCC, where varied outcomes have been demonstrated depending onthe p53 mutation and cell context used. Importantly, none of these studies examinethe impact of p53 mutations on HCC in vivo. Further study into particular mutationsin specific contexts is required to determine if p53 gain<of<function occurs in HCC,and if it is important for HCC progression.
Scope of ThesisKLF6 has been found to contribute to tumorigenesis in several cancers,including HCC. While it is known that KLF6 is a tumor suppressor for HCC, the
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impact of KLF6 loss on HCC progression and metastasis is unknown. The work inChapter II explores the role of KLF6 in affecting progression<related phenotypes ofHCC, particularly migration and metastasis. In Chapter III, I investigate themechanism of KLF6 function in HCC by elucidating its transcriptional targets. Twotarget genes, Vav3 and Cdc42ep3, are investigated further for regulation of in vitromigration effects downstream of KLF6.In addition to characterizing the role of KLF6 in HCC progression, I sought toclarify the role of p53R172H in HCC. While several in vitro studies point to evidence ofgain<of<function p53 activity in HCC, some data is contradictory. As of yet, p53 gain<of<function activity has not been investigated in HCC in vivo. Loss of p53 activity haspreviously been shown to be a crucial driver of HCC progression, and Chapter IVinvestigates the possibility that the p53R172H mutant has an increased capacity forinducing HCC progression.Together, this work highlights the activities of two tumor suppressors, KLF6and p53, and their involvement in the formation and progression of hepatocellularcarcinoma.
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CHAPTER II
KLF6 is a repressor of HCC cell migration, tumor formation, and metastasis.
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Preface
The BL185<M1 and BL185<I1 subpopulations described in Figure 2.1 wereisolated by Ya<Wen Chen.Lihua (Julie) Zhu performed bioinformatics analysis on the gene expressionprofiling study discussed in this chapter and located in Appendix A.David Klimstra scored the KLF6 tissue microarray in Figure 2.7 and assessedthe histology of the tumors generated during the study. He also kindly took thephotographs shown in Figures 2.7A and 2.16.
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IntroductionHepatocellular carcinoma is a common malignancy worldwide that affectsover 800,000 people per year, and is the 2nd<leading cause of cancer<related death(Ferlay et al. 2013). Survival for patients with HCC is generally poor, with a 5<yearsurvival rate of 16.1% in the United States. However, patient prognosis issignificantly better for patients with localized disease that can be surgicallyresected, where the survival rate increases to 29% (Hayat et al. 2007). Conversely,treatment options are limited for patients with invasion or metastasis (El<Serag2011). Despite its potential impact on patient outcome, little is known about thespecific genes and pathways involved in HCC progression and dissemination. Giventhe prevalence of invasive and metastatic disease, studies into these mechanismsmay provide opportunities to improve the clinical outcome of a significant fractionof HCC patients.Metastatic disease occurs through a multistep process by which cancer cellsescape the primary tumor and establish one or more secondary tumor siteselsewhere in the body. In solid tumors, this process begins when invasive cellsbreak attachments from the primary tumor. These cells then actively invade throughthe extracellular matrix, while resisting detachment<induced apoptosis, or anoikis(Liotta and Kohn 2004). These invasive cancer cells then enter lymphatic or bloodvessels, a process termed intravasation. Living tumor cells are readily detectable inthe circulation of cancer patients, which leave the circulation through a processcalled extravasation (Chaffer and Weinberg 2011). Cell fate studies have determined
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that tumor cell intravasation and extravasation is an efficient process, but only afraction of these cells will successfully form metastases (Chambers et al. 2002).Upon leaving the blood or lymph, in the absence of a tumor<supportiveenvironment, many invasive cells will not grow, and become dormant or die(Chambers et al. 2002; Nguyen et al. 2009; Chaffer and Weinberg 2011). Anorthotopic cell tracking study found that over 80% of injected cells were able tosurvive and extravasate from the circulation, yet only 1 in 40 cells were able to formmicrometastases. Furthermore, most of these micrometastases did not continue togrow, as only 1 in 100 micrometastases persisted to form a macroscopic tumor(Luzzi et al. 1998). While survival and escape from circulation are efficientprocesses for tumor cells, most cells are incapable of generating a colony in foreigntissue, and either remain dormant or die.While inefficient, this process is successful in the approximately 37% of HCCpatients who present with extrahepatic metastasis. The most common site ofmetastasis is the lung, which occurs in 55% of patients with metastatic disease.Second is involvement of the abdominal lymph nodes, which occurs in 41% of thesepatients (Katyal et al. 2000). Invasion of cells to the portal vein is also a commonand deadly occurrence in patients with HCC. Portal vein tumor thrombosis (PVTT)was found to exist in 28% of HCC patients at diagnosis. Patients with PVTT have amedian survival of 3.5 months, versus 18.7 months for patients without it (Cheunget al. 2006).
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Gene expression profiling studies of HCC have revealed frequent changes tofamilies of genes involved in cell cycle regulation and hepatocyte differentiation(Andrisani et al. 2011). Factors affecting proliferation and differentiation status ofhepatocytes are likely important for tumor formation, but few genes are known tocorrelate with HCC progression. Aberrations that inactivate the p53 pathway aresome of the most frequent changes in HCC, and the absence of tumor suppressivep53 activity drives a more invasive phenotype in mice while correlating with poorersurvival in human HCC patients (Lewis et al. 2005; Villanueva and Hoshida 2011). Inaddition to loss of p53, increased IGF2 levels in HCC have been shown to be requiredfor HCC metastasis in mice (Chen et al. 2009), while higher levels of IGF2 correlatewith poor survival in humans (Iizuka et al. 2004).The zinc finger transcription factor KLF6 has been previously shown to be atumor suppressor in HCC, and low mRNA levels correlate with poor survival in HCCpatients (Tarocchi et al. 2011). Heterozygous deletion of Klf6 in vivo results inincreased hepatocyte proliferation and liver mass, and specific deletion of Klf6 inprimary hepatocytes enhances their proliferation (Tarocchi et al. 2011; Vetter et al.2012). In mice with liver<specific depletion of Klf6, treatment with the carcinogenDEN resulted in increased hepatocarcinogenesis as compared to mice with intact
Klf6 (Vetter et al. 2012). These data confirm a role of KLF6 as a tumor suppressor inHCC, yet data connecting KLF6 to HCC dissemination and metastasis are lacking.Experiments in other cancers have provided evidence that lower KLF6activity can drive metastasis. In prostate and breast cancers, increased expression of
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the dominant<negative splice variant KLF6<SV1 resulted in decreased survival andincreased rates of metastasis (Narla et al. 2008; Hatami et al. 2013). These datasuggest that decreased KLF6 activity may be a driver of tumor dissemination inaddition to tumor formation.Here I demonstrate that KLF6 expression is decreased in migratorysubpopulations of an HCC cell line. Reduced KLF6 expression correlates with thepresence of vascular invasion in HCC patients, and induces cell migration in vitro.Moreover, liver<specific deletion of Klf6 promotes both HCC formation anddissemination to the lungs in mice. This work connects KLF6 and HCC disseminationfor the first time.
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Results
Subpopulations of an HCC cell line display increased transformationLrelated
phenotypes.In order to study genes that may impact migration and metastasis in HCCcells, migratory subpopulations of a murine HCC cell line were isolated. BL185 is aheterogeneous, murine HCC line derived from a non<metastatic tumor. This tumorarose in a liver with conditional deletion of p53 and retroviral delivery of the PyMToncogene (Chen et al. 2007). BL185 displays an intrinsically low level of migration
in vitro. Migratory subpopulations were isolated by plating BL185 cells into atranswell migration chamber using 10% bovine serum as a chemoattractant. Cellsthat migrated through the membrane were selected and expanded as separatepopulations, which were termed BL185<M1 and BL185<I1.Both M1 and I1 subpopulations display a higher rate of proliferation (Figure2.1A) and soft agar colony formation (Figure 2.1B) as compared to the parent BL185cell line. Soft agar colony formation measures the anchorage<independent growth ofa cell line, which is used as a method of measuring its transformation status. Thesehigher proliferation and soft agar colony growth rates suggest these subpopulationsare more transformed than the parent population of BL185 cells.Importantly, M1 and I1 also show a ten<fold increase in migration ability overthe BL185 parent cell line (Figure 2.1C). Since the in vitro migration assay serves asa surrogate for measuring the initial, invasive steps of the metastatic cascade, these
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migratory subpopulations may be useful for modeling gene expression changesimportant for HCC dissemination.
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Figure 2.1. Subpopulations of an HCC cell line display increased proliferation,
transformation, and migration.A. Proliferation assay as measured by absorbance with MTS reagent in 24<hourincrements. By 48 hours, significant increases in growth are present in M1and I1 cells (p<values=0.0290 and 0.0047, respectively). These are moreexaggerated at 72 hours (p<values=0.0125 and >0.0001). Graph shown is arepresentative experiment of four replicates.B. Soft agar colony formation assay, where colonies are counted by sizeexclusion over 20 fields at 100X magnification. p<values calculated by t<testare 0.0131 and 0.0025 in M1 and I1 cells, respectively. Graph shown is arepresentative experiment of three replicates.C. Transwell migration assay, cells that migrated through the membrane werecounted per field at 100X magnification. p<values determined by t<test are0.0012 and >0.0001 in M1 and I1 cells, respectively. Graph shown is anaverage of three replicate experiments.
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One common mechanism for cells to acquire more migratory characteristicsis through epithelial to mesenchymal transition (EMT). EMT is a process wherebyepithelial cells lose their epithelial characteristics and enter a more mesenchymalstate. This process is thought to commonly occur in cancer cells to allow forincreased invasive capacity. Typically, EMT is detected in cell lines through themeasurement of decreased epithelial and increased mesenchymal markers.Commonly, E<Cadherin and α<catenin are used as epithelial markers while N<Cadherin and Vimentin are used as mesenchymal markers (Thiery 2002).To investigate if EMT was responsible for the increased migration capacity ofthe HCC subpopulations, I assessed common markers for EMT by Western blot(Figure 2.2). None of these markers were differentially expressed in thesubpopulations as compared to the parent BL185 cell line, indicating thesubpopulations are not more mesenchymal than the parent population. While EMThas been shown to be important for other systems, it is likely not what is driving thephenotypes seen in these cells. Notably, these cells express markers of bothepithelial and mesenchymal lineages, suggesting they may exist in an intermediatestate. An alternate explanation could be that the populations are heterogeneous forcells expressing either epithelial or mesenchymal markers.We hypothesized that these subpopulations possessed other gene expressionchanges that could account for the increased migration they displayed. Theseexpression changes may also be important for HCC progression in vivo.
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Figure 2.2. Differences in migration of HCC subpopulations are not due to
epithelial to mesenchymal transition. Expression of common EMTmarkers aredisplayed by Western blot. E<Cadherin and α<Catenin are epithelial markers, whileN<Cadherin and Vimentin are mesenchymal markers. β<Actin is used as a loadingcontrol. In the Vimentin blot, lysates from 3T3Li cells were included as a positivecontrol sample for Vimentin expression.
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Gene expression profiling of BL185 subpopulations reveals many
differentially expressed genes.In order to find gene expression changes in the migratory subpopulations,whole genome expression analysis was performed on BL185, BL185<M1, andBL185<I1 by microarray. Genes whose expression was in common between M1 andI1, yet significantly changed from the parent BL185 line were selected. This analysisidentified 313 genes that were either increased or decreased greater than two<foldin M1 and I1 cells as compared to BL185, with an adjusted p<value less than 0.01(Appendix A).Gene Ontology term analysis included categories related to cell cycle,angiogenesis, and migration (Table 2.1). These categories contain several genes thathave well<characterized roles in tumor progression and metastasis, such as Dlc1 and
Hif1α (Zhou et al. 2008; Lu and Kang 2010; Popescu and Goodison 2014). Thedetection of genes known to be important for tumor progression within my profilingstudy demonstrates that my approach is valid for investigating novel genes that mayaffect these processes.Several genes that were significantly changed in the microarray study werevalidated with separate RNA isolations by qRT<PCR (Figure 2.3). Gene expressionchanges validated by qRT<PCR vary from the microarray by fold change intensity,but largely the changes are consistent.To prioritize genes for continued study, several criteria were applied.Importantly, the gene could not be previously characterized as a driver of HCC
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progression. It was also important that the gene expression change seen in the M1and I1 cells correlated with human cancer or HCC specifically. Lastly, preferencewas given to genes whose known or proposed function would influence cellmigration or invasion. Several candidate genes that met these criteria were selectedfor further validation and analysis.
64
Table 2.1. Gene Ontology terms present in the subpopulation gene expression
profiling dataset. GO Term analysis was performed on the gene expressionprofiling dataset using the GOEAST program (Zheng and Wang 2008). Examples ofgenes present in the GO term category are provided in addition to p<valuescalculated with the program.
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Figure 2.3. Fold changes of several differentially expressed genes detected by
profiling analysis were validated by qRTLPCR. Ct values for each respective genewere normalized to β<actin as an endogenous reference. These values in the M1 andI1 samples were then normalized to those for the BL185 sample to calculate foldchange of a particular message in the subpopulations.
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KLF6 is reduced in migratory HCC subpopulations and frequently has reduced
activity in HCC.One gene that exhibited a significant change in expression in the migratorysubpopulations was Krüppel<like factor 6 (KLF6). KLF6 has been shown to bedecreased at the mRNA level in human HCC (Narla et al. 2001; Ito et al. 2004;Kremer<Tal et al. 2004; Kremer<Tal et al. 2007; Gehrau et al. 2010; Wang et al. 2010;Tarocchi et al. 2011), has tumor suppressor activity in HCC (Tarocchi et al. 2011),and also has target genes including E<Cadherin and MMP9 that are associated withmetastasis in vivo (DiFeo et al. 2006, Das et al. 2006). Thus, KLF6 satisfied thecriteria for further downstream analysis frommy expression profiling dataset.When M1 and I1 HCC cells were compared with their non<migratory BL185parent population, KLF6 was decreased at the mRNA level (Figure 2.3). Inagreement with KLF6 message levels, all species of KLF6 are decreased in M1 and I1subpopulations when compared to BL185 (Figure 2.4). I hypothesized thatdecreased levels of KLF6 in these HCC subpopulations was at least partlyresponsible for their increased growth and migration ability.
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Figure 2.4. KLF6 is reduced in migratory subpopulations of HCC. HCCsubpopulations were investigated for KLF6 protein levels by Western blot. β<Actinwas used as a loading control.
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To corroborate the data from my mouse HCC samples, I investigated severalsources of human HCC samples to determine KLF6 expression status. Data acquiredfrom the Roessler 2 dataset in Oncomine (Roessler et al. 2010) demonstrates thatKLF6 is reduced at the message level in HCC samples as compared to normal liver(Figure 2.5). This result was corroborated in other datasets as well. At the proteinlevel, full<length KLF6 is decreased in human HCC cell lines when compared to animmortalized hepatocyte cell line, Thle2 (Figure 2.6A). KLF6 protein levels are alsoreduced in 3 out of 4 human tumor samples obtained from the UMMS Cancer CenterTumor Bank versus their matched normal liver samples (Figure 2.6B). Together,these data suggest that KLF6 is commonly reduced in HCC at both the mRNA andprotein levels.
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Figure 2.5. KLF6 is commonly reduced in human HCC at the message level.KLF6 is reduced at the message level in a profiling study of 225 HCC samples and220 normal liver samples. These data come from the Roessler 2 profiling studypublicly available in Oncomine (Roessler et al. 2010). The p<value, calculated by t<test, is >0.0001.
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Figure 2.6. KLF6 is commonly reduced in human HCC at the protein level.A. Western blot displaying KLF6 protein levels in human<derived HCC celllines as compared to an immortalized hepatocyte cell line, Thle2. β<Actin isused as a loading control. The arrow in the figure indicates full<length KLF6.B. Western blot displaying KLF6 protein levels in human HCC samples.Samples were isolated from normal liver (labeled N) and paired HCC samples(labeled T) resected from human HCC patients. β<Actin is used as a loadingcontrol.
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Given that decreased KLF6 levels correlate to increased migration in my HCCsubpopulations, I sought to determine if KLF6 could function as a potentialprognostic marker for HCC. I performed KLF6 immunohistochemistry (IHC) on ahuman tissue microarray (TMA) containing 106 human HCCs. Tumor specimenswere then scored by an expert pathologist and rated as positive or negative. Thestaining pattern of positive specimens was then clarified based on predominantlocalization of KLF6, either cytoplasmic or nuclear (Figure 2.7A). Of 106 HCCsamples, 74 were positive for KLF6, and 32 were negative. Of these positive HCCs,43% had nuclear localization and 57% had cytoplasmic localization (Figure 2.7B).Intriguingly, KLF6 status did not correlate with HCC grade or survival as previousstudies using KLF6 mRNA levels have demonstrated (Tarocchi et al. 2011). My TMAdata suggests that KLF6 activity is commonly reduced in HCC via decreasedexpression or mislocalization.A dataset of HCC surgical specimens available in the Oncomine databasescores tumors as having the presence of vascular invasion or not (Wurmbach et al.2007). The HCC surgical specimens with vascular invasion have less KLF6expression at the mRNA level than HCCs without vascular invasion (Figure 2.7C).This correlation suggests a potential role for KLF6 in the regulation of HCCprogression. Despite no correlation to patient outcomes in my tissue microarray, Isought to determine if decreased KLF6 levels were impacting HCC biology.
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Figure 2.7. KLF6 is commonly deregulated in human HCC, but its status does
not correlate to tumor grade or overall survival.A. Examples of KLF6 localization in human tissue microarray HCC samples byIHC. From left to right, these samples were scored as having nuclearexpression, cytoplasmic expression, or being negative for KLF6.B. Distribution of KLF6 status in 106 unique human HCC samples from thetissue microarray after being scored as negative, cytoplasmic, or nuclear.C. Message levels of KLF6 were accessed from the Wurmbach Liver dataset,in the Oncomine database. The p<value, calculated by Student’s t<test, is0.0038.A
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KLF6 suppresses transformation andmigration of HCC cells.Since decreased full<length KLF6 expression and mislocalization of KLF6 arecommon in HCC, I sought to determine if decreased KLF6 has a direct impact onphenotypes associated with HCC progression. To test this, KLF6 was stably knockeddown by two, independent shRNAs in BL185 cells. As a control, BL185 cells weresimultaneously infected with a virus containing a GFP<targeting shRNA in place ofthe KLF6<targeting sequence (Figure 2.8A). Since two shRNA sequences were usedto achieve knockdown, this minimizes the chance that cell phenotypes are due tooff<target effects of the shRNA. These stable lines were subsequently assayed forsoft agar colony growth and migration. Upon KLF6 knockdown, soft agar colonyformation increased two<fold (Figure 2.8B) as compared to the GFP control. Thisresult supports this transcription factor’s previously known role as a tumorsuppressor gene. Yet, KLF6 knockdown also increased the migration ability of thesecells two<fold (Figure 2.8C), indicating that KLF6 is a repressor of HCC cellmigration, and suggesting that KLF6 may play a role in HCC dissemination.
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Figure 2.8. KLF6 suppresses transformation andmigration in murine HCC
cells. A. Western blot depicting shRNA<mediated knockdown of KLF6 in BL185cells, with GFP<targeting shRNA as a control. β<Actin was used as a loadingcontrol. Shown is a representative blot of three separate shRNA infections.B. Soft agar colony formation assay of KLF6 knockdown cells compared toGFP control. p<values, calculated by t<test, are 0.0055 and 0.0342 in KLF6 shAand shB, respectively. Shown is an average of 3 experiments performed in asingle shRNA<infected cell line.C. Transwell migration assay of KLF6 knockdown cells compared to GFPcontrol. p<values, calculated by t<test, are 0.0011 and 0.0013 in KLF6 shA andshB, respectively. Shown is a representative experiment of 4 replicatesperformed in 2 shRNA<infected lines.
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As described earlier, KLF6<SV1 is a splice variant of KLF6 that lacks a nuclearlocalization site, and is localized in the cytoplasm. KLF6<SV1 functions as a dominantnegative for full<length KLF6, and is increased in several tumor types (Vetter et al.2012). Studies in breast and prostate cancers previously found that increased KLF6<SV1 expression can increase metastasis (Narla et al. 2008; Hatami et al. 2013). Todetermine if this is similar for HCC, BL185 cells were infected with a retrovirusexpressing KLF6<SV1. Control viruses without a gene<coding insert were alsodelivered to BL185 cells. Levels of KLF6<SV1 were detected using an antibodyspecific to the splice variant (Figure 2.9A). Ectopic KLF6<SV1 expression in BL185cells increased cell migration (Figure 2.9B). This result mimics the conclusion foundby KLF6 knockdown shown in Figure 2.8, where KLF6 is found to be a suppressor ofHCC migration. Importantly, this result also indicates that the migration effect seenin KLF6 knockdown cells is not due to an off<target effect of the shRNAs, but due todecreased KLF6.
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Figure 2.9. Expression of KLF6LSV1 increases HCC cell migration.A. Western blot of KLF6<SV1 with β<Actin as a loading control. Cells wereinfected with retrovirus containing KLF6<SV1 or a control empty plasmid.B. Transwell migration assay of cells infected with KLF6<SV1 versus emptyvector control. p<value by t<test is 0.0188. Shown is a representativeexperiment of 3 replicates.
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One known transcriptional target of KLF6 is E<Cadherin. Investigation of E<Cadherin levels in KLF6 knockdown cells by Western blot revealed that E<Cadherinlevels are decreased in response to KLF6 knockdown (Figure 2.10). Evaluation ofother EMT markers revealed that they are not significantly altered upon KLF6knockdown (Figure 2.10). Similarly to what was seen in the BL185 migratorysubpopulations, KLF6 knockdown cells seem to express both epithelial andmesenchymal markers. A previous publication implicated KLF6<SV1 as a positiveregulator of EMT (Hatami et al. 2013), but in my HCC cell lines, KLF6 knockdowndoes not seem to impact the levels of EMT markers other than E<Cadherin. Despitechanges in E<Cadherin levels, cell morphology is not altered upon KLF6 knockdownin HCC cells (data not shown).Together, my data demonstrate that full<length KLF6 functions as a repressorof HCC cell transformation and migration.
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Figure 2.10. Some EMTmarkers are affected in response to KLF6 knockdown.Western blot EMT marker levels in KLF6 knockdown cells compared to GFP control.E<Cadherin and α<catenin are common markers of epithelial cells, while N<Cadherinis a mesenchymal marker. β<Actin serves as a loading control.
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SingleLcopy loss of Klf6 in an HCCmouse model increases tumorigenesis and
decreases overall survival.Since KLF6 knockdown resulted in an increase in migration and soft agarcolony formation in vitro, I sought to determine if decreased KLF6 in an HCC mousemodel would increase tumor progression in vivo. To model HCC in vivo, I utilized theRCAS<TVA system, where liver cells are rendered susceptible to infection by theRCAS retrovirus through expression of the TVA receptor under the Albuminpromoter (Lewis et al. 2005). After injection with an RCAS virus containing the
PyMT oncogene, mice that are AlbuminJtvJa, p53fl/fl, AlbuminJcre develop HCCs thathave the capacity to metastasize to the lung (Lewis et al. 2005; Chen et al. 2007).We conducted an analysis of the impact of KLF6 on HCC progression bycrossing a Klf6 conditional allele into the mouse model for HCC. The Klf6 conditionalallele was designed with LoxP sites flanking exons 2 and 3 of the Klf6 gene. Bydesign, deletion of the DNA between these sites would result in a loss of KLF6message and protein (Leow et al. 2009). However, instead of being a direct repeat,the second LoxP site was inadvertently inverted (Personal communication). As aconsequence, Cre expression results in an inversion event between exons 2 and 3instead of a deletion event. Inversion at these sites results in a frame shift thatresults in non<functional KLF6 message. With sustained Cre expression, theinversion can continue, resulting in expression of either wild<type or impaired KLF6message. This results in the expression or deletion of Klf6 in a mosaic fashion,instead of a permanent deletion. With this in mind, I crossed AlbuminJtvJa, p53fl/fl,
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AlbuminJcre mice to AlbuminJtvJa, KLF6fl/wt, p53fl/fl, AlbuminJcre mice to allow fordirect littermate comparison. Approximately half of the mice in each litter have a
Klf6 floxed allele, and half of the mice retained two wild<type Klf6 alleles.Over the course of nine months, a cohort of mice was assessed for tumor<freesurvival. Mice were sacrificed when illness became apparent. If the cause of illnessin a sacrificed mouse was not due to the presence of HCC, the mouse was censoredfrom the study. At nine months, all remaining mice in the study were sacrificed andassessed for presence of HCC, providing a total of 16 animals in the Klf6wt/wt group,and 23 mice in the Klf6fl/wtgroup. Of five Klf6fl/wt mice injected with RCAS<GFP, noneformed liver tumors. The study demonstrated that single copy loss of Klf6 in theliver significantly impairs tumor<free survival as compared to wild type littermates(Figure 2.11A). This reduction in survival is due to an increase in the incidence ofHCC in Klf6 heterozygous mice, as proportionally more mice from the Klf6fl/wt group(74%) developed HCC than in the KLF6 wild<type group (38%) (Figure 2.11B). Thisincrease in tumorigenesis echoes the in vitro result of increased soft agar colonyformation (Figure 2.8B), and previously published work describing the role of KLF6as a tumor suppressor in HCC.
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Figure 2.11. SingleLcopy loss of Klf6 reduces overall survival and increases
HCC incidence.A. Kaplan<Meier curve displaying tumor free survival of GFP<injected Klf6fl/wtmice, and PyMT<injected Klf6fl/wt and Klf6wt/wt littermates. Mice were assessedover a period of 9 months and sacrificed when illness was apparent. Onlymice whose death was perceived to be due to HCC were included, otherwisethe mouse was censored. Censored animals are represented in the figure astick<marks on the day of death. p<value by Log<rank test between Klf6fl/wt and
Klf6wt/wt PyMT<injected mice is 0.0398.B. Number of mice with gross HCC in Klf6fl/wt and Klf6wt/wt groups over thecourse of 9 months. Mice with tumors present upon sacrifice at 9 months areincluded. p<value by Fisher’s exact test is 0.0258.
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RNA isolated from murine Klf6fl/wt HCCs demonstrate that KLF6 is expressedat 50% of Klf6wt/wt tumor levels in most cases (Figure 2.12). One Klf6fl/wt tumorretained wild<type levels of KLF6 expression, which may be caused by unsuccessfulrecombination of the conditional Klf6 allele. An additional tumor lacked detectableKLF6 expression levels, which may indicate loss of the remaining Klf6 allele.
83
Figure 2.12. FullLlength KLF6 levels are reduced in Klf6fl/wtHCC tumors versus
Klf6wildLtype tumors. Full<length KLF6 message was detected by qRT<PCR in RNAderived frommurine tumor samples. Ct values for each sample were normalized toβ<actin message levels as an endogenous reference. The average Ct values for the
Klf6wild type tumors were set to 1. All samples were then normalized to thisaverage value in order to obtain a fold change. The p<value, calculated by t<test, is0.0050.
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Despite a difference in the incidence of HCC in my mouse model, tumorburden per mouse was not significantly changed between the two groups in thesurvival cohort (Figure 2.13A). I hypothesized that I was not seeing a difference intumor burden due to the fact that mice in the survival cohort were only sacrificedwhen displaying illness or distress. Likely, the tumor burden is normalized to thetumor volume at which mice become ill from HCC. To determine if Klf6 deletionaccelerated HCC development or growth, I generated a separate cohort of miceinjected with RCAS<PyMT. These mice were sacrificed at 4.5 months of age, prior todisplaying symptoms of illness and assayed for tumor size. In this cohort of animals,the tumor burden in Klf6fl/wt mice is significantly greater than tumors formed in thewild<type group (Figure 2.13B).
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Figure 2.13. Klf6fl/wt HCC tumors are larger at an early study timepoint, but this
difference does not persist in the survival cohort. All liver tumors weremeasured in three dimensions in millimeters. Half of the lengths of each of theseaxes is represented as variables a, b, c in the following formula. Tumor burden wascalculated by using the formula for the volume of an ellipsoid, where V=(4/3)π*abc.If a mouse had multiple liver tumors, volumes were summed to arrive at total tumorburden per mouse.A. Tumor burden in the survival cohorts of Klf6wt/wt and Klf6fl/wt mice.B. Tumor burden in Klf6wt/wt and Klf6fl/wt mice at 4.5 months of age. p<valueby t<test with Welsh’s correction is 0.0212, p<value by F<test is 0.0003.
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To investigate if Klf6fl/wt tumors were proliferating faster or forming earlier,tumors harvested from the 4.5<month cohort of mice were stained for Ki67. Ki67 isa marker of cell proliferation commonly used to detect recent mitoses in tissuesections (Scholzen and Gerdes 2000). Cells with Ki67 positive nuclei were countedin relation to the number of cells that stained negative for Ki67. Tumors from
Klf6fl/wt mice did not have different rates of proliferation when compared to tumorsfrom Klf6wt/wt mice (Figure 2.14). Immunohistochemistry for Cleaved Caspase 3(CC3) was also performed to detect cells undergoing apoptosis (Persad et al. 2004).Cells positive for CC3 were generally rare, and equal between Klf6fl/wt and Klf6wt/wttumors (data not shown). Since rates of proliferation and apoptosis are similarbetween the tumor types, and Klf6fl/wt tumors are larger than Klf6wt/wt tumors at 4.5months (Figure 2.13B), I hypothesized that Klf6fl/wt tumors may be initiating earlierthan in Klf6wt/wt mice.Although Klf6fl/wt mice have a greater incidence of tumor formation than
Klf6wt/wt mice, these mice have equivalent numbers of liver tumors per mouse(Figure 2.15). One Klf6 wild<type mouse had as many as 8 separate liver tumors,while one Klf6fl/wt mouse had 12 discrete liver tumors, yet most animals had onlyone grossly visible tumor. The number of gross liver tumors is the same per mousedespite the result that single<copy Klf6 loss allows for tumors to form earlier thanwild<type animals.
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Figure 2.14. Proliferation rates in HCCs from 4.5Lmonth old mice do not differ
based on Klf6 status. Sections of HCC from 4.5<month old mice were stained forKi67 by IHC. Cells with Ki67<positive and negative nuclei were counted in order toobtain the percentage of cells within an HCC section that were Ki67 positive. Fivefields in each tumor section were counted to obtain an average, except for onetumor section, which was entirely covered by 3 fields of view (the third tumor in the
Klf6wt/wt group).
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Figure 2.15. The number of liver tumors per mouse does not differ based on
Klf6 status. The number of liver tumors in each mouse was counted based on grossvisibility. Best judgment was used to determine which tumor segments weredistinct and which were contiguous.
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Despite differences in the tumor incidence and the earlier expansion of thesetumors, HCCs with single<copy loss of Klf6 do not display different histology thantumors with wild<type Klf6 (Figure 2.16). To determine if single<copy deletion of
Klf6 impacts tumor histology, normal livers (A,B) and tumor samples (C<F) fromeach group of mice were stained with hematoxylin and eosin (H&E) to visualize celland tissue structure. Livers without tumor appear similarly normal between Klf6wild<type and heterozygous mice. The different regions of histology observed in themouse tumors also commonly occur in human HCC. Among the tumor histologyobserved is the occurrence of non<invasive tumors composed of large cells withvacuolated cytoplasm (Figure 2.16C,D). Previous studies using this mouse modelhave associated this vacuolated cytoplasm with the accumulation of fat (Lewis et al.2005). Also, these tumors display similar frequencies of more cellular, dense, andfibrotic areas (Figure 2.16E,F). Even though single<copy loss of Klf6 facilitates earlierand more frequent tumor formation, it does not impact the appearance of theseHCCs. Pathological analysis determined that neither the grade nor differentiationstate of HCCs in our study differed by Klf6 status.
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Figure 2.16. The histological patterns of mouseLderived HCC do not change
with Klf6 status. Panels (A) and (B) are normal liver in mice absent of HCC. Panels(C) and (D) display cells with accumulation of lipid in the cytoplasm. Panels (E) and(F) display regions of necrosis and fibrotic deposition, respectively.
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SingleLcopy loss of Klf6 increases metastatic burden and affects poorL
prognosis genes.
Interestingly, in addition to an increase in tumor formation, proportionallymore mice from the Klf6fl/wt survival cohort had lung metastases (6/17) than fromthe KLF6 wild<type group (0/6) (Figure 2.17A). This difference is significant by Chi<Square (p=0.0453), though it is not statistically significant by Fisher’s Exact Test,given the relatively small number of mice that developed metastasis, and the smallnumber of tumor<bearing mice in the Klf6wt/wt group. Intact lungs from animals inthe survival cohort that presented with a grossly visible liver tumor were stepsectioned in 200um increments. Each step was stained with H&E and examined forthe presence of metastases. A single metastatic lung colony was found in KLF6 wild<type mice with HCC. This single colony was detected microscopically, while severalmetastases present in the Klf6fl/wt cohort were grossly visible (Figure 2.18).Quantified areas of these metastases are shown in (Figure 2.17B). This excitingfinding demonstrates that single<copy loss of Klf6 in HCC increases the metastaticburden to lung.
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Figure 2.17. SingleLcopy loss of Klf6 increases metastatic burden.A. Number of mice with lung metastases present in the populations of micewith primary HCC by gross detection.B. Quantified areas of liver metastases present in the lung. A graticule wasused to obtain the lengths of the major and minor axes of lung colonies. Areawas calculated using the formula for an ellipse, where A=πab, where a and bare representative of half the lengths of each the major and minor axes.A
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Figure 2.18. Lung metastases present in Klf6fl/wtmice are larger than Klf6wt/wt
mice. H&E stained sections of the lungs were investigated for HCC metastases.Images A, C, E and F were taken at 50X magnification. Images B and D were taken at200X magnification, of the metastases in A and C respectively. Arrowheads indicatemetastatic colonies, while asterisks indicate normal lung.A. Single metastatic nodule identified in a KLF6 wild<type mouse.B. Enlarged image of metastatic nodule in A.C. Metastasis in KLF6 heterozygous mouse.D. Enlarged image of metastatic nodule in C.E<F. Example metastasis found in KLF6 heterozygous animals
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HCCs isolated from the survival cohort of mice were assayed for expressionof markers that are associated with poor prognosis of HCC patients. Levels of α<fetoprotein (AFP) and Insulin<like growth factor 2 (IGF2) are elevated in HCCpatients and are correlated with poor prognosis (Izumi et al. 1992; Iizuka et al.2004). mRNA levels of AFP and IGF2 are increased in several of the HCCs from the
Klf6fl/wt group (Figure 2.19) when compared to the average levels of the Klf6wt/wttumors. The variance in expression in tumors from the KLF6 heterozygous group issignificantly different from those in the wild<type group for both poor<prognosisgenes (p<value<0.0001 by F<test), indicating the tumor populations are not equal.Taken together, these data indicate that single<copy loss of Klf6 results in anincrease in HCC development and metastasis, and negatively impacts tumor<freesurvival. These findings demonstrate a novel consequence of decreased KLF6activity in promoting HCC progression and lung metastasis.
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Figure 2.19. SingleLcopy loss of Klf6 results in higher expression of poorL
prognosis genes for HCC. α<fetoprotein (AFP) and Insulin<like growth factor 2(IGF2) levels were assessed by qRT<PCR in RNA derived frommouse HCC tumors. Ctvalues in each sample were normalized to β<actin as an endogenous reference. Tocalculate fold change, all samples were normalized to the average Ct value of Klf6wild<type tumors. The fold changes are plotted on a log2 scale. p<values for AFPexpression is 0.1510 and 0.0883 for IGF2 expression as determined by t<test. p<values for both genes by F<test were <0.0001.
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Materials and Methods
Cell culture, isolation of migratory subpopulations.All mouse HCC cell lines were cultured in high<glucose DMEM (LifeTechnologies) with 10% FBS and 1% Pen/Strep, termed “Growth Medium.” Allmammalian cell lines were grown at 37°C. The BL185 cell line was derived from ap53<null mouse HCC (Chen et al. 2007). BL185<M1 and BL185<I1 subpopulationswere isolated from BL185 using a transwell migration chamber, or transwellinvasion chamber (BD Biosciences 354578; 354480). BL185 cells were plated in theupper levels of each respective chamber in serum<free DMEM. Few cells migrated to10% serum in the lower chamber, but these were scraped from the membranes andplated in growth medium. BL185<M1 cells came from a migration insert whileBL185<I1 cells came from an invasion insert.DF1 chicken fibroblast cells were cultured in growth medium at 39°C. DF1cultures in 60mm dishes were transfected with 5ug of RCAS<GFP or RCAS<PyMTusing 25uL of Superfect transfection reagent (QIAGEN, 301305). DF1 cells wereincubated with transfection complexes for 3 hours at 39°C. Viral titers werecalculated using the minimum concentration of serial dilutions of viral supernatantrequired for naïve DF1 infection. Cells used in mouse experiments required adilution factor of 2x107 to be suitable for injection. Infections were confirmed byisolating genomic DNA from DF1 cells, and amplifying an RCAS virus sequence byPCR (F: CAG TCT CTC CCT AAC ATT AC; R: CTA CCT TGT GTG CTG TCG ACC).
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Infected DF1 cells were only maintained in culture for 1 month before transfectionswere repeated. Stable KLF6 knockdown cell lines were generated from lentiviral delivery ofpLKO.1 library shRNAs directed to mouse KLF6 (Thermo Scientific; shA:TRCN0000085628, shB: TRCN0000085632). Lentiviruses were produced in 293Tcells that were transfected with plasmids containing envelope glycoprotein,required packaging sequences, and pLKO.1 shRNAs. Transfections were performedusing Effectene Transfection Reagent (QIAGEN, 301425). HCC target cells wereinfected with 1 mL of lentiviral supernatant in a well of a 6<well plate using 1ug ofpolybrene. Cells were subsequently selected in 5ug/mL puromycin prior toexperimental analysis.
In vitro migration and soft agar colony analysisFor in vitro migration analysis, 2.5x104 cells were plated on a migrationinsert (BD Biosciences 354578) in serum<free DMEM. Growth Medium was platedinto the bottom of the migration chamber. After 20 hours, the cells were fixed withmethanol, and stained with Giemsa. Non<migrating cells from the top of themembrane were removed with a cotton swab. Remaining cells were counted in 5fields per membrane at 100X magnification.For soft agar colony formation experiments, a 1.4% hard agar solution wascombined with 2X DMEM with 20% FBS and 2% Pen/Strep and plated onto 100mmtissue culture plates. After hardening, 1x105 cells were mixed with equal parts of a
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0.8% soft agar solution and 2X growth media and added to the top of the hard agarlayer. After the soft agar solution hardened, 8mLs of 1X growth media was added tothe dishes, which were incubated for 2 weeks at 37°C. Colonies were counted in 20fields per plate at 100X magnification. Size exclusion was used to ensure thatcolonies had grown in the dish, and were not just cell clumps.Proliferation experiments were conducted in 96<well plates. 1000 cells wereplated in triplicate wells for each day assayed. Cell Titer 96 MTS reagent (Promega,G3580) was added to wells for 30<minute incubations. Following the incubation,absorbance was read at 490nm using a 96<well plate reader. Empty wells treatedwith an equal volume of reagent were used as a control absorbance reference.Absorbance values were averaged across the triplicate wells, and the absorbancefrom the reference was subtracted.Error bars used for graphical representation of these experiments representthe standard deviation of the dataset. Student’s t<tests were used to calculate p<values.
Gene Expression Profiling Analysis of Migratory Subpopulations by MicroarrayRNA was isolated from BL185, <M1, and –I1 cells using Trizol reagent (LifeTechnologies, 10296010). The RNA samples were labeled using the 3’ IVT ExpressKit (Affymetrix, 901228). Gene Expression profiling was conducted using GeneChipMouse Genome 430 2.0 arrays (Affymetrix, 900495). Two different RNA isolations
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were used as technical replicates. Microarray chip analysis was performed by theUMass Medical School core facility. To summarize the probe data and normalize the data, the RMA method in theAffymetrix package (Bioconductor) was used. Genes of interest for follow<up studywere those whose expression was significantly different in the M1 and I1 cells ascompared to the BL185 parent population. Significance was defined as having anadjusted p<value under 0.01 with a fold change greater than 2<fold. Bioinformaticsanalysis was performed by Lihua (Julie) Zhu (UMMS).The raw data files in addition to normalized expression data have beendeposited in the NCBI GEOArchive under the accession number GSE54757.Gene Ontology terms were determined through the use of the Gene OntologyEnrichment Analysis Software Toolkit (GOEAST) program (Zheng and Wang 2008).
Western blottingProtein lysates were generated in RIPA buffer, where concentrations werenormalized by Bradford Assay. 20ug of lysate were used for each Western blotsample. 10% acrylamide gels were used for SDS<PAGE, and subsequently blottedonto PVDF membranes. Western blots were blocked for one hour at roomtemperature in 7.5% nonfat dry milk in TBS. Antibodies for Western blotting wereused as described in Table 2.2.
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ImmunohistochemistryPortions of each tumor were fixed in formalin and embedded in paraffin.Tissue sections were deparaffinized with heat and rehydrated in decreasing alcoholconcentrations. After rehydration, antigen retrieval was performed by microwavingslides in Antigen Unmasking Solution (Vector, H<3300). Endogenous peroxidaseactivity was inactivated by adding 3% hydrogen peroxide for 10 minutes. Slideswere blocked in goat serum in PBS for one hour at room temperature. For KLF6 IHC,biotin blocking was performed prior to adding primary antibody in order to reducebackground (Vector, SP<2001).Primary antibody was added as described in Table 2.2. Biotinylated Rabbitsecondary antibody was diluted in goat serum in PBS and added to the slides for onehour at room temperature. Goat serum, secondary antibody, and developingreagents were from Vector ABC kits (PK<4001). Pigment was developed in thetissues using a NovaRed Peroxidase Substrate (Vector, SK<4800). Afterdevelopment, slides were co<stained in hematoxylin, dehydrated, and mounted.Human HCC tissue microarrays were a kind gift from David Klimstra. Alongwith human control slides, these were processed and stained for KLF6 in the samemethod described above. Samples were scored for having either positive or negativestaining for KLF6. In samples positive for KLF6, the presence was scored as beingprimarily cytoplasmic or nuclear.
KLF6 Expression in human HCC datasets
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The Oncomine database was used for KLF6 expression data in Figures 2.5Aand 2.7. The data in Figure 2.5A was derived from the Roessler Liver<2 dataset, andfeatures 220 normal liver and 225 hepatocellular carcinoma samples (Roessler et al.2010). Figure 2.7 was derived from the Wurmbach Liver dataset and features 17non<invasive and 18 invasive hepatocellular cancers (Wurmbach et al. 2007).
Gene Expression qRTJPCR analysis
 
 RNA from cell lines was isolated using Trizol, and converted to cDNA usingFirst<Strand cDNA synthesis kit (Life Technologies, 18080<051). qRT<PCR wasperformed using SYBR Green (VWR, 95072) in an ABI 7300 machine using 50ngcDNA. Primers used for analysis are listed in Table 2.3.Ct values for each sample were averaged, and normalized to β<actin Ct valuesas an endogenous reference. In each case the Comparative Ct Method was used tocalculate fold change, where fold change = 2<ΔΔCT.
Mouse breeding, tumor analysis
Klf6fl/fl mice on a C57/Bl6 background were generously provided byGenentech and obtained from Scott Friedman’s laboratory. These mice were crossedwith my RCAS<TVA HCC model to obtain AlbuminJtvJa, p53fl/fl, AlbuminJcre, KLF6fl/wtmice. These mice were crossed with AlbuminJtvJa, p53fl/fl, AlbuminJcre, KLF6wt/wtmice to obtain littermates that were either heterozygous or wild<type for Klf6 to be
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used for direct comparison. These mice were injected in the liver at 3 days old with2x106 DF1 cells producing RCAS<GFP or RCAS<PyMT virus (Chen et al. 2007). Micewere assigned to either a survival study or a timepoint study. Mice designated to thetimepoint study were sacrificed at 4.5 months of age. Mice in the survival cohortswere sacrificed before suffering was apparent as determined by my mouse protocol,or at 9 months of age, which was the predetermined study endpoint. Kaplan<Meierstatistics were performed using the Log<rank test. Tumors found in mice weremeasured in three dimensions before allocating portions for fixing in formalin orfreezing for downstream analysis.To count and measure lung metastases, FFPE lungs from each mouse with aprimary tumor were sectioned in 200um steps. A section from each step was H&Estained and examined for the presence of metastases to lung. Using an eyepiecegraticule, lung metastases were measured at their longest and shortest axes. Areasof the metastases were calculated using the formula for area of an ellipse.
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Table 2.2. Antibody conditions used for Western blotting and
immunohistochemistry.
Target Manufacturer ID number Dilution Diluent ConditionKLF6 Santa Cruz sc<7158 1:1000 5% milk in TBS Overnight at 4°CE<Cadherin BDBiosciences 610181 1:2000 5% milk in TBS Overnight at 4°CN<Cadherin BDBiosciences 610920 1:2000 5% milk in TBS Overnight at 4°CVimentin ThermoScientific MS<129<P0 1:2000 5% milk in TBS Overnight at 4°Cα<Catenin BDBiosciences 610193 1:2000 5% milk in TBS Overnight at 4°CKLF6<SV1 LifeTechnologies 39<6900 1:2000 5% milk in TBS Overnight at 4°Cβ<Actin Santa Cruz sc<1615<R 1:2000 5% milk in TBS 1 hour at 21°CKLF6 Santa Cruz sc<7158 1:250 Goat serum inPBS Overnight at 4°CKi67 Abcam ab66155 1:500 Goat serum inPBS Overnight at 4°C
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Table 2.3. Primers used for amplification of target genes by qRTLPCR.Target F Primer R Primerβ<Actin Tcctcctgagcgcaagtactct cggactcatcgtactcctgcttKLF6 Cggtatgctttcggaagtg cgcactcacacaggagaaaaAFP Cagcagcctgagagtccata ggcgatgggtgtttagaaagIGF2 Tgagaagcaccaacatcgac cttctcctccgatcctcctgDLC1 Cggccgagcctcaactc tatttctgcagcaggttcatctgAurKA Gcttctgacctgctccaagtt tcctgtgtccttctaactcccagTGFβ3 Tctccactgaggacacattga attcgacatgatccagggacID1 Gagtccatctggtccctcag gcgagatcagtgccttggID3 Cgctgaccaccctgaacac tcgacataagctcagaagggaatCdkn2c Ctccggatttccaagtttca gggggacctagagcaacttac
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DiscussionIn this work, I sought to uncover additional gene expression changes that areresponsible for HCC progression and metastasis. To do this, I used BL185, a low<migrating cell line isolated from a non<metastatic murine HCC, and migratorysubpopulations isolated from BL185, termed BL185<M1 and BL185<I1. I employedgene expression profiling of these cell lines to determine expression changes thatmay be responsible for the increased migration capacity of M1 and I1 cells.Profiling of these cells revealed several genes already known to participate intumor progression and metastasis. For example, the expression of known pro<metastatic transcription factor TWIST2 (Fang et al. 2011; Mao et al. 2012) isincreased in the migratory subpopulations. Also, transcription factors ID1<3 areincreased in the migratory subpopulations as compared to the parent line.Inhibition of ID1 and ID3 has been shown to inhibit metastasis in gastric andpancreatic cancers (Tsuchiya et al. 2005; Shuno et al. 2010), suggesting theirexpression is important for metastasis. Since these known metastatic drivers werepresent in our dataset, it suggests that my profiling approach was successful atdetecting genes important to migration or metastasis in HCC cells. The profilingdataset likely includes many more genes important to progression or metastasis,and can be interrogated further to characterize novel factors for progression andmetastasis in HCC.In this work, I demonstrate that KLF6 expression is reduced in BL185<M1and I1, correlating with an increase in cell migration. Expanding on the known role
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of KLF6 as a tumor suppressor, I found KLF6 is a suppressor of HCC progression aswell. When KLF6 knockdown is performed in the BL185 cell line, both soft agarcolony formation and migration are increased. The more transformed phenotypesdisplayed in response to KLF6 knockdown suggested that a reduction of KLF6 in
vivo may result in an increase in HCC progression. Indeed, KLF6 is not onlycommonly decreased in HCC cell lines and tumor samples as compared to normalliver, but is also decreased in HCCs with vascular invasion as compared to non<invasive tumors.Using the RCAS<TVA model of HCC, mice with single<copy loss of KLF6displayed phenotypes consistent with the in vitro data. Klf6fl/wt mice displayincreased tumorigenesis, larger metastases, and decreased tumor<free survivalcompared to Klf6wt/wt mice. Based on these results, a decrease in KLF6 seems tofacilitate earlier formation not just of primary HCC tumors, but metastases as well.Notably, only one metastatic focus was found in Klf6wt/wt mice, and it was onlyvisible upon step<sectioning, while many metastases formed in Klf6fl/wtmice weregrossly visible.At this time, the mechanism for the increase in metastasis in Klf6fl/wt mice isnot precisely known. In culture, we see an increase in HCC cell migration inresponse to KLF6 knockdown, so my hypothesis is that HCC cells with reduced KLF6display increased dissemination in vivo. Another possibility is that KLF6 levels donot affect the rate of dissemination from the primary tumor, yet the metastases aremore frequent and larger in Klf6 heterozygous HCC because of an increased capacity
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for survival in the bloodstream, or lung colonization. Indeed, the most significantpoint of disseminated cell attrition occurs after extravasation into new tissue, wheremost cells remain dormant or die instead of proliferating to form a colony (Luzzi etal. 1998). Lastly, the metastases may be larger because Klf6 heterozygous tumorcells were able to disseminate earlier compared to Klf6 wild<type tumor cells. Ifound that in 4.5 month<old Klf6 heterozygous mice, primary liver tumors werelarger than in wild<type mice. Proliferation rates of these tumors wereapproximately equal, suggesting that tumor initiation may have occurred earlier in
Klf6 heterozygous animals. This earlier initiation of Klf6 heterozygous tumors mayhave allowed for earlier dissemination and initiation of metastasis, which could leadto larger metastatic burden in animals from the survival cohort.My work is complimentary to studies performed by other groups that havedemonstrated KLF6 tumor suppression in HCC. My study corroborates the previousfinding that decreased KLF6 levels in hepatocytes results in increased tumorformation (Tarocchi et al. 2011; Vetter et al. 2012). Importantly, the previousapproaches used a carcinogen<induced model, while my study validates the findingusing a different, oncogene<induced model of HCC.One major difference between previous studies of KLF6 in HCC and my own,is that my model describes HCC formation in the background of p53 deletion, whileprevious HCC studies examined tumor development in a p53 wild<type background.Inactivation of p53 in combination with Klf6 heterozygosity may increase oraccelerate the effects seen with Klf6 heterozygosity alone. This difference may
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account for why effects on migration or metastasis were not previously detected instudies of KLF6 in HCC. In fact, previous studies have implicated a relationshipbetween p53 and KLF6. KLF6 transcriptional preferences change depending on p53status, which may be due to direct interaction between KLF6 and p53 (Rubinstein etal. 2004). Also, regulation of KLF6 levels in response to stress varies depending onthe status of p53 (Gehrau et al. 2011). The role of KLF6 in cancer, particularly HCC,is likely dependent on the status of p53.Together, these results suggest that KLF6 could function as a prognosticmarker for HCC patients, where decreased nuclear KLF6 may indicate a poorerprognosis. However, the results from a human HCC tissue microarray for KLF6demonstrate that while KLF6 was commonly decreased or mislocalized in HCC, thismisexpression did not correlate with tumor grade or patient outcomes. This result isin disagreement with previously published results describing a correlation betweenKLF6 mRNA levels and HCC tumor grade or patient survival (Tarocchi et al. 2011).This discrepancy could be explained by the isoform detection method. While SV1mRNA can be directly detected by qRT<PCR, our TMA detects all variants, includingnon<SV1 splice variants that may be contributing to cytoplasmic localization ofKLF6. Another possible explanation could reflect the sampling of the tissuemicroarray. The samples that compose the array are surgically resected samples,which are typically localized and non<metastatic. Thus, the array may be biasedagainst advanced stage disease. My hypothesis is that in a sample set includingadvanced tumors, KLF6 status may predict invasiveness or survival.
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Since the induction of metastasis in our model occurred in combination with
p53 deletion, KLF6 may be a successful prognostic marker when assessed incombination with p53 status. Inactivation of p53 is already known to correlate withpoor prognosis in HCC (Woo et al. 2011; Liu et al. 2012), and it would be interestingto investigate if its prognostic accuracy could be improved by including assessmentof KLF6 localization. However, based solely on the results of my study, KLF6localization is not a good candidate for use as a prognostic marker in HCC.Intriguingly, the major histological appearance of tumors in our study is avacuolated cytoplasm, which often represents a fatty change in HCC. Previousstudies have associated this appearance with less invasive HCC tumors (Lewis et al.2005). Both Klf6fl/wt and Klf6wt/wt tumors display equal frequencies of this histology,despite Klf6fl/wt tumors generating larger numbers of lung metastases. However inour study, tumors with this histology do form metastases to the lung. Importantly,these vacuolated cells are also present in the lung colonies, indicating these cells arecapable of metastasis.Even though the tumors in Klf6 heterozygous and wild<type mice arehistologically similar, some Klf6fl/wt tumors display increased expression of the poorprognosis markers AFP and IGF2. Increased AFP is detected in the serum of patientsfor diagnosis of HCC, but it is also increased further in the serum of patients withpoor prognosis (Izumi et al. 1992). IGF2 expression is increased in HCCs with poorprognosis as well, and is known to directly participate in HCC metastasis (Iizuka etal. 2004; Chen et al. 2009). While our survival data clearly demonstrate Klf6fl/wtmice
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have impaired survival, the increased expression of these poor prognosis markersparallels the expression of these markers in human disease.Few mechanisms are known which can contribute to the progression of HCCto invasive or metastatic disease. Here, determination of the role of KLF6 as asuppressor of HCC progression is not only important for HCC, but may be importantto several other cancers where KLF6 is also misexpressed. Further experimentationregarding the precise activities of KLF6 in HCC progression, such as gene expressionprofiling and characterization of transcriptional activity, would be an excitingavenue for research.
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CHAPTER III
KLF6 suppresses RHO family GTPase activity through transcriptional
repression of VAV3 and CDC42EP3
112
Preface
The RHO family GTPase activity assays shown in Figure 3.2 were performedby Hsiao<Chien Chu and Ya<Wen Chen.Lihua (Julie) Zhu kindly performed the bioinformatics analysis required forthe ChIP<sequencing peak calling and gene expression profiling describedthroughout this chapter and represented in Figure 3.5, Table 3.1, and Appendix B.
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IntroductionIn the previous chapter, I characterized KLF6 as a suppressor of HCC cellmigration, dissemination and tumor formation. Next, I sought to determine amechanism by which KLF6 regulates these processes. Here, we find that decreasedKLF6 levels impact the activity of RHO family GTPases, particularly CDC42, RAC1,and RHOA, providing a novel function of KLF6 in regulating RHO GTPase activity inHCC. RHO GTPases belong to the RAS superfamily, and accordingly function asmolecular switches that cycle between GDP and GTP<bound states (Hall 1998). Theexchange of GDP for GTP is promoted by RHO family guanine nucleotide exchangefactors (GEFs) (Rossman et al. 2005). Inversely, hydrolysis of GTP to GDP isfacilitated by a group of enzymes called GTPase activating proteins (GAPs)(Bernards 2003). Within Rho family GTPases, proteins are divided into subgroupsmost homologous to RHOA, most homologous to RAC1 and CDC42, and those thatlack GTPase activity (Hall 2012).When bound to GTP, RHO GTPases are in an active conformation, whichrenders them capable of signaling to many downstream effectors (Schmidt and Hall2002). Activation of these effectors impacts a variety of cell processes, includingpolarity, morphology, motility, gene expression, proliferation, and survival (Hall2012), as shown in Figure 3.1. Accordingly, increased activity of these GTPases iscommonly seen in tumors, particularly those that are invasive and metastatic (Sahaiand Marshall 2002; Hall 2012). Interestingly, inhibitory mutations in RAC1 and
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CDC42 have been shown to block RAS<mediated transformation in culture (Qiu et al.1995a; Qiu et al. 1995b; Qiu et al. 1997). Clearly, these proteins play a crucial role intransformation. In addition, RHO GTPases are known to affect the actincytoskeleton, particularly when inducing cell motility (Hall 1998). CDC42 isrequired for formation of filopodia, RAC1 for the formation of lamellipodia, andRHOA for cell contractile force (Hall 1998). Together, these proteins allow fordirectional cell movement, which is the initial step in cancer cell dissemination(Sahai and Marshall 2002; Hall 2012). In this work, we show that decreased KLF6results in altered GTPase activity in HCC cells. The activity of these GTPases isrequired for the migration induced by KLF6 knockdown.KLF6 functions as both a transcriptional activator and repressor. KLF6 is atranscriptional activator of p21 (Narla et al. 2001), TGFβ1 (Kim et al 1998), ATF3(Huang et al 2008), and E<cadherin (DiFeo et al. 2006). KLF6 is a repressor oftargets such as MDM2 (Tarocchi et al. 2011), PTTG1 (Lee et al 2010), and MMP9(Das et al. 2006). Furthermore, KLF6 has been linked to the regulation of EGFRsignaling in lung cancer cells (Sangodkar et al. 2012). Consistent with the commonmisregulation of KLF6 expression in cancers, these target genes are known to beimportant for tumor development and progression. Yet, the mechanisms by whichKLF6 inactivation contributes to HCC development and progression remain poorlyunderstood.
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Figure 3.1. RHO family GTPases are molecular switches which activate
downstream effector signaling. RHO GTPases are inactive when bound to GDP.Through interactions with GEFs, GDP is exchanged for GTP, which renders theGTPase active. In this state, the protein can signal to downstream effectors toinfluence cell processes. GAPs catalyze the hydrolysis of the GTP molecule to a GDP,returning the protein to an inactive state.
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In order to determine the transcriptional targets of KLF6 that could bedriving HCC formation and progression, I used two unbiased approaches. KLF6ChIP<sequencing and gene expression profiling of KLF6 knockdown cells wereconducted and combined to create a list of KLF6 transcriptional targets whoseexpression changed as a result of KLF6 knockdown. Among these are CDC42EP3 andVAV3, known regulators of RHO family GTPase function.VAV3, a GEF, is responsible for catalyzing the exchange of GDP for GTP onRHO family GTPases, particularly RAC1. In NIH3T3 cells, VAV3 overexpression led toincreased focus formation and cell motility (Sachdev et al. 2002). VAV3<mediatedfocus formation was dependent on RAC1, RHOA, and to a lesser extent, CDC42activity. However, cell motility was dependent on RAC1 and CDC42, but not RHOAactivity (Sachdev et al. 2002). Overexpression of VAV3 has been shown to increasecell migration through RAC1 in lymphoid, fibroblastic, vascular smooth muscle cells,and endothelial cells (Colomba et al. 2008; Brantley<Sieders et al. 2009;Toumaniantz et al. 2010). In addition to driving migration in normal cells, VAV3 hasalso been implicated in dissemination of cancer cells. VAV3 is overexpressed in 81%of breast cancers, particularly in those that were poorly differentiated (Lee et al.2008). Similarly, increased VAV3 expression is common in migratory and invasiveprostate and gastric cancers. Knockdown of VAV3 in these cancer cell types reducescell migration and invasion (Lin et al. 2012a; Tan et al. 2013).CDC42EP3, or CDC42 effector protein 3, is also called BORG2, which standsfor Binder of RHO GTPases. CDC423EP3 contains a CDC42/RAC Interactive Binding
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(CRIB) domain, through which it binds to TC10 and CDC42 in a GTP<dependentmanner (Joberty et al. 1999). Overexpression of CDC42EP3 in NIH3T3 fibroblastsinduced pseudopodia formation. Importantly, when the overexpression wasperformed in combination with a dominant<negative CDC42 or using a CRIB mutant,pseudopodia did not form (Joberty et al. 1999). Similarly, overexpression ofCDC42EP family members in keratinocytes resulted in increased stress fiberformation and loss of E<Cadherin from adherens junctions (Hirsch et al. 2001).These data indicate that CDC42EP3 functions downstream of active CDC42 toimpact cell shape and motility, though its precise activities are unknown.I found that HCC cell migration stimulated by KLF6 inactivation is dependenton VAV3 and CDC42EP3 activity. As these proteins are known to mediate theactivities of RHO family GTPases, I have found a novel function of KLF6 in regulatingRHO GTPase activity in HCC cells.
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Results
Knockdown of KLF6 impacts activation of RAC1 and CDC42I sought to characterize the mechanism of KLF6<mediated suppression ofmigration and dissemination in HCC. In a previous study on the effects of KLF4 inour HCC cell lines, enhanced migration was dependent on CDC42 activity (Lin et al.2012b). I hypothesized that KLF6 knockdown was also impacting the activationstatus of small family GTPases. CDC42, RAC1, and RHOA activity were measured asrepresentatives of their respective GTPase families. Upon KLF6 knockdown inBL185 cells, protein levels of CDC42 and RAC1 were similar between knockdownand control cells. However, levels of RHOA are reduced by almost half in cells withKLF6 knockdown when compared to control cells infected with GFP shRNA (Figure3.2A). Assessment of the GTP<bound status of these proteins reveals that there is anincrease the amount of active CDC42 and RAC1 upon KLF6 knockdown, while thereis a slight decrease in RHOA activation (Figure 3.2B).These data demonstrate that KLF6 is an upstream regulator of RHO familyGTPase activity. Based on known roles for RHO GTPases, I hypothesized that thealtered activity of these proteins was responsible for the effects seen upon KLF6knockdown in HCC cells, namely increased migration.
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Figure 3.2. KLF6 knockdown results in higher RAC1 and CDC42 activity, and
lower RHOA activity.A. Total protein input of RAC1, CDC42, and RHOA in BL185 cells infected withKLF6 shRNA or GFP shRNA as a control. Graph shown is an average of fourexperiments.B. Relative amounts of RAC1, CDC42, and RHOA in the active conformation inKLF6 knockdown and shGFP cells. p<values as determined by t<test are 0.043for CDC42, 0.062 for RAC1, and 0.020 for RHOA. Graph shown is an averageof four experiments.
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RAC1 activity is required for HCCmigration downstream of KLF6 knockdown.The altered activation of CDC42, RAC1, and RHOA could be responsible forthe increase in migration seen in response to KLF6 knockdown. To determine if anyof these family members impact HCC cell migration, BL185 cells with KLF6 shRNAwere infected with a second shRNA targeting GFP, CDC42, RAC1, or RHOA. Thesecells were assessed for knockdown of the appropriate protein by Western blot(Figure 3.3A). These cells were subsequently assessed for migration ability. Asdescribed previously, addition of KLF6 shRNA to BL185 cells results in increasedmigration as compared to control cells (Figure 2.8). The additional knockdown ofeither CDC42 or RHOA did not significantly alter the amount of cell migration.However, RAC1 knockdown in these cells does negatively impact migration (Figure3.3B). This result suggests that RAC1 is required for KLF6 knockdown<inducedmigration.
121
Figure 3.3. Knockdown of RHO GTPases demonstrates that RAC1 is required
for mediating migration downstream of KLF6.A. Western blots of CDC42, RAC1, and RHOA in KLF6 knockdown cells thathave been subsequently infected with shRNA targeting GFP, CDC42,RAC1, or RHOA. β<Actin was used as a loading control. shRNA infectionswere performed twice.B. Transwell migration assay of BL185 cells infected with shGFP, or shKLF6.Those infected with shKLF6 were also infected with shGFP, shCDC42,shRAC1, or shRHOA and assayed for migration. p<values as determined byt<test are 0.0492 and 0.0008 for the KLF6 and RAC1 knockdown cells,respectively. Shown is the average of four experiments, where themigration activity of shGFP cells is normalized to 100%.
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I sought to determine if chemical inhibition of RAC1 would also reduce KLF6knockdown<induced migration, to validate the effects seen by shRNA infection. Todo this, KLF6 knockdown cells were treated with 50uM RAC1 inhibitor, NSC23766.RAC1 inhibition alone in shKLF6, shGFP cells reduced migration by half (Figure 3.4),concordant with the results seen with shRNA<mediated knockdown of RAC1 (Figure3.3). This result indicates that RAC1 activity is required for the migration that isinduced by KLF6 knockdown.While CDC42 knockdown alone did not have an effect on HCC cell migration,we sought to determine if CDC42 knockdown would cooperate with RAC1 inhibitionto reduce HCC cell migration further. We found that in cells with both KLF6 andCDC42 knockdown, RAC1 inhibition resulted in a greater decrease in HCC cellmigration (Figure 3.4). While RAC1 inhibition results in more significant effect onHCC cell migration than CDC42 knockdown alone, the combination of RAC1 andCDC42 inhibition has an additive effect to inhibit cell migration, indicating thatCDC42 is also contributing to migration regulation in HCC cells.
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Figure 3.4. Cells with KLF6 knockdown have impaired migration with RAC
inhibition, and this is further decreased with CDC42 knockdown. Cells withKLF6 knockdown were treated with 50uM RAC1 inhibitor NSC23766 upon platinginto a transwell migration assay. Cells that migrated through the membrane werecounted at 100X magnification. Differences between control and RAC1 inhibitor<treated cells resulted in p<values of 0.028 and 0.0070 in shGFP and shCDC42 cells,respectively. Between RAC1 inhibitor<treated groups, the addition of shCDC42yields a difference with a p<value of 0.037. Shown is a representative replicate ofthree experiments.
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Identification of KLF6 transcriptional targets using a combination of ChIPL
sequencing and gene expression profilingSince KLF6 knockdown results in altered GTP<bound states of CDC42, RAC1,and RHOA, we hypothesized that KLF6 functions as a transcription factor for aregulator of GTPase activity. We therefore sought to determine the transcriptionaltargets of KLF6 in HCC and which of these targets could be impacting HCCprogression and GTPase activity.To identify transcriptional targets of KLF6 in HCC, we performed two globalanalyses of KLF6 target genes: gene expression profiling, and Chromatinimmunoprecipitation<sequencing (ChIP<seq). Gene expression profiling wasperformed on cells with KLF6 knockdown compared to cells with a control infectionusing a GFP<targeting shRNA in order to identify genes whose expression changedupon KLF6 knockdown. ChIP<sequencing determined the binding locations of KLF6throughout the genome in HCC cells. I hypothesized that establishing the overlap ofgenes between these datasets would enrich for direct transcriptional KLF6 targetgenes that may be important for regulating the effects seen in response to KLF6knockdown.Gene expression profiling was performed on KLF6 knockdown cells using awhole mouse genome microarray chip. Three sets of infections were performed andanalyzed as biological replicates. This analysis resulted in approximately 600 geneswith a 1.5<fold or greater fold change and a p<value under 0.01. Target genes fromthe profiling experiment result in enriched GO terms such as Angiogenesis (p<
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value=0.0164), Cell Adhesion (p<value=0.0379), and Cell Proliferation (p<value=3.54x10<4). Importantly, KLF6 was detected as being decreased in ourmicroarray analysis, as these cells are infected with KLF6<targeting shRNA.Additional targets of interest include Notch signaling components JAG1 and RBPJ,and VEGFC, all of which are increased upon KLF6 knockdown. The gene expressionprofiling datasets for the HCC subpopulations and KLF6 knockdown cells share 75genes in common. Notable genes on the overlap list include Jag1, Dlc1, Id2, and
Twist2.To perform ChIP<sequencing, a cDNA encoding a V5 epitope<tagged versionof the full<length form of KLF6 was expressed in BL185 cells. Chromatinimmunoprecipitation was then performed with a V5<targeting antibody. Twoseparate libraries were isolated for sequencing, and were compared to inputcontrols. ChIP peaks that were enriched in the KLF6 IP libraries compared to theinput libraries were called and annotated to the gene with the nearesttranscriptional start site.The ChIP<seq dataset demonstrated that KLF6 binding is primarily locatednear transcriptional start sites (TSS) (Figure 3.5A), though binding also occurred atdistant sites, both upstream and downstream from a TSS. The location of KLF6binding did not correlate with whether the target gene had increased or decreasedexpression in response to KLF6 knockdown. Using a separate ChIP library than wasused for deep sequencing, several peaks called in our dataset were validated byChIP<PCR (Figure 3.5B). The ability to amplify these regions in a separate KLF6 ChIP
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indicates that our deep sequencing experiment recognized valid KLF6 binding sites.As a negative control, a gene desert region was amplified, and not detected in ourKLF6<IP sample. This indicates that our IP did not enrich for all genomic DNA, andsupports the specificity of the identified ChIP peaks.
127
Figure 3.5. Transcriptional targets of KLF6 were identified by ChIPL
sequencing.A. A density plot shows the number of peaks that fall at noted distances fromtranscriptional start sites (TSS), which are set to zero.B. Examples of ChIP peaks identified in the ChIP<seq experiment, validated byChIP<PCR. The library used for validation was from a separate chromatinisolation and immunoprecipitation experiment than the libraries used fordeep sequencing. Here, the IPs performed are listed on the top: V5 IP in cellstransfected with either V5<tagged KLF6 or LacZ, or Rabbit IgG IP (Rb IgG).The “No Template” sample served as a PCR negative control. The Inputsamples are for the V5<tagged KLF6 and LacZ transfected samples,respectively.A
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The intersection between the ChIP<seq and profiling experiments wasdetected to find common targets between both datasets. Performing both of theseanalyses provided us with a set of genes that are putative direct KLF6transcriptional targets. Genes whose expression increased or decreased in responseto KLF6 knockdown are about equally represented (Table 3.1). Importantly, apublished transcriptional target of KLF6, E<Cadherin (CDH1), was detected in ourprofiling and ChIP<seq studies. The finding that KLF6 directly binds near the E<Cadherin TSS, and that it is decreased in response to KLF6 knockdown serves as aninternal validation that our study is detecting genuine KLF6 target genes.Interestingly, the binding sites for many of the putative KLF6 target geneswere not only located proximally to transcriptional start sites, but also within thegene and downstream. This suggests that KLF6 may be regulating gene expressionfrom distant sites, not just from proximal promoters.Using this list of KLF6 target genes in HCC, we chose to examine which ofthese expression changes were responsible for the effects that occur downstream ofKLF6 knockdown. In particular, given the connection between cell migration andtumor metastasis, we were interested in genes that might mediate KLF6’s regulationof HCC cell migration.
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Table 3.1. Transcriptional targets of KLF6 as detected by ChIPLsequencing and
gene expression profiling of KLF6 knockdown cells.
Gene ID Chromosome Peak Start Peak End
Binding
Location
Fold Change
(log2)
ENPP2 15 54803450 54803757 upstream 2.072589649
CAR8 4 8145255 8145577 Intron 1.803000883
LILRB4 10 51135250 51135606 upstream 1.530690933
ANK2 3 126876596 126876894 Intron 1.516568098
CLDN1 16 26254098 26254460 downstream 1.334778266
SEMA4A 3 88266618 88266868 upstream 1.113849616
BTBD11 10 84998171 84998559 Intron 1.040213397
GPR116 17 43555305 43555509 Intron 0.981431899
RPS6KA6 X 108530052 108530405 Intron 0.980977038
PTGER4 13 5229494 5230260 upstream 0.973715479
CDC42EP3 17 79694967 79695224 downstream 0.936901219
GFRA1 19 58533225 58533645 upstream 0.932708065
LRCH2 X 144002098 144002543 upstream 0.89374528
HAS2 15 56275124 56275624 downstream 0.874945939
PDZRN3 6 101167668 101167902 Intron 0.864179566
ST3GAL1 15 67284287 67284778 upstream 0.818984451
FLRT2 12 96990500 96990773 Intron 0.767922281
VEGFC 8 55264906 55265248 Intron 0.763817576
SLC4A7 14 15506611 15507331 upstream 0.733950487
VAV3 3 109181903 109182224 Intron 0.714780465
ZFHX4 3 5262877 5263151 Intron 0.707143135
GJA1 10 56115883 56116235 downstream 0.691949349
JAG1 2 136867703 136868005 downstream 0.64423835
MREG 1 72208117 72208319 Intron 0.642418158
PPP3CA 3 136365892 136366269 Intron 0.638465421
OSMR 15 6926550 6926939 upstream 0.634226854
FAM71F1 6 29276886 29277280 Intron/Exon 0.597405284
RBPJ 6 45892447 45892829 downstream 0.585798883
RBPJ 5 54005867 54006240 Intron 0.585798883
MAPRE2 18 23756837 23757250 upstream Q0.586599061
FAM19A5 15 87798350 87798623 downstream Q0.589000873
RHOB 12 8537505 8537813 upstream Q0.591417425
KLF4 4 55550029 55550445 upstream Q0.605786332
EPB4.1L5 1 121619152 121619464 upstream Q0.613637985
CCDC68 18 70026691 70027011 upstream Q0.623281785
DMRT2 19 26016534 26017138 downstream Q0.631332278
ARHGEF16 4 153688134 153688328 upstream Q0.658444838
SPIRE1 18 67785189 67785793 upstream Q0.671742014
HMGCR 13 97486685 97486961 upstream Q0.688581361
B4GALT6 18 20892660 20893030 Intron Q0.703995706
PLOD2 9 92796968 92797282 downstream Q0.732403504
BMP7 2 172665995 172666423 downstream Q0.793876593
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EIF4E3 6 99584734 99584987 Intron Q0.799969177
CDH1 8 109126915 109127149 upstream Q0.805352699
IFI204 1 175739583 175739877 upstream Q0.809598051
KLF6 13 5863651 5864920 Intron/Exon Q0.824362282
13 5860546 5861201 Intron/Exon Q0.824362282
13 5865504 5866305 Intron/Exon Q0.824362282
13 5669699 5669426 upstream Q0.824362282
CDKN2D 9 123844234 123844559 downstream Q0.832964627
4631416L12Rik 3 61963003 61963281 upstream Q0.837324781
ITGB6 2 60513302 60513877 Intron Q0.900977262
ANXA10 8 64719939 64720559 upstream Q0.917630286
GGH 4 20110191 20110425 downstream Q0.954220703
MEGF9 4 70179409 70179915 Intron Q0.99976632
RAB28 5 41840319 41840800 downstream Q1.062217563
LYRM2 4 32898800 32899149 downstream Q1.218567249
ALG14 3 121002359 121002723 Intron Q1.660480034
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GenomeLwide target gene analysis of KLF6 reveals KLF6 is a repressor of
CDC42EP3 and VAV3.Our experiments found that single<copy loss of Klf6 resulted in HCCprogression and dissemination, while KLF6 knockdown resulted in increased in
vitromigration. This increased migration was dependent on altered GTPase activity,primarily RAC1. We were interested in finding KLF6 transcriptional targets that mayimpact migration and/or GTPase activity. Two putative KLF6 targets detected in thisstudy were CDC42EP3 and VAV3. CDC42EP3 is known to bind to small GTPases andimpact migration in fibroblasts (Joberty et al. 1999; Hirsch et al. 2001). VAV3 is aGEF for several small GTPases, including RAC1, and is known to drive migration inseveral cell types (Sachdev et al. 2002; Toumaniantz et al. 2010; Lin et al. 2012a;Tan et al. 2013). According to our profiling experiments in KLF6 knockdown cells,CDC42EP3 and VAV3 message levels are increased in cells with KLF6 knockdown(Table 3.1). Indeed, validation of this result by qRT<PCR and Western blotdemonstrates that CDC42EP3 and VAV3 expression are increased in KLF6knockdown cells at both the message level (Figure 3.6A) and the protein level(Figure 3.6B). KLF6 binds directly downstream of CDC42EP3, and within the VAV3gene, indicating that KLF6 is likely directly repressing transcription of these mRNAs(Figure 3.5B).
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Figure 3.6. CDC42EP3 and VAV3 expression is increased in response to KLF6
knockdown.A. qRT<PCR of CDC42EP3 and VAV3 in cells with KLF6 knockdown. Foldchange was calculated by normalizing Ct values of the shKLF6 sample to thatof the shGFP sample. β<Actin was used as an endogenous reference for allsamples.B. Western blot of CDC42EP3 and VAV3 in KLF6 knockdown cells ascompared to an shGFP control. β<Actin was used as a loading control.
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In the previous chapter, human HCC cell lines were shown to have lowerlevels of KLF6 than an immortalized hepatocyte cell line, Thle2 (Figure 2.6A). Inthese same cell lines, CDC42EP3 and VAV3 levels are increased as compared to theThle2 line (Figure 3.7A). In these human HCC cell lines, there is a correlationbetween reduced KLF6 expression and increased CDC42EP3 and VAV3 expression,which is to be expected based on our finding that KLF6 is a repressor of these genes.In the tumors generated in our mouse study, VAV3 is increased at themessage level in mice with single<copy Klf6 loss compared to Klf6 wild<type mice.However, CDC42EP3 expression is not significantly changed at the message levelbetween these tumor groups (Figure 3.7B). It is likely that there are other factorsinvolved in the regulation of these genes that are currently unclear. An additionalpossibility is that CDC42EP3 levels may only change upon a more complete deletionof Klf6.
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Figure 3.7. CDC42EP3 and VAV3 are deregulated in HCC.A. Western blot of CDC42EP3 and VAV3 in human HCC cell lines, with theimmortalized hepatocyte cell line Thle2 as a control. β<Actin was used asa loading control.B. qRT<PCR of CDC42EP3 and VAV3 in HCCs derived from Klf6wt/wt or
Klf6fl/wtmice. Ct values of each gene were averaged and normalized to β<Actin as an endogenous reference. Samples were normalized to theaverage Ct value from Klf6wt/wt tumors in order to calculate fold change.
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CDC42EP3 and VAV3 impact migration in HCC cells.Since CDC42EP3 and VAV3 protein levels are increased in response to KLF6knockdown, we sought to determine if these proteins were responsible for theincrease in migration that is seen upon KLF6 knockdown. Two siRNAs targetingCDC42EP3 were transfected into cells infected with either GFP or KLF6<targetingshRNAs, and assayed for CDC42EP3 expression by Western blot (Figure 3.8A).When a migration assay using these cells was performed, KLF6 knockdownincreased the level of migration, as expected. This increase in migration alsocorresponded to an increase in CDC42EP3 levels (Figure 3.8A). However, whenCDC42EP3 and KLF6 knockdown were combined, the level of migration decreasedto the same level seen in cells with a control infection (Figure 3.8B). This resultindicates that CDC42EP3 is required for KLF6 knockdown<induced migration, andidentifies CDC42EP3 as a novel regulator of HCC cell migration.
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Figure 3.8. CDC42EP3 is required for migration downstream of KLF6.A. CDC42EP3Western blot of cells containing GFP or KLF6<targetingshRNAs with addition of CDC42EP3<targeting siRNAs. β<Actin was usedas a loading control. siRNA<mediated knockdown was performed 3 times.B. Transwell migration assay of cells containing GFP or KLF6<targetingshRNAs with addition of CDC42EP3<targeting siRNAs. Migrating cellswere counted at 100X magnification. p<values as calculated by t<test, are0.0113 for siRNA 1, and 0.0252 for siRNA 2. The p<value between the GFPcontrol and KLF6 knockdown is 0.0184. GFP control cells transfectedwith CDC42EP3 siRNAs have p<values of 0.1218 and 0.0130, respectively.Shown is a representative experiment of four replicates, with the numberof migrating control cells normalized to 100%.
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To determine if VAV3 is important for migration downstream of KLF6, VAV3<targeting shRNAs were added to cells with KLF6 knockdown. As a result, VAV3protein levels are depleted when compared to an empty vector control (Figure3.9A). Cells with both KLF6 and VAV3 knockdown exhibit reduced levels ofmigration compared to cells with KLF6 knockdown alone. This suggests that VAV3activity is required for the migration induced by KLF6 knockdown (Figure 3.9B).Here, we demonstrate a novel mechanism for increased migrationdownstream of KLF6 knockdown, detailed in Figure 3.10.
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Figure 3.9. VAV3 is required for migration downstream of KLF6.A. Western blot depicting VAV3 knockdown in KLF6 knockdown cells. β<actinwas used as a loading control. pGIPZ represents cells infected with an emptyvector control. The arrow denotes VAV3. VAV3 knockdown was performedtwice.B. Transwell migration assay of control cells infected with shGFP and KLF6knockdown cells that have additionally been infected with an empty vectorcontrol, or VAV3<targeting shRNAs. Migrating cells were counted at 100Xmagnification. p<values, as determined by t<test, are 0.0119 for shVAV3 A,and 0.0204 for shRNA B. Shown is a representative graph of two replicatesperformed for each set of VAV3 knockdown cell lines.
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Figure 3.10. A novel KLF6LRHO GTPase axis regulates cell migration and HCC
dissemination in vivo.A. KLF6 is a repressor of Vav3 and Cdc42ep3 transcription. When KLF6 isexpressed, VAV3 and CDC42EP3 levels are low, which results inproportionally higher levels of RAC1 in the GDP<bound, inactiveconformation. In this state, cell migration levels are low.B. When KLF6 expression is decreased, expression of Vav3 and Cdc42ep3 is nolonger repressed, and their expression level increases. Increased VAV3expression leads to proportionally higher levels of RAC1<GTP, which isfunctionally active. RAC1<GTP can then signal to its downstream effectors toinfluence migration. CDC42EP3 can additionally signal to effectorsdownstream to increase cell migration.A
B
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Materials and Methods
Small GTPase Activity AssayCell lysates from BL185 cells containing GFP or KLF6<targeting shRNA wereincubated with beads conjugated with glutathione S<transferase (GST)<PAK1 orGST<RBD. PAK1 interacts with active CDC42 and RAC1, while RBD interacts withactive Rho. Beads were then eluted to obtain the proteins bound to the GSTconstructs. Bound lysates were analyzed by Western blot for RHOA (Millipore 05<778), CDC42 (Millipore, 07<1466), and RAC1 (Millipore, 05<389). Relative intensityof Western blot bands was calculated using ImageJ.
Cell CultureStable knockdown of RAC1, CDC42, and RHOA was established throughlentiviral infection of shRNAs from the pLKO.1 library. The shRNAs used to targetRAC1, CDC42, and RHOA were TRCN0000310888, TRCN0000331498, andTRCN0000068200, respectively. A plasmid with shRNA targeting GFP was also usedas a control. VAV3 knockdown was obtained through lentiviral delivery of shRNAtargeting murine VAV3. Plasmids containing shRNAs were obtained from the pGIPZshRNA library. Clones used for knockdown were V3LMM_425535 andV3LMM_425534. An empty pGIPZ vector was used as a control. Two sets ofinfections were performed for validation of migration effects. Lentivirus wasproduced in 293T cells and added to BL185 cells infected with shRNA targeting
141
KLF6, as described in Chapter II. Since cells were already puromycin resistant at thetime of the second infection, there was no drug selection period before cells wereassayed for knockdown by Western blot.The inhibitor to RAC1, NSC23766 (Millipore, 553502) was solubilized inwater and filter sterilized. Inhibitor was added to cells as they were plated in atranswell migration chamber to a final concentration of 50uM. The migration assaywas then completed as described below.Knockdown of CDC42EP3 was obtained through transfection of CDC42EP3<targeting siRNA. The siRNAs targeting mouse CDC42EP3 transcript are MissionsiRNAs (Sigma) with IDs Mm01_00059270, and Mm01_00059271. Transfectionswere performed using Lipofectamine 2000 reagent (Life Technologies, 11668027).BL185 cells that were infected with shGFP or shKLF6 were transfected with siRNAat a final concentration of 500pM with 10uL of Lipofectamine 2000 reagent in a60mm plate. As determined by Western blot, cells transfected with CDC42EP3<targeting siRNA had knockdown at 24 and 48 hours post<transfection, but thisknockdown was gone by 72 hours.
In vitro migration analysisFor in vitro migration assays, 2.5x104 cells were plated on a migration insert(BD Biosciences 354578) in serum<free DMEM. Growth medium was plated into thebottom of the migration chamber. After 20 hours, the cells were fixed withmethanol, and non<migrating cells were removed from the membrane with a cotton
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swab. Remaining cells, which had passed through the membrane, were stained withGiemsa. Cells were counted in 5 fields per membrane at 100X magnification.Error bars used for graphical representation of these experiments representthe standard deviation of the dataset. Student’s t<tests were used to calculate p<values.
ChIPJSequencingCells for ChIP were transfected with pcDNA3.1 construct containing KLF6<V5or LacZ<V5. Cells were fixed in 1% formaldehyde for 10 minutes at roomtemperature. This crosslinking reaction was inhibited with the addition of glycine.Nuclei were isolated from crosslinked cells per the provided protocol in theSimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling, 9002). Chromatin withinintact nuclei was digested with 2.5uL of micrococcal nuclease for 20 minutes at37°C. Nuclei were lysed by sonication for three 20<second pulses. These chromatinlysates were clarified by centrifugation at 10,000rpm for 10 minutes at 4°C.35ug of cross<linked chromatin was pre<cleared in protein G beads for onehour at 4°C. After pre<clearing, either 10uL V5 antibody (Abcam, 9116) or RabbitIgG were added to the pre<cleared chromatin. Antibody<chromatin mixtures wereplaced on a shaker at 4°C overnight. The next morning, 30uL of protein G beads,premixed with salmon sperm DNA, were added to each chromatin sample. Thesewere returned to the shaker at 4°C for 5 hours.
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Beads were then washed in salt buffers included in the SimpleChIPEnzymatic Chromatin IP Kit. Samples were washed four times, three in low<saltbuffer, and the last wash in a high<salt buffer. Beads were eluted at 65°C for 30minutes. Eluent from the beads was digested with proteinase K for 2 hours at 65°Cto remove residual protein. DNA remaining in the sample was purified by column.Following isolation of immunoprecipitated DNA, samples were prepared fordeep sequencing on the Illumina platform. Beginning with 50ng of DNA for bothinput and KLF6 immunoprecipitation samples, fragments were blunt<ended(Epicentre, ER0720). Blunt fragments were cleaned in a column, and A<tails wereadded using Exo<Minus Klenow Polymerase (Epicentre, KL11250). IlluminaGenomic DNA Adapters could then be added to our library DNA. These adapterswere ligated to the A<tailed DNA using the Fast<Link Kit (Epicentre, LK11025).These fragments were then isolated and column cleaned using a MinElute ColumnKit (QIAGEN, 28004).Following the ligation of the adapter sequences to the library DNA, librarieswere amplified by PCR twice using Solexa Genomic Illumina Primers 1.1 and 1.2,with Stratagene PfuUltra II Fusion HS DNA Polymerase (600670) as described in themanufacturer’s protocol. The PCR was performed for 18 cycles. After the first PCR,the PCR product was run on a 2% agarose gel, which was subsequently cut toextract the smear of DNA products from 150<500 basepairs. Gel extraction wasperformed with the QIAquick Gel Extraction Kit (QIAGEN, 28706), and DNA waseluted into a volume of 30uL of EB buffer for each sample. This size<selected PCR
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product was used as the template for the second round of PCR, which was repeatedusing the same conditions as the first.Libraries were sequenced on the Illumina platform using a single<end, long76<basepair read. Sequence reads were mapped to the mm9 genome using theIllumina Genome Analyzer Pipeline. Reads that were uniquely mapped with two orfewer mismatches were retained for peak detection. Peak detection was conductedusing the MACS 1.3.6 algorithm. Enriched peaks in the KLF6 IP sample weredetermined in relation to the total input sample. Peak calling for the ChIP<sequencing experiment was kindly performed by Lihua (Julie) Zhu (UMMS).ChIP<sequencing raw files and annotated peaks are accessible in theGEOArchive under accession GSE54763.
Gene Expression ProfilingThree sets of KLF6 shRNA and shGFP infections were performed in BL185cells. RNA was isolated from the three knockdown lines and respective controlsusing TRIzol reagent (Life Technologies, 10296010). The RNA samples were labeledusing the 3’ IVT Express Kit (Affymetrix, 901228). Gene Expression profiling wasconducted using GeneChip Mouse Genome 430 2.0 arrays (Affymetrix, 900495) atthe Memorial Sloan Kettering Cancer Center.  To summarize the probe data and to normalize, the RMA method in theAffymetrix package (Bioconductor) was used. Genes of interest for follow<up studywere those whose expression was significantly different in all of the KLF6
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knockdown lines when compared to the infection controls. Significance was definedas having an adjusted p<value less than 0.01 with a fold change greater than 1.5.Analysis of the gene expression profiling was performed by Lihua (Julie) Zhu(UMMS).The raw data files in addition to normalized expression data has beendeposited in GEOArchive under the accession number GSE54762.
Gene Expression by qRTJPCRRNA from cell lines was isolated using TRIzol, and converted to cDNA usingFirst<Strand cDNA synthesis kit (Life Technologies, 18080<051). qRT<PCR wasperformed using SYBR Green (VWR, 95072) in an ABI 7300 machine using 50ngcDNA per reaction. Amplification of murine VAV3 was performed with forwardprimer ATT CCA AAG GTA TCG CAG CA, and reverse primer GAA GGA GAT CAA CCTGAG GC. CDC42EP3 was amplified with forward primer CCT TCC ACA GCT CAG AGAAA and reverse primer GCA CCA GCG AGG ACT GTT. β<Actin message was amplifiedas an endogenous reference using forward primer TCC TCC TGA GCG CAA GTA CTCT and reverse primer CGG ACT CAT CGT ACT CCT GCT T.Ct values for each sample were averaged and normalized to β<Actin Ct valuesas an endogenous reference. In each case the Comparative Ct Method was used tocalculate fold change, where fold change = 2<ΔΔCT.
Western blotting
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Protein lysates were generated in RIPA buffer and concentrations weredetermined and normalized by Bradford Assay for loading. 20ug of lysate were usedper lane. 10% acrylamide gels were used for SDS<PAGE, and subsequentlytransferred onto PVDF. Membranes were blocked for one hour at room temperaturein 7.5% nonfat dry milk in TBS. Antibodies for Western blotting were used asdescribed in Table 3.2.
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Table 3.2. Antibodies and conditions used for Western blotting.
 
Target Manufacturer ID number Dilution Diluent ConditionKLF6 Santa Cruz sc<7158 1:1000 5% milk in TBS Overnight at 4°CRHOA Santa Cruz sc<418 1:1000 5% milk in TBS Overnight at 4°CRAC1 Upstate 05<389 1:2000 5% milk in TBS Overnight at 4°CCDC42 Santa Cruz sc<8401 1:1000 5% milk in TBS Overnight at 4°CVAV3 Bioss bs<4286R 1:2000 5% milk in TBS Overnight at 4°CCDC42EP3 Bethyl A301<723 1:5000 5% milk in TBS Overnight at 4°Cβ<Actin Santa Cruz sc<1615<R 1:2000 5% milk in TBS 1 hour at 21°C
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Discussion
We sought to determine the mechanism by which KLF6 knockdown triggeredan increase in HCC cell migration, as this mechanism may be crucial tounderstanding KLF6’s impact on tumor formation and metastasis. An investigationinto the activation status of RHO family GTPases found that RAC1 and CDC42activity were increased upon KLF6 knockdown, while RHOA activity was decreased.Our experiments demonstrate that RAC1 activity is required for the increasein migration seen upon KLF6 knockdown. While RAC1 seems to be the primarymediator of this effect, a combination of CDC42 knockdown and RAC1 inhibitortreatment resulted in greater migration impairment than treating cells with RAC1inhibitor alone. This result suggests that CDC42 and RAC1 may be cooperating toimpact HCC migration downstream of KLF6.Since KLF6 is a transcription factor, we hypothesized that a transcriptionaltarget of KLF6 was responsible for the altered GTPase activity seen upon KLF6knockdown. To investigate such targets, we conducted gene expression profilingusing KLF6 knockdown cells in order to find gene expression changes that occurupon KLF6 loss. These changes may mimic those that occur upon decreased KLF6 in
vivo. Since gene expression profiling would likely provide a number of targets thatwere not due to direct impact of KLF6 knockdown, we also performed ChIP<sequencing using full<length KLF6. Together, these strategies generated a list ofgenes whose expression is affected by decreased KLF6, yet also have direct KLF6
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binding in proximity of the gene’s TSS. Our hypothesis was that this strategy wouldenrich for genes important to mediating the in vivo effects of decreased KLF6activity.Our strategies revealed that KLF6 was bound to a number of locations on thegenome, including the published KLF6 target, E<Cadherin (DiFeo et al. 2006). Theeffects we see in vitro and in vivo in response to decreased KLF6 levels are due, atleast in part, to the misexpression of these target genes. Two such genes are
Cdc42ep3 and Vav3. Expression of these genes is increased in response to KLF6knockdown, suggesting that KLF6 normally acts to repress their expression. Indeed,KLF6 was found to bind to the genomic loci of Cdc42ep3 and Vav3, indicating theirrepression by KLF6 is direct. While increased expression of VAV3 has previouslybeen shown to drive cell migration and metastasis (Sachdev et al. 2002; Lin et al.2012a; Tan et al. 2013), our study is the first to describe its increased activity inHCC. CDC42EP3 has also been shown to drive cell migration, yet it has never beenassociated with cancer cell migration. Here, we show that these two proteins arerequired for mediating migration downstream of KLF6 knockdown, as diagrammedin Figure 3.10.What role CDC42EP3 is playing in the cell is still unclear, but based on itsknown role in binding to active GTPases, it may be mediating the effects of increasedRAC1 or CDC42 activity. The increase in VAV3 expression in response to KLF6knockdown is a likely contributor to the increase in GTP<bound RAC1 and CDC42that occurs upon KLF6 knockdown. Thus, KLF6 suppresses migration via the
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repression of a RHO GTPase signaling axis, which is mediated in part through a RHOGEF, VAV3, and a GTPase effector protein, CDC42EP3.While our experiments demonstrate that RAC1 is the primary mediator ofKLF6 knockdown<induced migration, we have not ruled out the potentialimportance of decreased RHOA activity in these cells. Aside from decreased RHOAactivity, RHOA is also decreased at the protein level upon KLF6 knockdown. WhileRHOA was not detected in my transcriptional profiling analyses, these experimentsdid determine that KLF6 is a direct transcriptional repressor of RHOB. Whileknockdown of RHOA or RHOB did not affect HCC cell migration, this does not ruleout their importance downstream of KLF6 in HCC.Impaired KLF6 activity is important to cancers other than HCC, includingbreast and prostate (Narla et al. 2001; Ito et al. 2004; Hatami et al. 2013). In thesecancers, KLF6 has been shown to impact a host of cell processes, includingproliferation, apoptosis, survival, and migration (DiFeo et al. 2009). Here, we showthat decreased KLF6 results in an increase of active RAC1 and CDC42, which impactmany cellular processes themselves (Sahai and Marshall 2002; Hall 2012).Potentially, the effects seen upon KLF6 knockdown in other cancers are alsomediated through increased activity of RHO family GTPases. Investigating thispossibility may be an interesting avenue for research, and could provide moreinsights into the mechanism of KLF6<mediated tumor and metastasis suppression.Additionally, such work could reveal new opportunities for drug targetingdownstream of KLF6 inactivation.
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Our studies implicate RAC1 as a primary driver of HCC cell migrationdownstream of KLF6 knockdown. Excitingly, there are several chemical inhibitors ofRAC1 that impair its activity. Inhibition of RAC1 may be a potential therapeuticstrategy for tumors with low KLF6 activity, as this may inhibit invasion andmetastasis in these tumors. In fact, several early studies of RAC1 inhibition in celllines and mouse models suggest a potential benefit. RAC1 inhibition preventedgrowth of prostate cancer xenografts (Zins et al. 2013), reduced breast cancer cellgrowth and metastasis (Rosenblatt et al. 2011; Bid et al. 2013), reducedproliferation and migration of non<small cell lung cancer (Akunuru et al. 2011;Gastonguay et al. 2012), and suppressed motility in HCC cells (Liu et al. 2008).Inhibition of RAC1 activity may have clinical benefit in a variety of human cancersand further study is certainly warranted.Few mechanisms are known which contribute to the invasive progression ofHCC. Here, we find that decreased KLF6 expression leads to increased RAC1 activity,which is required for increased HCC cell migration. In addition to the potentialimportance of this signaling activity to HCC, this mechanism may also occur in otherhuman cancers that see frequent misregulation of KLF6. Inhibition of RHO familyGTPases, particularly RAC1, may be a potential therapeutic strategy for invasivecancers with low KLF6 levels.
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CHAPTER IV
The p53R172H mutant does not enhance hepatocellular carcinoma development
and progression.
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Preface
David Klimstra analyzed the histology of murine tumors isolated during thisstudy. His photographs are shown in Figure 4.3.
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IntroductionHepatocellular carcinoma is a common and highly deadly malignancyworldwide. At present, there are no curative options for patients with unresectabledisease, and the current treatment, Sorafenib, extends survival by only 2.8 months(Llovet et al. 2008). Therefore, understanding the molecular mechanismsunderlying HCC dissemination is of great importance for improving the prognosisfor HCC patients.One mechanism known to be important for HCC progression is inactivationof the tumor suppressor TP53, which often occurs through missense point mutation(Hollstein et al. 1991). In HCC, TP53 gene mutation is observed in over 30% of cases(Liu et al. 2012). Loss of heterozygosity in this region occurs in 25<60% of cases,depending on the study (Kusano et al. 1999; Wong et al. 1999b; Buendia 2000).Interestingly, TP53 mutations are absent in hepatic adenomas, while the frequencyof TP53mutation increases with tumor grade and differentiation status, occurring in54% of poorly differentiated HCCs (Oda et al. 1992; Buendia 2000). This suggeststhat mutations in the TP53 gene occur later in HCC development, and potentially areselected for over time.Indeed, TP53 mutations are associated with a higher rate of relapse anddecreased overall survival in HCC (Woo et al. 2011; Liu et al. 2012). Furthermore, ina non<metastatic HCC mouse model, deletion of Trp53 resulted in tumors with moreaggressive histology and increased metastasis to the lungs (Lewis et al. 2005).
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Together, these findings suggest a specific role for p53 inactivation in promotingHCC progression and metastasis.In addition to inactivating wild<type p53, some p53missense point mutationshave been found to exert both dominant negative and gain<of<function effects (Sigaland Rotter 2000). One particular mutation, p53R172H, which corresponds to human
p53 hotspot R175H, has been shown to inhibit wild<type p53 function (Kern et al.1992; Unger et al. 1992; de Vries et al. 2002), thus functioning as a dominantnegative. However, in the absence of wild<type p53, mutant p53 can contributeoncogenic effects. Mice with a single<copy of a knock<in LSLJp53R172H allele werecompared to p53<null mice. These mice had comparable survival rates, but the typesof tumors that formed differed. Trp53mutant mice had an increase in the number ofcarcinomas, which formed throughout the mouse (Olive et al. 2004). Interestingly,many of these carcinomas were invasive or metastatic, which rarely occurred in
p53<null animals. This change in tumor formation and increase in metastasissuggested a gain<of<function role for p53R172H in cancer (Olive et al. 2004).Subsequently, p53 gain<of<function activity was also characterized in tissue<specific contexts. In both the pancreas and skin, p53R172H expression was found tocooperate with oncogenic KRAS to increase tumor formation and metastasis ascompared to oncogenic KRAS and p53 nullizygosity (Caulin et al. 2007; Morton et al.2010). p53R172H and oncogenic KRAS were also found to cooperate in the oralepithelium. In this tissue, the presence of the p53 mutant increased tumor formationand progression to carcinoma, while the p53<null tumors remained benign (Acin et
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al. 2011). Lastly, mice with p53R172H were found have an increased rate of tumorformation in models of breast and colon cancer as compared to p53<null mice(Cooks et al. 2013; Lu et al. 2013). In these tissue contexts, p53R172H contributed toboth increased tumor formation and increased metastasis in vivo.Yet, p53 mutants do not display gain<of<function properties in every context.In a UV<induced skin cancer mouse model, p53R270H exerted dominant negativeeffects against wild<type p53 that resulted in increased tumor formation anddecreased survival as compared to p53 heterozygous mice. But when mice with asingle copy of p53R270H were compared to p53fl/flmice, there was no change in tumorformation or survival, indicating that the p53 mutant did not exert gain<of<functioneffects in this skin cancer model (Wijnhoven et al. 2007).The role of p53 gain<of<function activity in liver cancer is unclear, as previousstudies have only been performed using ectopic expression of mutants in HCC celllines. One study found that overexpression of several p53 mutants in HCC cell linesdecreased apoptosis in response to stress (Schilling et al. 2010). Another study,using the aflatoxin<induced p53R249S mutant, found that ectopic expression did notconfer any growth benefit to an HCC cell line. However, in an HCC cell line withendogenous expression of p53R249S, p53 knockdown decreased proliferation andincreased cell death (Gouas et al. 2010). These data demonstrate that phenotypes ofcell lines may vary depending on endogenous or exogenous expression of thesemutants. Additionally, cell context and the type of p53 mutant may also beimportant factors dictating p53 gain<of<function activity in HCC.
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One mechanism for p53R172H gain<of<function activity is through inhibition ofthe p53<related transcription factors p63 and p73, (Lang et al. 2004; Li and Prives2007). The p63 and p73 genes each encode multiple protein products. Expression of
p63 and p73 can occur from two distinct promoters, resulting in TA or ΔN isoforms.Additionally, several splice sites result in multiple protein products from each of theTA and ΔN promoters (Benard et al. 2003). Importantly, the transcriptional targetsof p63 and p73 vary depending on which particular isoform and splice variant isexpressed. In general, TA variants are thought to transcribe similar targets as p53,while ΔN variants can behave as dominant negatives to other p53 family members.However, ΔN isoforms also have additional transcriptional targets unique from theTA isoforms (Murray<Zmijewski et al. 2006). Based on these roles, TA isoforms arecharacterized as tumor suppressors, while ΔN isoforms have oncogenic behavior.Mice with heterozygous deletion of p63 or p73 develop spontaneous tumorswith accompanying loss of heterozygosity, indicating that these transcription factorsact as tumor suppressors (Flores et al. 2005). Moreover, inhibition of p63 or p73exacerbates tumor development and progression in p53<deficient animals,suggesting that they have non<overlapping tumor suppressor functions with p53(Flores et al. 2005; Oren and Rotter 2010).However, unlike the pattern of p53 inactivation seen in HCC patientspecimens, p63 and p73mutations and allelic loss have not been detected (Pan et al.2002; Petitjean et al. 2005). Interestingly, p63 and p73 expression from the TApromoter is increased in HCCs as compared to normal liver (Stiewe et al. 2004;
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Petitjean et al. 2005). In the case of p73, higher expression levels are correlated withp53 inactivation (Herath et al. 2000; Sayan et al. 2001) and poorer prognosis(Tannapfel et al. 1999). Yet, mice with single<copy loss of both p53 and p73 developspontaneous HCC, and many of these tumors lose the remaining p73 allele (Flores etal. 2005).Given the absence of homozygous TP53 deletion in human HCCs, and becausep53R172H has been shown to contribute to metastasis in other mouse models, Isought to determine whether p53R172H enhances HCC progression relative to p53nullizygosity. To approach this question, I utilized the RCAS<TVA mouse model forHCC (Lewis et al. 2005; Chen et al. 2007) in conjunction with a conditional p53R172Hknock<in allele (Olive et al. 2004).
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Results
p53R172H does not promote HCC development, progression, and metastasis in
vivo. To determine if p53R172H exhibits gain<of<function properties in HCC, Igenerated AlbuminJtvJa, Trp53LSLJR172H/flox, AlbuminJcre mice and AlbuminJtvJa,
Trp53flox/flox, AlbuminJcre littermates (Figure 4.1). The Trp53LSLJR172H allele expressesp53R172H under the endogenous p53 promoter upon Cre expression, when its stopcassette is excised (Olive et al. 2004). The Trp53flox allele results in excision of exons2<10 at the p53 locus upon Cre expression (Jonkers et al. 2001). These mice wereinjected with DF1 cells producing RCAS<PyMT to induce HCC, as done previously(Lewis et al. 2005; Chen et al. 2007). In this model, loss of p53 function is requiredfor metastasis, which can be enhanced through concomitant deletion of Ink4a/Arf(Lewis et al. 2005; Chen et al. 2007). Therefore, if p53R172H has gain<of<functionproperties, these should be observed in this model. I found that the presence of themutated p53 allele did not impact tumor<free survival (Figure 4.2A). In addition,mice with the p53R172H mutant did not have significantly different rates of metastasisas compared to p53<deleted littermates, with 17% of p53<deleted, and 25% of
p53R172H mice displaying metastasis to the lungs (Figure 4.2B). One mouse withmetastasis to the ovary was the only instance of metastasis detected in an organother than the lung.In addition to these characteristics, I assessed whether tumor burden ortumor histology differed between tumors induced in p53 mutant and nullizygous
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mice. I found that the total tumor burden for each mouse in the survival study wasnot statistically different between the two groups (Figure 4.2C). Moreover, thetumors induced in the two groups appeared to be histologically similar. Evaluationof H&E stained tissue sections demonstrated that regions of unique HCC histologyappear at similar frequencies in both groups (Figure 4.3). The most commonappearance of HCCs in the PyMT<driven model is the presence of very large cellswith vacuolated cytoplasm, often indicative of the accumulation of fat, representedin the middle panel. Another histology frequently seen includes dense regions ofless<differentiated cells, as shown in the bottom panel. The cells in these areas haveabnormal nuclei, and have lost the normal trabecular architecture typical of normalliver. Both of these tumor morphologies also commonly occur in human HCC.To determine if proliferation rates were different between tumor groups,Ki67, a marker of proliferation, was evaluated in mouse tissue sections.Quantification of Ki67 staining revealed that the proliferation rates are similarbetween tumors with or without the p53 mutant (Figure 4.4). Indeed, variationbetween tumors within the same group was greater than variation between the twogroups.
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Figure 4.1. Schematic diagram of p53R172H mouse study approach.
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Figure 4.2. The p53R172Hmutation does not decrease survival or enhance
metastasis in an HCCmouse model as compared to p53 deletion.A. Kaplan<Meier curve displaying tumor free survival of p53fl/fl and p53R172H/fllittermates. Mice were assessed over a period of 9 months and sacrificedwhen illness was apparent. Only mice whose death was perceived to be dueto HCC were included, otherwise the mouse was censored. Censored animalsare represented in the figure as tick<marks on the day of death. Survivalstatistics were calculated by the log<rank test.B. Number of mice with gross metastasis in the survival cohort, as measuredover a period of 9 months.C. Total tumor burden in survival cohort mice. Individual tumor volume wascalculated using the formula for an ellipsoid. All of the tumor volumes for agiven mouse were summed to arrive at the tumor burden per animal.A
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Figure 4.3. H&E staining depicting common architectural morphologies in
p53R172H/fland p53fl/fl HCCs.
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Figure 4.4. p53R172H/fl and p53fl/fl HCCs do not have different rates of
proliferation.A. Representative images of Ki67 IHC in normal mouse liver and HCC from
p53fl/fl and p53R172H/fl mice from the survival cohort. Arrows in the imagesindicate examples of positive nuclei.B. Cells with Ki67<positive and negative nuclei were counted to obtain thepercentage of cells within an HCC section that were Ki67 positive. Fivefields in each tumor section were counted to obtain an average. In eachcluster of bars, the first bar is the quantification of Ki67 staining in a liverwithout the presence of gross HCC.
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p53R172H does not accelerate tumor onset or metastasis in vivo.Since p53 gain<of<function properties were not seen in a cohort of animalsassessed over nine months, I sought to determine if the p53 mutant could exactgain<of<function effects at different steps in tumorigenesis. For example, tumorinitiation or time to metastasis may differ between groups of mice. To ascertain ifp53R172H accelerated tumor formation or metastatic progression in this model, aseparate cohort of animals was sacrificed at timepoints of three, six, or eightmonths, unless the mouse displayed signs of high tumor burden and had to beeuthanized in accordance with the approved animal protocol.Because of illness, several mice were sacrificed prior to their designatedtimepoints. Due to the variation in age, mice are represented in groups of 12<16, 17<24, and 25<35 weeks (Table 4.1). At each of these timepoints, the incidence of HCC issimilar between p53R172H and p53<null groups. Additionally, the proportion of micewith primary tumors that progressed to metastatic disease is almost equal at eachrange of time assessed. These results indicate that there is no acceleration of HCCformation or progression when p53R172H is expressed in the liver.When all of these ranges of time are combined, the proportion of mice thatdeveloped primary HCC and progressed to metastasis is almost identical betweenp53<null and p53<mutant groups, which reflects the result found in the survivalstudy.
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Table 4.1. The incidence of HCC or gross metastases is not different at any
period of time in HCC development.
p53 fl/fl
p53R172H/fl
Weeks Tumors/Mouse (%) Metastases (%)12<16 9/16 (56) 3/9 (33)17<24 6/8 (75) 1/6 (17)25<35 9/16 (56) 1/9 (11)Total 24/40 (60) 5/24 (21)
Weeks Tumors/Mouse (%) Metastases (%)12<16 4/13 (31) 2/4 (50)17<24 6/8 (75) 1/6 (17)25<35 8/12 (67) 1/8 (13)Total 18/33 (54) 4/18 (22)
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Analysis of genomic DNA isolated from a selection of mouse tumorsconfirmed recombination of the LSL cassette in the p53R172H tumors. Additionally,recombination of the appropriate sites in the p53 floxed allele was confirmed(Figure 4.5).
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Figure 4.5. Recombination of the p53LSL7R172H cassette and the floxed p53 allele
occurred as predicted. Genomic DNA isolated from representative mouse livertumors were examined by PCR for allelic recombination. In the top gel, the bandrepresenting 1 LoxP site demonstrates that recombination occurred at the LSLcassette in the p53LSLJR172H allele. The lower band, labeled “wild<type” represents the
p53 allele that does not contain an LSL cassette. The band on the lower gelrepresents recombination of the p53fl allele, demonstrating that deletion of exons 2through 10 occurred.
wild-type 
             p53 fl/fl      p53 R172H/fl NTC 
1 LoxP site 
Δ2-10 
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TumorLderived cell lines from p53R172HLcontaining HCCs do not display
enhanced properties relative to p53Lnull cell lines.To investigate potential gain of function properties in vitro, I generated acollection of HCC cell lines isolated from tumors induced in p53 null and p53 mutantlivers. Eight tumor cell lines, four from each group, were compared to determinewhether the presence of p53R172H enhanced cell transformation or migration in
vitro. Tumor<derived cell lines from mutant animals expressed p53 as expected,while nullizygous cell lines had no detectable p53 (Figure 4.6A). Importantly,expression of the p53 target p21 was not induced in mutant cell lines relative to nulllines following Gemcitabine treatment, consistent with the absence of functionalp53 protein (Figure 4.6A).To ascertain whether p53R172H enhances HCC cell migration, a phenotype thatserves as an in vitro surrogate for metastatic capability, I performed transwellmigration assays. I found that p53 null cell lines migrated as well as p53 mutantlines (Figure 4.6B). Thus, the presence of mutant p53 does not enhance thisproperty, an outcome consistent with the similar rates of metastasis observed in
vivo. Similarly, I found that p53R172H does not enhance anchorage<independentgrowth, relative to p53 nullizygosity, as measured by a soft agar colony formationassay (Figure 4.6C). These data are consistent with the similar rates of tumorincidence and tumor size found in the mouse study. Thus, in combination with the in
vivo results, my in vitro data suggest that the p53R172H mutant does not promote anenhanced tumor phenotype in HCC.
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Figure 4.6. Cell lines derived from p53R172HLcontaining HCCs do not display
enhanced properties when compared to p53Lnull HCCs.A. Western blots demonstrating expression of p53 and p21 in selected mousetumor<derived cell lines. β<Actin was used as a loading control.B. Transwell migration assay of HCC cell lines derived from p53fl/fl and
p53R172H/fl tumors. Graph shown is a representative experiment performed 4times.C. Soft agar colony formation assay of HCC cell lines derived from p53fl/fl and
p53R172H/fl tumors. Graph shown is a representative experiment performed 3times.A
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p53R172H is required for HCC cell transformationLrelated phenotypes with
endogenous mutant expression.In previous studies analyzing the gain<of<function properties of mutant p53proteins, a hallmark experiment was the demonstration that knockdown of mutantp53 abrogated the transformed phenotype (Olive et al. 2004). I thereforedetermined whether depletion of mutant p53 similarly impacted p53R172H<containing HCC cell lines. I knocked down p53R172H in two cell lines derived frommurine mutant tumors. As a control for potential off<target effects, I introduced thep53<targeting shRNA into a p53<null cell line. Knockdown of p53 was confirmed byimmunoblotting (Figure 4.7A). I observed that p53 knockdown impaired cellmigration (Figure 4.7B) and soft agar colony formation (Figure 4.7C) relative tocontrols. Interestingly, this result suggests that mutant p53 is required for thesephenotypes in p53R172H<expressing HCC cell lines. Importantly, expression of thep53<targeting shRNA in p53 null cell lines did not impact cell migration or soft agarcolony formation, confirming that these effects result from suppression of mutantp53 and not off<target effects.
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Figure 4.7. p53R172H is required for transformationLrelated phenotypes in HCC
cell lines.A. Western blot of p53 depicting 3 HCC cell lines infected with shRNA ascompared to an empty vector control labeled pGIPZ. β<Actin was used as aloading control.B. Transwell migration assay of p53 shRNA<infected HCC cell lines. A p53<null cell line was used as an experimental control p<values, calculated byStudent’s t<test are 0.020 and 0.022 for R172H lines 1 and 2, respectively.Shown is the average of 2 experiments, with the number of migrating cells ineach pGIPZ control infection set to 100%.C. Soft agar colony formation assay of p53 shRNA<infected HCC cell lines. Ap53<null cell line was used as an experimental control. p<values, calculatedby Student’s t<test are 0.044 and 0.004 for R172H lines 1 and 2, respectively.Shown is the average of 2 experiments, with the number of colonies for eachpGIPZ control infection set to 100%.A
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p53 family transcriptional activity is similar in p53 null and p53R172HL
expressing HCC lines.The above data reveal that p53R172H is required for transformation<associated phenotypes in HCC cells that express the mutant, but the presence ofmutant p53 does not enhance these properties beyond what is observed in p53 nulllines. This suggests, potentially, that similar pathways are impacted in bothcontexts. Since p53R172H is known to bind to, and inhibit, other p53 familytranscription factors as a gain<of<function mechanism, I examined the mRNA levelsof a collection of genes known to be regulated by the related p63 and p73 proteins. Ifound that the mRNA levels of p53 family target genes involved in cell signaling(Figure 4.8A), DNA damage (Figure 4.8B), and cellular processes (Figure 4.8C), areunchanged between p53mutant and nullizygous cell lines.
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Figure 4.8. p53mutant and p53Lnull HCC cell lines do not display differential
expression of p53 family transcriptional targets. p53 family transcriptionaltarget levels were assessed by qRT<PCR in RNA derived frommouse HCC cell lines.Ct values in each sample were normalized to β<actin as an endogenous reference. Tocalculate fold change, all samples were normalized to the average Ct value of p53fl/flcell lines, so the average of the p53fl/fl cell lines is set to 1. The Comparative Ctmethod was used to calculate fold change. Dark circles indicate p53fl/fl cell lines,while open circles are p53R172H/fl cell linesA. qRT<PCR of DNA damage<related targets of p53 family transcriptionfactors.B. qRT<PCR analysis of p53 family targets related to cell signaling.C. qRT<PCR analsysis of p53 family targets related to other cell processes.A
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p53 family target gene expression is increased upon knockdown of mutant
p53. Tumor<derived cell lines containing p53R172H do not have enhanced in vitroproperties as compared to p53 null cell lines. This could in part be attributed tosimilar levels of p53 family transcriptional activity as shown in Figure 4.8. However,upon knockdown of p53R172H, transformation<related properties decrease,indicating that mutant p53 is required for the phenotypes displayed in these cells(Figure 4.7).We therefore evaluated a subset of the target genes analyzed in Figure 4.8 todetermine whether their mRNA levels increased upon knockdown of p53R172H. p53shRNA was added to two additional p53R172H tumor<derived cell lines andknockdown was confirmed by immunoblot (Figure 4.9A). When combined with thetwo knockdown lines previously generated (Figure 4.7), this generated a panel offour knockdown cell lines, and paired controls, for analysis. I found that the levels ofthe p63 and p73<regulated genes, p21, Cldn1, and Rad51were consistently increasedin knockdown cells relative to paired control cells (Figure 4.9B). This suggests thatmutant p53 suppressed their expression, potentially by functionally interfering withp63 and p73.
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Figure 4.9. Knockdown of p53R172H in p53mutant HCC cell lines results in
increased expression of several p53 family transcriptional targets.A. Western blot demonstrating knockdown of p53 from cell lines derivedfrom LSLJp53R172H/fl mouse HCCs as compared to pGIPZ empty vector controlinfections. β<Actin was used as a loading control.B. Quantitative RT<PCR analysis of p53 family transcriptional targets in fourmouse HCC cell lines with knockdown of p53R172H. Ct values in each samplewere normalized to β<Actin as an endogenous reference. Fold changes werecalculated by normalizing all samples to the average Ct value of the cell line’spGIPZ control. The Comparative Ct method was used for fold changecalculation.
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Materials and Methods
Animal Studies
Trp53 LSLJR172H mice (Olive et al. 2004) were obtained and crossed with
AlbuminJtva, p53 flox/flox, AlbuminJcre mice (Chen et al. 2007). AlbuminJtva, Trp53
LSLJR172H/flox, AlbuminJcre mice were crossed to AlbuminJtva, Trp53 flox/flox,
AlbuminJcremice in order to obtain littermates for direct comparison. Three day<oldpups were injected in the liver with 2x106 DF1 cells producing RCAS<PyMT in 5uL ofserum free DMEM (Chen et al. 2007). Mice in the tumor study were divided intoeither a survival or timepoint cohort. 30 injected mice were enrolled in a survivalstudy. In the survival study, mice were sacrificed when distress was apparent asdefined by my mouse protocol, or at the age of 9 months, whichever came first. Micewhose cause of death was likely due to tumor burden or metastatic disease werecounted in the Kaplan<Meier curve. Mice that died without primary HCC werecensored. Kaplan<meier statistics were calculated using the Log<rank test. Anadditional cohort of mice was assigned to timepoint groups of 3, 6, or 8 months asthey were enrolled in the study. Mice were sacrificed at these timepoints, or whendistress was apparent. For both the timepoint and survival studies, liver and lungtissues from each mouse were harvested. Individual tumors were counted andmeasured in three dimensions. Portions of fresh HCC were excised from harvestedtissue in order to establish cell lines. Additionally, portions of tumor were flashfrozen in liquid nitrogen for later isolation of nucleic acids and protein. Remaining
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liver and lung tissue from each animal were formalin<fixed and paraffin<embeddedfor further analysis.
Cell CultureTumor<derived cell lines were isolated by mincing mouse tumor tissue andculturing in high<glucose DMEM with 10% FBS and 1% Pen/Strep. Appropriate p53expression was confirmed by Western blot.Stable p53 knockdown was performed using pGIPZ library shRNA directed tomouse Trp53 (Thermo Scientific, V3LHS_646511). An empty pGIPZ plasmid wasused as a control. Lentiviruses were produced in 293T cells that were transfectedwith plasmids containing envelope glycoprotein, required packaging sequences, andpGIPZ plasmid. Transfections were performed using Effectene Transfection Reagent(QIAGEN, 301425). HCC target cells were infected with 1 mL of lentiviralsupernatant in a well of a 6<well plate using 1ug of polybrene. Following infection,cells were selected in 6ug/mL puromycin before experimental analysis. To inducecell stress and p53 expression, 50nM Gemcitabine was added to growth media for24 hours before generating protein lysates.
Transwell migration assayMigration of cell lines was assessed by plating 2.5x104 cells on a migrationinsert (BD Biosciences, 354578) in serum<free DMEM. DMEM containing 10% FBSwas placed in the lower chamber as a chemoattractant. After 20 hours, non<
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migrating cells were removed from the upper membrane, and migrating cells werestained with Giemsa. The migrating cells per well were determined by averaging thecell numbers across 5 fields at 100X magnification. Error bars on migration assaygraphs are representative of standard deviation. p<values were calculated byStudent’s t<test.
Soft agar colony assayFor soft agar colony formation experiments, a 1.4% hard agar solution wascombined with 2X DMEM with 20% FBS and 2% Pen/Strep and plated onto 100mmtissue culture plates. After hardening, 1x10^5 cells were mixed with equal parts of a0.8% soft agar solution and 2X growth media. After the soft agar solution hardened,8mLs of 1X growth media was added to the dishes, which were incubated for 2weeks at 37°C. Colonies were counted in 20 fields per plate at 100X magnification.Size exclusion was used to ensure that colonies had grown in the dish, and were notjust cell clumps. Error bars on migration and soft agar colony experiments arerepresentative of standard deviation. p<values were calculated by Student’s T<test.
Western blottingProtein lysates from cell lines were generated in RIPA buffer, whereconcentrations were normalized by Bradford Assay. 20ug of lysate were used foreach Western blot sample. 10% acrylamide gels were used for SDS<PAGE, andsubsequently blotted onto PVDF. Western blots were blocked for one hour at room
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temperature in 7.5% nonfat dry milk in TBS. Antibodies for Western blotting wereused as described in Table 4.2.
ImmunohistochemistryPortions of each tumor were fixed in formalin and embedded in paraffin.Tissue sections were deparaffiniized with heat and rehydrated in decreasing alcoholconcentrations. After rehydration, Antigen retrieval was performed by microwavingslides in Antigen Unmasking Solution (Vector, H<3300). After cooling, endogenousperoxides were invactivated by adding 3% hydrogen peroxide for 10 minutes.Slides were blocked in goat serum in PBS for one hour at room temperature.Primary antibody was added as described in Table 4.2. Biotinylated Rabbitsecondary antibody was diluted in goat serum in PBS and added to the slides for onehour at room temperature. Goat serum, secondary antibody, and developingreagents were from Vector ABC kits (PK<4001). Pigment was developed in thetissues using a NovaRed Peroxidase Substrate (Vector, SK<4800). Afterdevelopment, slides were co<stained in hematoxylin, dehydrated, and mounted.
p53 family target gene analysisRNA from cell lines was isolated using Trizol, and converted to cDNA usingFirst<Strand cDNA synthesis kit (Invitrogen, 18080<051). qRT<PCR was performedusing Quanta Perfecta SYBR Green (VWR, 95072) in an ABI 7300 machine using50ng cDNA. p63 targets were amplified using the primers listed in Table 4.3.
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For qPCR studies on the tumor<derived cell line panel, average Ct values foreach cell line were determined for both the target gene and β<actin endogenouscontrol. Ct values for each individual cell line were normalized to the average Ctvalue for the p53<null cell lines, so that each cell line fold change is calculated inrelationship to the average of four p53 fl/fl cell lines. All individual lines werenormalized to β<actin as an endogenous reference.For assaying p53 knockdown cell lines, each shRNA<infected line wasnormalized to its respective pGIPZ<infected control, after normalizing to anendogenous reference. In each case the Comparative Ct Method was used tocalculate fold change, where fold change = 2<ΔΔCT.
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Table 4.2. Antibodies and conditions used for Western blotting and
immunohistochemistry.
Table 4.3. Primer sequences used for detection of transcripts by qRTLPCR.
Target Manufacturer ID number Dilution Diluent Conditionp53 Cell Signaling 1C12 1:2000 5% milk in TBS Overnight at 4°Cp21 Santa Cruz Sc<6246 1:1000 5% milk in TBS Overnight at 4°Cβ<Actin Santa Cruz Sc<1615<R 1:2000 5% milk in TBS Overnight at 4°CKi67 Abcam Ab66155 1:500 Goat serum in PBS Overnight at 4°C
Target Gene F Primer R Primerβ<Actin tcctcctgagcgcaagtactct cggactcatcgtactcctgcttBrca2 ggatggctcttcaggatcattcg gtgcttttgaagtaccattgacctttaMre11 cgaagaacgttgaaaggttcaaagc gggaacgactggggaatcctcaRad51 tgggaagctcaaaaccatctcttaac gtgtgtttctgtgaatgtatgcctaat14<3<3g ttggacagtggttcgttcag agcaactggtgcagaaagcEGFR ctgcaggctcagaaagtggt acactgctggtgttgctgacItga3 tgaggggacacaggtacaca agactgagcgacaacagcgItga5 gacagcaccaccttgcagta ttctccgtggagttttaccgCldn1 ctgcacagagagcaagggta agtggcagatgcagaaagtgFN1 actggatggggtgggaat ggagtggcactgtcaacctcAtg5 aagtctgtccttccgcagtc tgaagaaagttatctgggtagctcaAtg7 atgccaggacaccctgtgaacttc acatcattgcagaagtagcagccaCcng2 ctgagaaatgccaaagtgga gggccaagaatctatccaaaDcr1 tgatgggaacgctaacacat tctgctcagagtccatcctgp21 atcaccaggattggacatgg cggtgtcagagtctaggggaSharp1 gacagccattgaacatggac cttggtatcgtctcgcttca
183
Discussionp53 inactivation is an important step in HCC tumorigenesis that is associatedwith increased dissemination and poor prognosis (Lewis et al. 2005; Woo et al.2011; Liu et al. 2012). Point mutations in the p53 gene are prevalent in human HCC,and occur more frequently in advanced disease (Oda et al. 1992; Buendia 2000).Previous work has demonstrated that a common mutation, p53R172H, can contributeto enhanced tumorigenesis and metastasis in other tumor types, including breast,skin, colon, pancreas, and the oral epithelium (Olive et al. 2004; Caulin et al. 2007;Morton et al. 2010; Acin et al. 2011; Lu et al. 2012; Cooks et al. 2013). Takentogether, I hypothesized that the p53R172H mutation would enhance HCC progressionthrough gain<of<function properties.Using the RCAS<TVA model of HCC, I found that p53fl/fl and p53R172H/fl micedisplay equal tumorigenic properties. Mice with p53 deletion and mutation hadsimilar rates of tumor formation and metastasis at every time point examined. Also,tumor<free survival was virtually identical between p53fl/fl and p53R172H/fl mice.Lastly, cell lines derived from tumors in each of these groups display similar rates ofsoft agar colony formation and migration in vitro. These data indicate that for HCC,this particular p53 mutation does not contribute oncogenic effects that are worsethan p53 loss.Yet in Figure 4.7, I demonstrate that the migration and transformationcharacteristics of tumor<derived cell lines containing the p53R172H/fl mutation aredependent on the p53 mutant protein. Knockdown of the mutant in two R172H<
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containing HCC cell lines decreases migration and transformation levels. Whileconfusing, this piece of data suggests that the p53R172H mutant is contributing to cellphenotypes, despite the lack of enhancement in progression when compared to the
p53fl/fl tumors. The HCCs formed in p53fl/fl animals can achieve the same levels oftumor formation and progression as in p53R172H/fl mice, just via a differentmechanism than p53R172H gain<of<function activities.Concordant with my findings, a previous study indicated that forced<expression of p53 mutants in HCC lines did not affect proliferation or soft agarcolony formation. Yet, upon knockdown of p53 in HCC cells with endogenous p53mutations, proliferation decreased while apoptosis increased (Gouas et al. 2010).This outcome is similar to my study, where endogenous p53 mutations are requiredfor cell phenotypes, however do not necessarily enhance tumorigenic phenotypeswhen compared to p53<null lines.My data suggest that a possible mechanism for HCC progression in theabsence of functional p53 is through regulation of p63/p73 activity. Since studieshave demonstrated that one p53R172H gain<of<function mechanism is throughinactivation of the p63/p73 transcription factors (Lang et al. 2004; Li and Prives2007), I sought to determine if tumors with the p53R172H mutant and the p53fl/flalleles had similar levels of p63/p73 activity. HCCs from p53fl/fl tumors displaysimilar p63/p73 transcriptional activity as tumors from p53R172H/fl mice, as seen inFigure 4.8.
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Since it appears that p53R172H is suppressing activity of p63/p73, p53<familytranscriptional activity was measured in cells with p53R172H knockdown. Uponknockdown of the p53 mutant, several p53 family transcriptional targets wereincreased (Figure 4.9), reflecting a release of the suppression by p53R172H. This datasuggests an importance for p53 family transcriptional activity in HCC as a whole,which may be more important than p53 status alone.Where a p53mutation may inhibit p53 family transcriptional activity in othertumor contexts, in HCC there is no significant difference in p53 family activity when
p53R172H/fl and p53fl/fl tumors are compared. This indicates a potential explanationfor p53R172H not displaying enhanced oncogenic properties in HCC. Potentially, p53family activity in p53fl/fl tumors is reduced, resulting in an outcome similar to theinhibition provided by p53R172H.Previous work by Schilling et al. described the expression of tumor<associated p53 mutants in Hep3B cells and demonstrated that apoptosis is reducedwhen these mutants are expressed. Further, co<transfection experiments withp63/p73 and the p53 mutants demonstrate that the p53 gain<of<function mutantscan inhibit p63 and p73 transcriptional activity in HCC (Schilling et al. 2010). Thiswork supports my finding, in that the p53R172H mutant inhibits p53 familytranscriptional activity in HCC cells. However, my in vivo study demonstrates thatthe gain<of<function traits of p53R172H do not enhance HCC progression whencompared to p53 null tumors.
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My results suggest that the p53fl/fl tumors have reduced p63/p73transcriptional activity by another mechanism. It is possible that p53 status is lessimportant for HCC progression and metastasis than p53 family transcriptionalactivity as a whole. Detection of TAp73 and TAp63 in HCC reveals their expression isincreased (Stiewe et al. 2004; Petitjean et al. 2005). In the case of p73, thisupregulation has been associated with inactivation of p53 (Herath et al. 2000; Sayanet al. 2001; Stiewe et al. 2004). It is possible that the regulation of other p53 familymembers differs in the context of p53 loss versus p53 mutation. Changes in theexpression pattern or levels of p63 and p73 may account for the reason why p53<family target genes are unchanged between p53fl/fl and p53R172H/fl tumors.This outcome places a large importance on reduced p63/p73 function in thecontext of p53 inactivation in order for HCC progression to occur. Furtherexperimentation must be done in order to adequately demonstrate that p63/p73inhibition is responsible for HCC progression in the absence of functional p53.
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CHAPTER V
Discussion
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KLF6 and HCC disseminationHepatocellular carcinoma is a highly deadly malignancy due to its capacityfor dissemination and recurrence (Hayat et al. 2007; Jemal et al. 2011).Unfortunately, little is known about the precise molecular mechanisms driving theprogression and dissemination of the disease. Determining the important drivers ofHCC progression is critical to informing treatment strategies for patients who arenot eligible for curative surgery. In this work, I characterized the impact of impairedKLF6 activity in HCC progression.I began investigating genes involved in HCC migration through geneexpression profiling of migratory subpopulations of an HCC cell line, BL185. In thisprofiling study, KLF6 was decreased in migratory subpopulations compared to theless migratory parent cell line. Further analysis into human HCC cell lines and HCCtumor samples confirmed that KLF6 was not only commonly decreased in humanHCC when compared to normal liver, but was also decreased in HCCs with vascularinvasion compared to non<invasive HCCs.We do not know the mechanism by which KLF6 expression is reduced in ourmigratory HCC subpopulations. In these lines, KLF6 is reduced at both the messageand protein levels, indicating regulation is happening, at least in part, at thetranscript level. One possible mechanism for this change is an altered KLF6 splicingratio. KLF6<SV1 is a splice variant of KLF6 that functions as a dominant negative tothe full<length form (Narla et al. 2005; Vetter et al. 2012). Importantly, increasedKLF6<SV1 has been found to be oncogenic and a metastatic driver in breast and
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prostate cancers (Narla et al. 2008; Hatami et al. 2013). Examination of our HCC celllines indicates there is no increase in expression of other variants, suggesting thatthe decrease in full<length KLF6 is not due to a change in the splicing ratios betweenfull<length and KLF6<SV1. Several other possibilities could account for thesedifferences in expression. One is that the KLF6 promoter may have increasedmethylation in the subpopulations, which could result in decreased KLF6transcription. KLF6 promoter methylation has been demonstrated in esophagealcancer, and is responsible for reduced KLF6 levels in that tumor type (Yamashita etal. 2002).Another possibility for reduced KLF6 expression is that a transcription factorrequired for KLF6 transcription has altered expression in our subpopulations. In theabsence of a transcriptional activator, or overexpression of a repressor, KLF6transcript levels may be reduced. Transcriptional regulators of KLF6 have not beencharacterized and may be an interesting area for future research.A recently characterized source of KLF6 regulation is through its 3’ UTR.Interestingly, the full<length KLF6 message has decreased stability in HCC cellswhen compared with immortalized hepatocytes (Diab et al. 2013). The decrease inKLF6 mRNA stability in cancer cells suggests that a protein or microRNA is bindingto the message and impacting its stability. Potentially, the KLF6 message is lessstable in our HCC subpopulations, and this is the cause of the expression decreasethat I detected. If this is indeed the case, an interesting experiment would be toperform a screen for proteins which bind to the KLF6 3’UTR. A yeast three<hybrid
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approach can be used to detect the RNA binding proteins that interact with thissegment of the KLF6 message (SenGupta et al. 1996). Once these RNA<bindingproteins are identified, they can be individually validated using RNA cross<linkingand immunoprecipitation (CLIP) (Ule et al. 2003).In addition to RNA binding proteins, KLF6 message levels may also betargeted by a microRNA that is differentially expressed between our BL185 cells andmigratory subpopulations. Increased expression of a KLF6<targeting microRNA inthe subpopulations would result in increased decay or reduced translation of theKLF6 transcript. Previous studies have shown that KLF6 is targeted by miR<122 andmiR<181a (Tsai et al. 2012; Zhang et al. 2012a). Potentially, increased expression ofone of these microRNAs is responsible for the decrease of KLF6 message in themigratory subpopulations. Yet, miR<122 is often decreased in HCC compared tonormal liver (Coulouarn et al. 2009; Koberle et al. 2013; Nakao et al. 2014), which isinconsistent with the decreased KLF6 levels frequently encountered in HCC(Kremer<Tal et al. 2004; Kremer<Tal et al. 2007; Wang et al. 2010; Tarocchi et al.2011). This disparity is likely due to the fact that miR<122 is a regulator ofhepatocyte differentiation and maintenance (Chang et al. 2004; Deng et al. 2014),and additionally targets AKT3 (Nassirpour et al. 2013). Upon its loss, strong signalsof de<differentiation and increased AKT signaling may be more important tohepatocyte transformation than the impact of miR<122 on KLF6.To find other microRNAs that are impacting KLF6, algorithms, such asmiRanda, can predict possible KLF6<targeting microRNAs (Betel et al. 2008). This
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algorithm reveals that miR<181, miR<21, and several members of the miR<17<92family putatively target KLF6. Interestingly, these microRNAs are often elevated inhuman cancers, including HCC (Cho 2007; Connolly et al. 2008; Ji et al. 2009b; Oliveet al. 2010), which suggests they may be responsible for decreased KLF6 levels inhuman cancer. qRT<PCR could be employed to determine if the expression of one ormore of these particular microRNAs is increased in the HCC subpopulations ascompared to the BL185 parent line.In addition to being the causes of decreased KLF6 in our migratorysubpopulations, these mechanisms may also contribute to decreased KLF6 levels inHCC specimens. Since Klf6 mutations and allelic changes are rare events in humanHCC (Boyault et al. 2005; Pan et al. 2006; Song et al. 2006), it is likely that theseother mechanisms contribute to decreased KLF6 expression. While KLF6 iscommonly decreased, its transcript and protein are typically detectable (Kremer<Talet al. 2007; Wang et al. 2010; Tarocchi et al. 2011), which is unusual for a tumorsuppressor. This suggests that KLF6 dosage is important, consistent with my findingthat Klf6 heterozygous mice have increased tumor formation and metastasis.KLF6 was previously described as a tumor suppressor in HCC when KLF6<depleted livers had greater tumor formation upon DEN treatment (Tarocchi et al.2011; Vetter et al. 2012). Our data describe an additional role for decreased KLF6levels in HCC: an increase in HCC cell migration. Concordantly, tumors with single<copy loss of Klf6 generate greater metastatic burden to the lungs than those withwild<type Klf6.
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In our study, single<copy loss of Klf6 increases metastasis compared to wild<type mice, where only one metastatic colony was detected upon microscopicexamination. Several possible mechanisms could account for the increasedmetastatic burden in these mice, including enhanced tumor cell invasion anddissemination, survival in the bloodstream, or ability to establish colonies in thelungs. Lastly, another possibility could be that metastasis initiates earlier in thesemice, and thus colonies have more time to expand in the lung.Since in vitro migration is increased upon KLF6 knockdown in our HCC celllines, these cells may have increased invasion and dissemination in vivo, which couldresult in increased metastasis. To determine if more cells are disseminating in Klf6heterozygous mice, the number of circulating tumor cells (CTCs) could be examinedin Klf6 heterozygous versus wild<type mice. It may be possible to detect that a largernumber of disseminating cells are present in Klf6 heterozygous mice. Variousmethods of detecting CTCs based on expression of epithelial markers are available,including the EPISPOT assay, and several CTC<chips (Alix<Panabieres 2012; Zhang etal. 2012b).To test if KLF6<depleted cells have improved survival in the bloodstream,and colonization ability, comparing these cells by tail vein injection may be valuable.While not a measure of metastasis, it could determine if Klf6 heterozygous cells arebetter able to survive in circulation and subsequently establish lung coloniescompared to wild<type mice.
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Previous tracking studies of metastatic cells have demonstrated that thegreatest limiting step in the metastatic process is the formation of a colony afterextravasation into new tissue (Luzzi et al. 1998). Klf6 heterozygous tumors maydisseminate earlier than in wild<type, providing more time for cells to escapedormancy and proliferate in the lungs. This is a possibility, because my studyprovides evidence that HCCs are forming earlier in Klf6 heterozygousmice. In micesacrificed at 4.5 months, liver tumors from Klf6fl/wt animals were larger than in wild<type. Since proliferation rates in these tumors were similar, and apoptosis rates inthese tumors are very low, I hypothesized that Klf6 heterozygous tumors wereforming earlier. This may coincide with earlier dissemination of tumor cells as well.To test this, it would be necessary to perform an analysis of tumor and metastasisformation in these mice at multiple, early time points. Here, detection of CTCs mayagain be valuable to determine when dissemination is occurring in these animals.Surprisingly, single<copy loss of Klf6 was sufficient to drive HCC progressionand metastasis in our model, as tumor suppressor genes are traditionally thought torequire biallelic inactivation (Berger et al. 2011). However, this is not completelyunusual for KLF6 expression in the liver. Mice that have a single<copy germlinedeletion of Klf6 are phenotypically normal. However, upon treatment with ahepatotoxin, hepatocytes in Klf6 heterozygous mice have increased proliferation,(Tarocchi et al. 2011), resulting in enlarged livers that are more susceptible to HCCformation (Narla et al. 2007). These previous experiments demonstrate thathepatocytes are sensitive to single<copy Klf6 loss, and so it is not entirely surprising
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that we were able to see effects on tumorigenesis and metastasis with single<copyloss in the liver. Clearly, KLF6 levels are important for maintenance of hepatocytestasis. Notably, our KLF6 studies were performed in mice with liver<specific p53deletion. Additionally, our mouse<derived HCC cell lines also lacked p53 expression.This is important, since p53 deletion was previously shown to be sufficient to induceHCC metastasis in our PyMT<driven mouse model (Lewis et al. 2005). Our datasuggest that KLF6 may be involved in increasing metastasis that is alreadyfacilitated by p53 nullizygosity. The absence of p53 expression may be anothercontributor to why single<copy loss of Klf6 was sufficient to increase tumorformation and metastasis. Previous experiments that described KLF6 as a tumorsuppressor in HCC were performed in a p53 wild<type background (Tarocchi et al.2011; Vetter et al. 2012), which may explain why metastasis was not noted to haveoccurred in these studies.In addition to facilitating metastasis in our model, p53 loss may haveadditional importance for KLF6 activity, as previous studies have indicated there isa relationship between the two proteins (Gehrau et al. 2011). In the absence of p53,the target genes transcribed by KLF6 vary, as demonstrated with IGF1Rtranscription (Rubinstein et al. 2004). Since KLF6 transcriptional activity is differentwith impaired p53, it is possible that this different set of KLF6 target genes may beresponsible for the metastasis that occurred in our mouse model, and could accountfor why metastasis was not detected in other HCC studies on KLF6.
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Differences in the mouse model used could also account for the absence ofmetastasis in earlier studies. Previous work used the carcinogen DEN to induce HCCformation in mice (Tarocchi et al. 2011; Vetter et al. 2012). HCCs from this mousemodel are capable of generating lung metastases, though they mostly occur between80 and 90 weeks of age (Vesselinovitch et al. 1978). Indeed, DEN<treated miceanalyzed in these Klf6 studies were sacrificed at nine months of age (Tarocchi et al.2011; Vetter et al. 2012). In our mouse model, grossly visible lung metastases can bedetected as early as four to six months of age (Lewis et al. 2005; Chen et al. 2007),which may explain why I was able to detect an increase in metastatic burden.It would be interesting to determine if Klf6 loss alone is sufficient for drivingmetastasis in our model, independent of p53 inactivation. However, a previousstudy found that KLF6 is a direct transcriptional repressor of MDM2 (Tarocchi et al.2011). Therefore, even if the p53 locus were intact, decreased KLF6 expressionwould increase transcription of MDM2, subsequently leading to the degradation ofp53. Due to their linked expression, it would be challenging to determine the role ofKLF6 in the context of normal, wild<type p53 expression. In this study, I show thatKLF6 can function as a tumor suppressor for HCC, even in the absence of the KLF6<MDM2<p53 axis.Since my study examined the impact of single<copy loss of Klf6 on HCCprogression and dissemination, it may be valuable to also determine the impact oflosing both Klf6 copies. My hypothesis is that loss of both copies would increase andaccelerate tumor formation, while also further increasing metastatic burden. What
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would be very interesting to determine, is if complete Klf6 knockout in the liverwould be sufficient to drive HCC progression and metastasis in the absence of p53deletion. Based on the known KLF6<MDM2<p53 axis (Tarocchi et al. 2011), the levelsof active p53 would be relatively low in a Klf6<null hepatocyte, potentially resultingin a similar effect to compound Klf6 and p53 deletion.We performed a HCC tissue microarray to determine if KLF6 localizationcould be used as a prognostic indicator for HCC. We found that over a third of HCCsdisplay cytoplasmic KLF6, which has previously been described the presence ofKLF6<SV1 or SV2 (Narla et al. 2005; Vetter et al. 2012). KLF6<SV1 was found to berare in HCCs induced by HBV or HCV infection (Kremer<Tal et al. 2007), but otherstudies found that splicing of KLF6<SV1 was increased in advanced HCCs (Vetter etal. 2012). Since KLF6<SV1 has been found to be a dominant negative variant of full<length KLF6, cytoplasmic KLF6 often occurs in the absence of nuclear KLF6 (Narla etal. 2005; Vetter et al. 2012). In our study, the presence of cytoplasmic KLF6 wasmore frequent than was found in HBV and HCV<induced HCCs, yet it did notcorrelate to tumor stage or decreased patient survival.Another interesting finding in the HCC tissue microarray was thatapproximately a third of HCCs were largely negative for KLF6. Most previous studiesindicate that transcript levels of KLF6 are decreased in HCC as compared to normalliver, but transcripts are still detectable (Kremer<Tal et al. 2007; Wang et al. 2010;Tarocchi et al. 2011). Considering this information, the occurrence of so manytumors that appeared negative for KLF6 protein was surprising, and suggests that
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perhaps post<transcriptional regulation of KLF6 results in a further decrease inprotein expression despite the presence of transcript.Previous studies have described stepwise decreases in KLF6 transcript withincreasing HCC stage (Tarocchi et al. 2011). By performing a tissue microarray forHCC, I was expecting to find a similar correlation, where HCCs with nuclear KLF6would have a better prognosis than those with cytoplasmic or negative KLF6staining. However, I did not find any correlation to KLF6 localization and patientoutcome. There are several possible reasons for our TMA results disagreeing withthe published transcript data. One is that post<transcriptional regulation of KLF6may lead to a disparity between mRNA and protein expression. Also, tumorsselected in the previous study were from HCCs driven by HCV infection (Tarocchi etal. 2011), while the TMA was assembled from patients with mixed etiology.Different HCC etiologies may account for differences in KLF6 expression. Anotherpossibility is related to the selection of HCC samples for the tissue microarray. Thesamples included in the TMA were from patients who were eligible for surgicalresection or liver transplant. By nature of patient eligibility for surgical treatment,tumors included in the HCC TMA tend to be at an earlier, less invasive stage. Myhypothesis is that a bias toward HCCs of good prognosis in the TMA is the reasonwhy we did not see a correlation between KLF6 expression and prognosis.Potentially, p53 and KLF6 status could be combined to improve prognosticvalue. p53 is already used as a prognostic marker in HCC, where its inactivation isassociated with poor prognosis in HCC (Woo et al. 2011; Liu et al. 2012). Since the
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increased metastasis and decreased survival observed in our model occurred in thebackground of a p53 deletion, the prognostic value of KLF6 might rely oninactivation of p53. If patients were first stratified between those with intact orinactivated p53, it would be interesting to determine if subsequent assessment ofKLF6 status could improve prognostic predictions.In this study, I did not thoroughly investigate Klf6 loss of heterozygosity(LOH) in the primary tumor or the lung metastases. By qRT<PCR, all except one ofthe primary HCCs in Klf6fl/wt mice retained expression of the full<length KLF6transcript. KLF6 levels in most of the heterozygous tumors were reduced by half ofwhat was present in Klf6 wild<type tumors. As is common in other metastasissuppressors, it would be interesting to find if KLF6 expression was further reducedin the metastases as compared to the primary tumors. Also, it would be interesting ifthe KLF6 levels in the single Klf6 wild<type lung metastasis found during the studywere reduced as compared to its primary liver tumor. While only a single sample,this result would suggest that a reduction in KLF6 levels is required for HCCmetastasis.Studies of breast and prostate cancers found that an increase in the dominantnegative KLF6<SV1 variant increased metastasis (Narla et al. 2008; Hatami et al.2013). Of note, migration and metastasis in our model was not driven by an increasein KLF6<SV1, but by a decrease in total KLF6 levels. The importance of KLF6<SV1 inhuman HCC is unclear (Kremer<Tal et al. 2007; Vetter et al. 2012), but my data
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indicates that alternative splicing of KLF6 may be more common to human HCC thanpreviously described.While KLF6<SV1 has been well described as a dominant negative to full<length KLF6 (Narla et al. 2005; Vetter et al. 2012), KLF6<SV1 may have other roles inthe cell as well. In an HCC study, mice with liver<specific KLF6 depletion werecombined with transgenic mice expressing Klf6JSV1. Mice with both SV1 expressionand Klf6 deletion had increased tumor formation compared to mice with Klf6deletion alone (Vetter et al. 2012). If the only role for KLF6<SV1 were to inhibit full<length KLF6, then these two models would be functionally equivalent. The fact thatthe combination of SV1 expression and Klf6 deletion forms more tumors suggeststhat KLF6<SV1 has roles outside of inhibiting full<length KLF6. KLF6<SV1 may haveadditional oncogenic functions, including inhibition of transcription factors otherthan KLF6. Impacting the activity of several transcription factors would greatly altergene expression and could potentially drive tumorigenesis and dissemination. SinceSV1 expression has been shown to induce HCC formation (Vetter et al. 2012), itwould be interesting to find if transgenic expression of KLF6<SV1 would alsoincrease metastasis in our HCC model.After finding that decreased levels of KLF6 were important not just fordriving HCC formation but dissemination as well, I sought to determine themechanism by which KLF6 was regulating these processes. In breast cancer,increased KLF6<SV1 was found to drive EMT through increased expression ofTwist1 (Hatami et al. 2013). The role of KLF6<SV1 as an EMT regulator makes sense
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in the context of the previously described role for KLF6 as a transcriptionalactivator of E<Cadherin (DiFeo et al. 2006). However, I did not find evidence that anEMT was induced in our HCC cell lines. The migratory subpopulations did not havealtered expression of epithelial or mesenchymal markers, providing no evidencethat an EMT had occurred. Also, while KLF6 knockdown resulted in decreased E<Cadherin expression, there was not a significant change in other markers. Of note,our murine HCC cell lines express both epithelial and mesenchymal markerssimultaneously, indicating that our mouse HCC tumors exist in a state between thesetwo lineages. Of course, this study does not rule out the possibility that EMT isoccurring transiently during periods of migration, but I have no evidence that this isthe case. While EMT is a common mechanism in human cancer for increasinginvasion and metastasis (Kalluri and Weinberg 2009), this study does not suggest itis a primary cause of HCC dissemination in our model.To explore the mechanism of increased migration and metastasis in responseto decreased KLF6, I investigated the status of RHO family GTPases, particularlyRAC1, CDC42, and RHOA. As a result of these studies, I found that increased RAC1activity was required for the migration induced by KLF6 knockdown. My datasuggest that the use of a RAC1<targeting inhibitor may help to prevent the migrationof HCC cells in cancer therapy. Of course, RAC1 activity has also been shown toimpact cell proliferation and survival (Bustelo et al. 2007), so therapeutic doses mayhave a greater impact on a tumor cell beyond inhibition of motility. Several studieshave found that RAC1 activity is critical for mediating effects related to
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tumorigenesis, angiogenesis and metastasis, and have theorized the use of RAC1inhibition as a cancer therapeutic (Liu et al. 2008; Akunuru et al. 2011; Rosenblatt etal. 2011; Bid et al. 2013).To determine if RAC1 inhibition would be a useful therapy for HCC, it wouldbe interesting to compare survival of Klf6 heterozygous mice with and withoutRAC1<targeting treatment. A different approach would be to combine our Klf6heterozygous HCC mouse model with a liver<specific deletion of Rac1 (Glogauer etal. 2003). If RAC1 activity is required for the metastasis that occurred in Klf6heterozygous mice, its inhibition would decrease metastasis in these animals. Thesestudies would be additionally informative regarding the response of primary HCC toRAC1 inhibition or loss. As RAC1 has been associated with cell growth andangiogenesis (Bustelo et al. 2007; Bid et al. 2013) the formation of primary tumorsin mice with impaired RAC1 may also be negatively affected.After this finding, I sought to determine what transcriptional targets of KLF6were responsible for mediating the migration and metastasis effects seen inresponse to decreased KLF6. Prior to this study, one gene expression profilinganalysis that compared Klf6 heterozygous to Klf6 wild<type livers had beenperformed (Tarocchi et al. 2011). However, the analysis examined mouse livers thathad been treated with DEN before progression to HCC. Here, I used two globalapproaches: gene expression profiling of KLF6 knockdown cells, and ChIP<sequencing, in order to determine new transcriptional targets of KLF6 in HCC cells.Previous analyses of KLF6 binding sites have only examined the promoter regions of
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specific target genes through ChIP<PCR (DiFeo et al. 2006; Lee et al. 2010; Tarocchiet al. 2011). Notably, we found that while KLF6 binds to promoter regions proximalto transcriptional start sites, KLF6 also binds to sites distant from knowntranscriptional start sequences. Of target genes that were found in both theexpression profiling and ChIP<sequencing datasets, KLF6 was more likely to bebound at locations distal from the transcriptional start site. One identified target inparticular, E<Cadherin, was previously identified as a KLF6 transcriptional target(DiFeo et al. 2006), suggesting that my approaches are detecting genuine KLF6target genes. My study also uncovered several novel target genes that may beimportant for tumor formation and metastasis. Two such target genes include Vav3and Cdc42ep3.In this study, I found that KLF6 is a repressor of VAV3 and CDC42EP3transcription. Upon KLF6 knockdown, expression levels of these genes increase, andtheir expression is required for the increase in migration induced upon KLF6knockdown. I hypothesize, that through its known role as a GEF for RAC1 (Sachdevet al. 2002), VAV3 increases RAC1 activity and subsequently increases cellmigration. While its precise role is unknown, CDC42EP3 is likely mediating signalingdownstream of the active GTPases to regulate migration (Hirsch et al. 2001).Together, these proteins are responsible for mediating a GTPase cascade thatinduces HCC cell migration.However in its current state, the evidence connecting increased levels ofRAC1 and CDC42 activity with VAV3 and CDC42EP3 is circumstantial. To confirm
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this hypothesis, it would be necessary to demonstrate that upon VAV3 knockdown,the activity levels of RAC1 and/or CDC42 decrease. Also, a downstream readout forCDC42 activity would need to be measured in order to determine that CDC42EP3was indeed mediating effects downstream of active CDC42. While this is myhypothesis based on the known functions of these proteins, it has not been provento be the mechanism by which VAV3 or CDC42EP3 knockdown regulates migrationin our HCC cells. Indeed, they may have separate roles in the cell through which theyare driving migration.To further explore the potential relationship between KLF6 and CDC42EP3or VAV3 on migration and metastasis, it would be interesting to perform mouseexperiments with compound deletions. Similar to our in vitro study, I hypothesizethat Klf6 heterozygous mice with additional Cdc42ep3 or Vav3 deletion would havefewer HCC metastases than mice with Klf6 deletion alone. In this study, I did notexplore the impact of VAV3 or CDC42EP3 on cell proliferation or survival, but it ispossible that these proteins may also have an impact on tumor formation in additionto metastasis. VAV3 has previously been characterized as a proto<oncogene, and hasbeen shown to increase cell proliferation (Sachdev et al. 2002; Toumaniantz et al.2010; Tan et al. 2013). If this were also the case in HCC, a mouse with both Klf6 and
Vav3 deletion may also have decreased tumor formation compared to mice withdeletion of Klf6 only. Vav3 knockout mice are viable (Faccio et al. 2005; Sauzeau etal. 2006), so this knockout allele could be combined with our HCC model to explorethis possibility. If true, VAV3 would be implicated as a therapeutic target in HCC.
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While the function of CDC42EP3 is not well characterized, if it is mediatingsignaling effects downstream of CDC42 as described (Joberty et al. 1999; Hirsch etal. 2001), it may not be restricted to only affecting cell migration. CDC42 activity hasbeen shown to also affect cell cycle (Qiu et al. 1997), so CDC42EP3 may also beresponsible for mediating this effect. No current mouse models for CDC42EPmembers exist, but Cdc42ep3 deletion in the liver may also impact tumorigenesis aswell as metastasis in our HCC model.My data demonstrate that CDC42EP3 is required for migration induced byknockdown of KLF6 in HCC. While it was previously demonstrated that increasedCDC42EP3 expression increases migration of fibroblasts in culture (Hirsch et al.2001), it is unclear what precise role CDC42EP3 has in the cell. CDC42EP3 has beenshown to bind to CDC42 in a GTP<dependent manner (Joberty et al. 1999), but itsdownstream activities are not characterized. I have hypothesized that CDC42EP3 isbinding to CDC42<GTP, which is increased upon KLF6 knockdown cells, but thisinteraction has not been validated. What also remains to be characterized is whatpathways CDC42EP3 is affecting. Unlike some GTPase effectors, CDC42EP3 does nothave a kinase domain (Joberty et al. 1999), so it is unlikely to be directly impactingsignaling. While the formation of pseudopodia and changes in keratinocytemorphology are dependent on an intact CRIB domain (Hirsch et al. 2001), additionalCRIB mutant studies of CDC42EP family members demonstrated it could still inducecell shape changes in the absence of an interaction with CDC42 (Joberty et al. 1999).These data suggest that CDC42EP family members may have CDC42<dependent and
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independent functions. My hypothesis is that CDC42EP3 is behaving as a scaffoldingprotein for active CDC42 and other effectors that may directly impact signaling anddownstream functions of CDC42. An interesting experiment would be toimmunoprecipitate CDC42EP3 and perform mass spectrometry to identify itsinteracting proteins in HCC cells. This approach could potentially enlighten themechanism through which CDC42EP3 is impacting migration.While we have shown that VAV3 and CDC42EP3 are important for migrationdownstream of KLF6, other interesting genes were also found in our KLF6 targetanalysis. Some of these other targets include components of the Notch signalingpathway, such as JAG1 and RBPJ. Expression of both of these Notch pathwaycomponents is increased in response to KLF6 knockdown. Additionally, KLF6 wasfound to bind near the Hes1 gene, though differential expression was not detected inour gene expression profiling analysis. Potentially, KLF6 may mediate its tumorsuppressor activity in part via inhibition of multiple Notch pathway signalingcomponents. However, the role of Notch signaling in HCC is complicated. In somestudies, increased Notch signaling is tumor suppressive (Qi et al. 2003; Viatour et al.2011), while it is pro<tumorigenic in other cases (Lobry et al. 2011; Villanueva et al.2012). Notably, JAG1 expression in breast cancer cells was shown to facilitate theformation of metastases (Sethi et al. 2011), so increased JAG1 expression mayfacilitate metastasis in HCC as well. If Notch signaling is pro<tumorigenic or pro<metastatic in HCC, inhibiting the transcription of pathway components may be onemechanism through which KLF6 functions as a tumor and metastasis suppressor.
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To determine if Notch signaling is important downstream of KLF6 in HCC,our Klf6 heterozygous model could be combined with one of the several modelsavailable that impact Notch signaling. Based on the enriched Notch signaling uponKLF6 knockdown, my hypothesis is that Notch inhibition would reduce tumorformation and metastasis in this model. However, since some studies describe atumor suppressive role for Notch signaling in HCCs (Qi et al. 2003; Viatour et al.2011), this effect may be strongly dependent on cell context. It would be interestingto combine our KLF6 mouse model with conditional deletion of Notch1 (Yang et al.2004), or Jag1 (Loomes et al. 2007), to determine the pathway’s impact on HCCformation and metastasis. An additional approach could be to treat Klf6heterozygous mice with γ<secretase inhibitors to block Notch signaling (Shih Ie andWang 2007). This method may demonstrate a reduction in tumor formation ormetastasis as compared to a placebo treated cohort.Another interesting target found in our study is KLF4. Known for being atranscriptional regulator of “stemness” genes (Takahashi and Yamanaka 2006;Nakagawa et al. 2008), KLF4 has also been shown to physically interact with KLF6to affect transcription, particularly of Keratin 4 (Okano et al. 2000). My study foundthat KLF4 is directly targeted by KLF6 transcription. Importantly, KLF4 has beenshown to be a suppressor of proliferation and migration in HCC cell lines in additionto repressing subcutaneous tumor formation and metastasis (Li et al. 2012; Lin et al.2012b). As KLF6 and KLF4 can co<activate transcription, depletion of KLF4 in cellswith reduced KLF6 may impact a large number of target genes. It would be
207
interesting to determine if effects seen in response to KLF6 loss were in partmediated through a reduction in KLF4 activity, which could be performed throughthe use of a mouse with conditional deletion of Klf4 (Katz et al. 2002).Another intriguing target found in our analysis is KLF6 itself. It isunsurprising to find that the gene expression profiling experiment detected KLF6transcript levels were reduced, as the cells were treated with KLF6 shRNA.However, it was interesting to find that the Klf6 gene was directly bound by KLF6through the ChIP<sequencing study. This finding suggests that KLF6 may participatein a feedback loop regulating its own expression. As little is known about thetranscriptional regulation of KLF6, this finding provides insight for one newmechanism.I selected KLF6 from our gene expression profiling dataset of migratorysubpopulations for further study. Yet, the profiling study provided severalpotentially interesting targets that may be important for HCC progression andmetastasis. For example, ID proteins 1<3 have increased expression in our HCCsubpopulations. Increased ID1 and ID3 have been associated with increasedmetastasis in gastric, pancreas, and breast cancer (Tsuchiya et al. 2005; Gupta et al.2007; Shuno et al. 2010). Potentially, the increased ID protein expression may beimportant for HCC progression in addition to impacting migration in our HCC celllines. Also, several chromatin regulators appear in this dataset, including HMGA1and 2. Altered expression of these regulators have been demonstrated in severalhuman cancers (Fusco and Fedele 2007), and may result in a host of gene
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expression changes that could increase migration and metastasis in HCC cells.Previous studies have demonstrated promotion of metastasis as a result ofchromatin remodeling (Gupta et al. 2010). KLF6 was an excellent candidate forfurther study from the HCC subpopulation profiling study due to its expressionpattern in human cancer, and its known role as a tumor suppressor in HCC. Yet,deeper interrogation of this dataset may reveal additional factors important to HCCmetastasis.
p53R172H gainJofJfunction properties in HCCPrevious reports have found that some common p53 mutants have gain<of<function properties in cancer cells. These gain<of<function effects occur in thecontext of p53 deletion, so they are not simply due to loss of tumor suppressoractivity. Examples of this gain<of<function behavior include increased tumorigenesis,decreased survival, and increased tumor cell dissemination in mice with a p53mutant compared to tumors without p53 (Olive et al. 2004; Caulin et al. 2007;Morton et al. 2010; Acin et al. 2011; Cooks et al. 2013; Lu et al. 2013).Previously it was shown that p53 loss drives progression and metastasis ofHCC (Lewis et al. 2005). Also, p53 mutation is associated with a higher rate of HCCrelapse and poorer survival (Woo et al. 2011; Liu et al. 2012). Since p53 mutationsare enriched in late stage HCCs (Oda et al. 1992; Buendia 2000), I hypothesized thatone of these mutants, p53R172H, resulted in gain<of<function properties in HCC.
209
Instead of finding that p53R172H enhanced properties of tumorigenesis, wefound no differences between p53R172H/fl and p53<null tumors or tumor<derived celllines. The results of these experiments indicate that p53R172H does not enhancetumor<associated properties of HCC compared to p53 loss. Interestingly though, Ifound that p53R172H is required for the phenotypes of HCC cell lines thatendogenously express the mutant.If inhibitors to p53 mutant gain<of<function activities become available, myresults show that patients with p53<mutant HCCs may still benefit from thistreatment, despite no measureable differences between tumor types. Reduction ofthis activity, as shown in our cell lines with p53 knockdown, may impair growth andmigration of these tumors. An approach to test this possibility would be to use aninducible p53R172H mouse, where expression of the mutant could be reversed aftertumor formation. Despite not displaying enhanced properties when compared to the
p53<null tumors, deleting the p53 mutant in tumors that have grown dependent onit may reveal “oncogene addiction” to the p53 mutant. While no inhibitor exists forR172H, a compound has been developed which stabilizes a different structuralmutant, resulting in reactivation of wild<type p53 function (Liu et al. 2013b), soR172H may eventually become a druggable target.Exploration of p63/p73 target genes in our tumor<derived cell lines, andthose with p53 knockdown, revealed that p63/p73 activity was repressed in bothp53R172H and p53<null cell lines. My hypothesis is that p63/p73 deregulation is
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crucial for HCC formation or progression. Investigating this possibility would be anexciting avenue for HCC research.Modulation of the levels of these transcription factors in mice and HCC celllines is an interesting approach to determine if p63 or p73 are important for HCC.Interestingly, mice with heterozygous deletion of both p53 and p73 formspontaneous HCC (Flores et al. 2005), suggesting that there may be synergistictumor suppression in hepatocytes between these two proteins. In these tumors, theremaining copy of p73 is lost. However, mice with p63 and p53 heterozygosity donot form HCC (Flores et al. 2005), indicating that p73 loss alone may cooperate withp53 inactivation for HCC development. Yet, p63 and p73 expression is increased inHCC compared to normal liver (Stiewe et al. 2004; Petitjean et al. 2005). In fact,increased p73 levels are correlated with poor prognosis (Tannapfel et al. 1999),suggesting that further experimentation needs to be done to determine in whichcontexts p63 or p73 inactivation occurs, and which particular isoforms of theseproteins are being expressed.p63/p73 are expressed from two different promoters, TA and ΔN, fromwhich each message can be alternatively spliced (Benard et al. 2003). The ΔNisoforms are thought to function as dominant negative transcription factors, yetthey also have unique transcriptional targets as well. The TA isoforms generallyhave similar behavior to p53, and regulate many cell cycle<related genes (Courtoiset al. 2004; Murray<Zmijewski et al. 2006). It would be interesting to determine ifthe spectrum of p63/p73 isoform expression changed upon HCC formation or p53
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inactivation. During the course of my studies, I attempted to identify the expressionlevels of specific p63 and p73 isoforms in p53 null and p53R172H<expressing HCCcells, but these attempts were unsuccessful. Based on my studies of p53<familytarget gene expression, many of the targets affected by mutant p53 knockdownwere those that were targeted by the TA isoforms. However, expression of the genesassociated with the TA isoforms can also be impacted by the ΔN isoform’s dominantnegative activity (Murray<Zmijewski et al. 2006). Since previously used mousemodels delete all isoforms of p63 and p73 (Flores et al. 2005), it is difficult tointerpret how the balance of these isoforms impacts HCC in vivo. Instead,examination of HCC development and progression through the use of TA or ΔN<specific p63/p73 knockouts (Tomasini et al. 2008; Su et al. 2009; Wilhelm et al.2010; Romano et al. 2012) may prove more valuable. In addition to exploring theimpact of isoform<specific p63/p73 loss in HCC, it would also be interesting todetermine how increased expression of particular p63/p73 isoforms would impactHCC cell phenotypes in vitro.The only mechanism for gain<of<function I investigated is inactivation of p63and p73. Of course, other mechanisms of p53 gain<of<function activity may also beoccurring in the p53 mutant and p53<null HCC cell lines. For example, p53 mutantshave been shown to bind to and inactivate other transcription factors (Chicas et al.2000; Di Agostino et al. 2006; Freed<Pastor et al. 2012). Similarly to what I haveshown with p63/p73 activity, the activities of these other transcription factors maybe reduced in p53<null cells.
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In this study, I only examined a small number of p63/p73 target genes.Further analysis of p63/p73 transcriptional targets in HCC may be valuable fordetermining if the effects seen upon decreased p63/p73 activity are due to targetgenes that overlap with wild<type p53, or are unique to the other family members. Itmay be informative to modulate the expression levels of p63 and p73 in HCC cellsand subsequently perform gene expression profiling in order to determinetranscriptional target genes of these factors specific to HCC.One potentially important factor deregulated in our p53mutant and null cellsis Dicer. Dicer is a transcriptional target of p63, and upon mutant p53 expression, itstranscription is inhibited via p63 (Su et al. 2010). I showed that the p53R172H mutantrepressed Dicer expression in HCC cell lines, since its expression increased inresponse to p53 knockdown. Regulation of Dicer has been shown in many contextsto be important in cancer. In particular, decreased Dicer expression has been shownto induce metastasis (Han et al. 2010; Su et al. 2010; Muller et al. 2014). In tumorswith nonfunctional p53, Dicer may be one of the important mediators of tumorprogression and metastasis.Previous studies of p53 mutants in HCC used ectopic expression of themutants in p53 null cells to test for gain<of<function activity (Gouas et al. 2010;Schilling et al. 2010). I did not perform a similar experiment in this study. However,if my hypothesis is true, expression of p53R172H in p53<null cells would have noeffect, since p63/p73 activity is already inhibited in p53<null HCC. Also, ectopicexpression of p53 mutants may provide artifactual results. Since the mutant forms
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of p53 are not efficiently degraded, the mutant protein accumulates (Bartek et al.1991). However, its transcription is still regulated by endogenous conditions.Forced overexpression of these mutants may result in a larger accumulation thanwould typically occur. Since mutant p53 binds to many transcription factors to altertheir behavior, ectopic amounts of mutant p53 may result in greater transcriptionalinhibition that may not otherwise occur. In my studies described in this dissertation,the use of an in vivo knock<in construct likely resulted in lower levels of p53 mutantexpression than ectopic expression systems.In this study, I only examined the potential effects of the p53R172H mutant.This structural hotspot mutation, correlating to human R175H, occurs frequently inHCC (Olivier et al. 2010), however, the most frequent mutations occur in the DNAbinding domain (Oda et al. 1992). While p53R172H did not provide enhanced tumorproperties as compared to p53 loss, other p53 mutants, specifically those in the DNAbinding region, may provide enhanced tumor properties. Similar to the R172H alleleused in our study, a conditional knock<in allele exists for the DNA binding domainmutant R270H (Olive et al. 2004). Perhaps in combination with our HCC model, thisDNA binding mutant would provide enhanced gain<of<function characteristics.It would also be interesting to perform a similar experiment using thep53R249S mutant, which is associated with exposure to AFB1 (Bressac et al. 1991;Ozturk 1991; Stern et al. 2001). Since this mutation is enriched in HCC specifically(Thongbai et al. 2013), this mutation may provide advantages to the formation andprogression of HCC. In vitro studies of the R249S mutant demonstrated that cells
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that endogenously express the mutant rely on its expression for proliferation(Gouas et al. 2010). However, ectopic expression of this mutant in p53<null cells didnot provide a proliferation advantage (Gouas et al. 2010), reflecting a similaroutcome to my R172H data.While p53R172H did not enhance phenotypes in our PyMT<driven HCC model,the use of another HCC mouse model may provide a different outcome. A similarobservation has been made in models of skin carcinogenesis. In two mouse modelsof skin cancer, one demonstrated gain<of<function properties with p53 mutationversus p53 nullizygosity (Caulin et al. 2007), while a different mouse model showedno gain<of<function activity upon mutant expression (Wijnhoven et al. 2007).Clearly, the context in which these tumors are formed is important for dictating p53gain<of<function properties. PyMT is a very potent oncogene that results in relativelyfast HCC formation and metastasis, which can be detected beginning at 4 months ofage (Lewis et al. 2005). HCC mouse models induced by DEN or transgenic c<MYCdevelop tumors with a longer latency of approximately nine months to one year(Vesselinovitch et al. 1978; Sandgren et al. 1989). Rates of metastasis are also low inthese models (Heindryckx et al. 2009) relative to the RCAS<TVA system. Perhaps in atumor environment with a weaker oncogenic stimulus, p53 mutants would have theopportunity to display enhanced gain<of<function properties compared to p53<nullHCCs. Our study of p53R172H in HCC explains that the p53 mutant is acting in a gain<of<function manner through inhibiting p63 and p73 target genes. However, p63 and
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p73 transcription factors are also inhibited in p53<null cells, suggesting thatmultiple pathways converge on inhibition of p63 and p73 in HCC cells. This resultindicates that inhibition or loss of these factors is likely important for HCCdevelopment or progression. While KLF6 loss results in an increase in progression,p53R172H does not enhance HCC progression beyond loss of wild<type p53 function.
Factors regulating HCC progression and metastasisTogether, the data in this dissertation describe the roles of two transcriptionfactors in the progression of hepatocellular carcinoma. Both p53 mutations anddecreased KLF6 levels are common alterations in HCC. Interestingly, thesealterations occur most frequently in advanced HCCs (Oda et al. 1992; Tarocchi et al.2011), providing a correlation with p53 mutation or Klf6 loss and poor prognosis.While there is a correlation between each of these changes and progression of HCC,the direct impact of these factors on disease progression and metastasis had notbeen experimentally demonstrated in vivo.As p53 deletion has previously been shown to drive HCC progression (Lewiset al. 2005), I chose to determine if the addition of p53R172H or impairment of KLF6in a p53<deleted background would contribute further to HCC formation anddissemination. In the case of KLF6, reduced levels increased tumor formation andmetastasis in an HCC mouse model, indicating that the decreased KLF6 levels inhuman HCC are driving tumor progression, and are not simply correlative.Conversely, despite the correlation of p53 mutations with advanced HCC, p53R172H
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did not increase HCC formation or metastasis compared with p53<deleted HCCs.Since p53R172H is not significantly different from p53 deletion in HCC, the enrichmentof p53 mutations in advanced HCCs may be more important for the inactivation ofwild<type p53, not necessarily for p53 gain<of<function mutant effects.Many gene expression changes have been found which correlate with HCCformation and progression, but few of these have been experimentally validated(Buendia 2000; Guichard et al. 2012). As many of these gene expression changes ormutations are likely passenger alterations, and not drivers of disease formation andprogression (Stratton et al. 2009), it is of great importance to determine the impactof such changes on tumor biology in vivo. Here, my work clarifies the roles of twofactors that correlate with disease progression, but had not yet been experimentallyvalidated.In both cases, my studies revealed deeper mechanisms of HCC progression.The p53R172H study highlighted the important role of deregulation of all p53 familytranscription factors in the development and progression of HCC, while the KLF6study demonstrated that modulation of RHO GTPase activity, particularly RAC1, wascritical for HCC progression. In addition to describing the impact of thesetranscription factors, my work raises additional questions regarding the preciseroles of p53 family transcription factors and RHO family GTPases in HCC. Furtherinquiries into these mechanisms of action may provide valuable insights into themolecular biology of HCC progression and metastasis.
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APPENDIX A
Gene Expression Profiling of BL185, BL185LM1, and BL185LI1
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Gene Symbol pAvalue
BL185 vs M1
Fold Change
BL185 vs I1
Fold Change
Mycn 2.39EQ05 18.6375787 21.92951528
Dmrta1 3.20EQ05 13.43135873 13.79859477
Krt14 5.45EQ05 0.405941934 0.100849029
Clca6 7.88EQ05 49.46753717 48.73798558
Hpgd 0.000129027 2.70054023 0.345928549
Ly6c 0.000129027 0.376424315 0.249573755
Krt14 0.000129027 0.335509077 0.051971174
Ndg2 0.000143443 13.91304206 7.244953207
Mgam 0.000184463 5.366939524 5.286514101
Gzme 0.000184463 0.455505339 0.250239357
Mcm5 0.000185127 0.159742875 0.209918025
Gdf15 0.000229696 24.76443866 19.77608647
Gm566 0.000229696 12.74775397 9.999858263
Trim15 0.000229696 11.50037045 9.865779468
Stmn2 0.000229696 4.342090262 0.118859642
Prom1 0.000260977 7.598896642 6.666250826
Birc5 0.000267867 0.132577809 0.154837931
Col5a1 0.000312657 0.130465841 0.173618314
Tuba1a 0.00033154 0.246154762 0.223663286
Rrm2 0.000339447 0.259549069 0.212695281
2810417H13Rik 0.000408539 0.109033935 0.124625055
Mki67 0.000512992 0.096584723 0.134327603
Hmgn2 0.000573548 0.072591042 0.078038154
Rhox5 0.000575766 9.51929988 6.648035149
Cd68 0.000575766 9.241268579 8.284852645
Kif22 0.000609119 0.291821874 0.277267085
Gsta2 0.000681866 1.672830462 0.461679204
B4galnt2 0.000681971 31.00832904 5.398460685
Aldh1a3 0.00078359 13.57021799 11.74228475
Ccna2 0.00078359 0.160327391 0.210230541
Kif23 0.000821484 0.206486363 0.229328161
Shcbp1 0.000821484 0.132108326 0.117017508
Birc1a 0.000831581 7.397381319 6.451565196
Ccna2 0.000831581 0.207521022 0.209499818
B4galnt2 0.000858941 13.43900288 6.905011745
Fxyd5 0.000858941 0.549493176 0.500280512
S100g 0.000938233 0.203420138 0.133831786
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Rrm2 0.001001502 0.309522535 0.273187889
Col6a2 0.001001502 0.228811206 0.178982549
Cxcl12 0.001065678 0.379581912 0.331175989
Ccl2 0.001150694 0.0587104 0.141226559
Sprr2a 0.001167813 0.461653513 0.186225514
H2QQ10 0.001188912 5.196063734 4.502334444
Ceacam18 0.001188912 3.85500891 2.573901319
S100a4 0.001188912 0.192772807 0.093405326
Crip1 0.001188912 0.155366895 0.165823822
Vip 0.001388077 42.96012439 10.19985173
Car2 0.001388077 3.703279751 2.935311531
Nat8l 0.001479271 8.50595813 3.701949288
Slc25a30 0.001485264 4.757805021 4.645708015
Cdca3 0.001506506 0.102361965 0.102684126
Gtpbp2 0.001565198 5.784610987 5.793257624
Rnf125 0.001565198 5.364633199 4.1211531
2310042E22Rik 0.001565198 4.507976615 2.021794581
C2 0.001565198 2.748384477 2.118224761
Tmem150 0.001565198 2.639858073 2.891269735
Fabp5 0.001565198 0.261182698 0.352207506
Kif2c 0.00164263 0.164520983 0.147895914
Lgals2 0.001679597 0.45963143 0.29286788
Pbk 0.001679597 0.233091385 0.22720511
Ndg2 0.00168768 11.09178021 6.366892347
1500012F01Rik 0.00168768 3.048062774 2.92992758
Scn5a 0.00168768 0.357007272 0.432910309
Tk1 0.00168768 0.13246388 0.154810843
Rrm2 0.001710233 0.250778068 0.231417167
Cln8 0.001795062 3.235371296 3.010591634
Cdc2a 0.001795113 0.301991565 0.342410119
Itm2a 0.001863812 8.113299015 6.417352279
Col6a1 0.001863812 0.302883597 0.232177251
Cdc20 0.001863812 0.239972407 0.223270708
Tcf19 0.001988745 0.246090294 0.236449549
Gjb2 0.002025843 4.089875847 2.765315961
Gnas 0.002025843 2.668365898 2.712254741
Pbp2 0.002074216 4.597375368 3.149178861
Ttc7b 0.002074216 3.993139349 4.384765123
Slc43a3 0.002092196 8.539500955 3.740860053
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Col6a2 0.002111372 0.152533389 0.104357651
Ddit3 0.00225376 7.674901119 5.462215623
Cdc42ep2 0.00225376 0.314670964 0.250770079
Tanc2 0.002276568 8.353457533 7.519863658
Car8 0.002277827 13.40770237 9.669765711
Satb1 0.002277827 9.980816392 2.998524811
H2afj 0.002277827 0.288601132 0.308472515
Satb1 0.002305913 7.387540883 4.123368563
Aldh1l1 0.002315686 1.850749281 1.62166328
Serac1 0.002319768 2.129592902 2.630595998
Akr1b7 0.002347205 10.00415576 9.023839623
Tmem56 0.002404173 4.265227354 4.287337653
Car6 0.002407202 11.76049839 10.67819155
9130404D08Rik 0.002421784 2.456459733 2.5650147
AI427515 0.002421784 0.133804922 0.245275532
5430416N02Rik 0.002428494 6.521265278 5.847574995
Lpl 0.002428494 4.995256933 4.179503256
Larp7 0.002428494 0.485891191 0.44865231
Heph 0.002448915 1.97756035 1.785323755
0610040J01Rik 0.002609922 3.170831449 2.212745637
Maoa 0.002628791 6.200781364 6.392601621
Sh3kbp1 0.002628791 2.945509819 3.146046524
Cnp1 0.002628791 0.6148689 0.56719914
Havcr2 0.002660547 2.789643321 2.49425754
Tuba3a 0.002660547 0.266672981 0.278331475
BC049816 0.002762239 0.076571467 0.09472858
Sacs 0.002800323 1.978546638 2.790111466
Ube2c 0.002800323 0.356289528 0.391130866
Mga 0.002807775 2.067792488 2.37923582
Myd116 0.002863067 11.0015357 8.389082981
Scn8a 0.00289813 1.682878867 1.493569168
Ccnb2 0.002910421 0.203910928 0.195201907
Dsc2 0.002915285 5.089732546 3.884417611
Anapc13 0.002915285 0.448165939 0.411443085
Fstl1 0.002915285 0.080751652 0.057807969
Sprr2a 0.002923687 0.427996513 0.198106631
Reep6 0.002946149 4.308801874 3.64443214
Wnt4 0.002946149 0.137831842 0.184229124
Cdca8 0.002956814 0.371015488 0.354524363
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2310005L22Rik 0.003005639 7.071257653 6.977522197
Raet1a 0.003005639 2.951882895 2.482828103
Cdca5 0.003053732 0.208856415 0.253185529
Plf 0.003160388 16.87659228 2.864550974
Slc43a2 0.003160388 0.413383025 0.4108956
D17H6S56EQ5 0.003160388 0.231502028 0.150070873
Avil 0.003231914 10.86951594 9.710844132
Hmga1 0.003276515 2.174638153 2.808999473
Tnfaip8l1 0.003316898 0.617146926 0.428423737
Stbd1 0.003343569 9.424871693 6.97270258
Nupr1 0.003343569 7.030942443 2.802195248
Cenpa 0.003343569 0.326684987 0.31820146
9830002I17Rik 0.003345046 0.320290408 0.509076082
Aqp9 0.003346091 9.725736834 4.471851405
Aqp9 0.003355926 5.061157756 5.119970407
Lztr2 0.003370842 8.110647202 7.690225763
Pgf 0.003370842 6.068129433 1.986675282
Lig1 0.003370842 0.289228131 0.318503238
Jag1 0.003380836 8.441030547 7.609053136
Ctsb 0.003380836 5.762991784 4.697654329
Huwe1 0.003380836 3.230397832 3.780980187
Ddi2 0.003380836 2.535337211 2.634034996
Otop1 0.003380836 2.386642494 2.341595805
Epas1 0.003380836 2.184525182 1.892805152
Smc2 0.003380836 0.267271479 0.309817248
Angptl6 0.003387493 6.379059112 6.176217693
Akap8l 0.003413976 2.469212931 2.426041069
Rest 0.003418441 1.767371977 1.65779857
Ncapd2 0.003418441 0.22014273 0.218884139
BC049816 0.003418441 0.135254683 0.187225885
Hgfac 0.00342034 3.418429355 1.898945349
Lsm3 0.003429556 0.27056332 0.318569166
2210401J11Rik 0.003545207 4.471608043 2.475072819
Cep55 0.003584969 0.199142696 0.202241445
1810032O08Rik 0.00370203 6.386847794 5.639073389
Tgfb3 0.003736714 0.259113616 0.274210174
Mfap3l 0.003761304 2.408058941 2.311745334
Fstl1 0.003761304 0.062336499 0.038959192
Cd53 0.003765784 3.155197537 2.7467338
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Cxcl5 0.003769452 0.077580132 0.046876531
Huwe1 0.003964862 3.142123289 3.719125522
Ank2 0.003964862 3.068432553 3.539632603
Trib3 0.003998194 6.131089217 4.436612157
Cyp3a13 0.004015636 11.07515808 3.562844286
Twist2 0.004160686 0.312499903 0.489143177
Pole 0.004257385 0.322122536 0.460566342
Cxxc5 0.004261471 0.375735093 0.353465612
Grpel2 0.004296769 2.865441868 3.026812365
Pbxip1 0.004296769 2.181578256 1.71670266
Tuba4a 0.004296769 0.4770419 0.418422345
Timp1 0.004296769 0.281109068 0.237884929
Spbc24 0.004296769 0.21058255 0.226910994
Crisp1 0.004296769 0.047731174 0.245570826
D730039F16Rik 0.004335042 1.762606882 1.535282971
Ptprn 0.004335042 0.643962612 0.543054104
Id1 0.004335042 0.369807147 0.344101804
D1Ertd471e 0.004335042 0.290024105 0.290143477
Spbc25 0.004335042 0.237648931 0.209267228
Cdkn3 0.004335042 0.216093608 0.222060151
Pmm1 0.004380462 3.854389798 5.244775151
Eomes 0.004427627 2.263818863 2.540458063
B230342M21Rik 0.004444724 5.169177764 5.626542628
Cd55 0.004499567 2.650051684 2.817223611
BC046404 0.004525636 3.354977946 1.729799874
Ank2 0.004525636 3.079181469 3.091242588
B4galnt2 0.004537752 4.287928948 4.688302614
Slu7 0.004537752 2.000053604 2.329546268
Tm4sf1 0.004562696 2.464366268 2.747697856
Acot2 0.004660806 5.037065763 4.150102355
Jmjd3 0.004672581 3.336412631 3.071116775
Tuba3a 0.004672581 0.466450303 0.515030789
Pcp2 0.004672581 0.400490811 0.290675938
Mst1 0.00468969 3.12507587 2.648749214
Lphn2 0.00468969 2.754194166 2.545547858
Ak5 0.004716756 1.834402562 1.992410279
Cd55 0.004779253 2.982454609 3.347356478
Bre 0.004779253 1.785713869 2.01396938
Tubb2c 0.004839628 0.298692208 0.309187368
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Uhrf1 0.005012925 0.218668144 0.268281785
Ces2 0.005068817 2.990894277 2.67604044
Cp 0.005123234 0.26846989 0.20060232
Nid1 0.005156882 3.899856036 3.299288401
Gm440 0.005281574 4.315897494 2.326937588
Cdca2 0.005290859 0.336689025 0.349005791
Atf6 0.005298598 2.640694983 2.511624153
D2Ertd750e 0.005298598 0.275068403 0.264191367
Bub1b 0.005299275 0.209473312 0.186626628
Ahcyl1 0.005304355 3.008933793 3.308694694
Snai2 0.005360215 1.660494723 1.712081211
Fkbp11 0.005404579 6.551865835 3.124299458
Sparc 0.005453296 0.165383853 0.159509936
AI788777 0.005538418 0.362509817 0.290067576
Rrm1 0.00555708 0.321307301 0.323304876
Sqstm1 0.005610451 3.894036414 3.448486413
Opa3 0.00574786 0.635147915 0.52200986
Pttg1 0.005765046 0.327759801 0.346709267
Btbd11 0.005776891 7.052830376 3.212251214
Tacc3 0.005776891 0.235314541 0.202752938
Nup98 0.0058216 2.424878723 2.818199664
D17H6S56EQ5 0.005914234 0.251538051 0.151888159
Nrip1 0.006055285 6.105619172 6.545867466
Mxra7 0.006055285 0.459141196 0.634460063
Rbbp6 0.006190431 2.641662691 2.898644339
Ndrg1 0.006272831 6.191152368 4.35462388
Col27a1 0.006272831 0.334014453 0.396889817
Btbd11 0.006311773 5.429511859 3.670597348
Cul2 0.006311773 3.13900827 3.866685054
Ogt 0.006311773 2.365527919 2.628122714
Dlc1 0.006311773 2.105636175 2.402184807
Pcolce 0.006311773 0.269214586 0.209143523
Sparc 0.006323938 0.22004752 0.224062226
Soat2 0.006376737 7.084411896 3.798369162
Ppp1r3b 0.006386857 10.58282098 3.378103779
Cdkn2c 0.006420512 0.239964022 0.264767418
Gpt2 0.006430655 3.826563971 3.972113943
Napb 0.00644782 2.729279802 2.198240615
Cd38 0.006460134 1.606239004 1.571578078
224
Rps25 0.006460134 0.317540211 0.345471896
Abcc2 0.006558454 2.50420391 2.636925648
Zfp397 0.006657147 2.339503569 3.386951791
Ereg 0.006700752 17.15577855 8.59044318
Cxcl1 0.006700752 0.246422779 0.220447473
Tyms 0.006722994 0.248980217 0.244217182
Zfand2a 0.006742236 4.277176127 4.093326388
Nr4a1 0.006746412 2.553788111 2.522113538
Sh3bgrl2 0.006828712 3.206613344 2.767700949
1200009I06Rik 0.006847792 0.147158072 0.194759019
Trim35 0.00686979 4.997793564 4.045270863
Ppp1r2 0.00686979 2.295819596 2.107389121
Aurka 0.006883334 0.269317248 0.28400712
Hist1h2ao 0.006883334 0.260059986 0.30599703
Spns2 0.006883334 0.220127279 0.244512902
Fgb 0.006897418 3.440699749 3.821076678
Obfc2a 0.006918388 5.336790648 5.362519937
Ddit4l 0.007019898 0.495832534 0.356366039
Pvr 0.007025532 6.071980281 7.379161519
Glrb 0.007093003 2.938551132 3.039268773
4930402H24Rik 0.007132943 3.042041509 1.893389324
B230112P13Rik 0.007158195 5.046418004 3.97071133
Adar 0.007158195 2.022404273 2.107131558
Cp 0.007205511 0.348095145 0.272988514
Tmem140 0.007263509 4.24390777 3.124400018
Clybl 0.007300366 4.04136411 2.677648644
Etv5 0.007300366 1.976105101 2.302483
Klf6 0.007304121 3.448900107 3.433727988
2410014A08Rik 0.007456514 0.249784684 0.204646276
Col27a1 0.007492421 0.326163463 0.472722706
9430098F02Rik 0.007646717 1.995878058 2.347690936
Plk1 0.007646717 0.200046085 0.202035917
Pitpnb 0.00776292 2.097710663 2.984063107
Ptprt 0.007766094 5.719380232 5.884702622
Msn 0.007766094 4.448308361 5.625372626
Tiparp 0.007766094 3.902708192 3.950750787
Zfand2a 0.007766094 3.691311831 5.035703903
Stom 0.007766094 3.417598009 3.716305706
Ankrd11 0.007766094 2.975994968 2.79775562
225
Cdr2l 0.007766094 2.948897314 3.532654819
B3gnt2 0.007766094 2.841474759 3.194691351
Pcdh19 0.007766094 0.408328151 0.411071256
AW552393 0.00777326 2.169005285 2.43482012
Igf2r 0.007822466 1.878529116 2.076339412
Lhfpl2 0.007948874 6.346813839 5.902136867
Hmmr 0.008042175 0.250816633 0.210438821
Ccnb1 0.008046787 0.318796849 0.313160084
Cxadr 0.008068775 3.927920599 4.549661769
Lrrc14 0.008068775 2.615768667 2.823374088
Cela1 0.008093119 4.362505475 4.922844857
H2afx 0.008108546 0.320313556 0.495122063
D10627 0.008205985 2.800107958 3.32109035
Dnaja3 0.008207976 2.900585138 3.064245352
Lmna 0.008304088 0.299720215 0.239380289
Tspyl1 0.008313343 1.651126984 2.080666997
Efemp2 0.008313343 0.268142172 0.303809938
D430039N05Rik 0.008328109 5.037348891 6.41977022
Ptpn22 0.008328109 3.048130019 3.498230938
Bub1b 0.008328109 0.245386719 0.247852777
Zfp655 0.008342735 2.354780819 3.027205273
Ocln 0.008419169 3.340707802 2.215239498
Napb 0.008438884 3.065011026 2.815338161
D1Ertd448e 0.008664401 4.083053616 5.651186879
Itpk1 0.008707775 4.652633434 2.366706372
Rfc5 0.008707775 0.33189261 0.395448626
6720460F02Rik 0.008758216 0.239979922 0.281063629
Plxna2 0.008995637 0.537509571 0.537032246
Tnrc15 0.009079687 2.960500154 3.1737458
Uqcrh 0.009079687 0.54532322 0.492810174
Ncapg 0.009079687 0.23704754 0.231459724
Cldn23 0.00911783 2.589381383 2.626006565
5730410E15Rik 0.009177103 2.588479403 3.165095723
Cenpf 0.009369253 0.185049472 0.254900737
Pmm1 0.009503746 4.211083819 3.794669233
Acsl1 0.009618901 1.89648253 2.20310998
0610012G03Rik 0.009732567 20.83775615 11.46154
Bmp1 0.009775294 0.404826029 0.374812676
Casp4 0.009916431 1.696185077 1.801113569
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Slc43a2 0.009920598 0.484457602 0.511793495
H2QQ8 0.009954765 2.337085793 2.557542925
Mbnl2 0.009976159 2.709514363 2.832646077
Hif1a 0.01001529 3.656682431 4.102682672
Tmed5 0.010021225 3.149186124 3.340402744
Arhgap5 0.010021225 2.863143686 2.299248759
227
APPENDIX B
Gene Expression Profiling of HCC Cells with KLF6 knockdown
228
Gene Symbol pAvalue
Fold Change
(log2)
Knockdown
v. Control Gene Symbol pAvalue
Fold Change
(log2)
Knockdown
v. Control
Plau 3.85EQ06 1.762227291 Spata6 0.002453886 Q0.593753526
Uap1 1.35EQ05 Q1.458238381 Gstm2 0.002467081 0.984571765
Uap1 2.37EQ05 Q1.595251461 Epcam 0.002472838 1.709331708
Dlc1 2.46EQ05 1.860343451 Lrrfip1 0.002490078 Q0.600132767
Mycl1 3.07EQ05 1.187973114 Tgfbi 0.002501542 2.082084519
Smpdl3b 3.28EQ05 1.393190011 Gm11818 0.002508045 Q0.74861109
Ppm1a 3.42EQ05 Q1.235872998 Pabpc4 0.002523909 Q0.620052197
Fam107a 3.81EQ05 1.603192983 Mtm1 0.002526668 0.5885022
Dlc1 3.87EQ05 1.649607222 Enpp1 0.002530293 0.832551137
Prkaa2 4.15EQ05 Q1.228875689 Leprot 0.002546544 Q0.649815254
Ctnnal1 4.88EQ05 1.091069077 N4bp2l1 0.002610284 1.664306702
1200002N14Rik 5.64EQ05 1.153656265 Smpd3 0.002623292 Q0.742017872
Lamb1Q1 8.06EQ05 1.37449819 Skp2 0.002631105 0.641314392
Crip1 8.46EQ05 Q1.444911446 Twist2 0.002641133 Q0.902721013
Prom1 9.48EQ05 1.064690626 Hoxb5 0.002641651 0.686547268
A030004J04Rik 9.64EQ05 2.240787245 Ddhd1 0.002649767 0.743719439
Gpr116 9.70EQ05 0.981431899 Ly6c1 0.002659032 1.407139429
Fbln1 9.71EQ05 1.944755032 Wiz 0.002668493 0.66522312
Tor1b 0.000104083 Q1.06211018 Bicd1 0.002677934 Q0.748573055
Avpr1a 0.000106961 1.293061077 Ston2 0.002706969 Q0.638325833
Car12 0.000116075 1.051635899 Leprot 0.002720669 Q0.793291941
Flrt2 0.000127149 1.069131875 Id2 0.002726102 Q1.240178267
Macc1 0.000140945 1.80713777 Nudt6 0.002727083 0.691211849
Cmtm3 0.000141562 1.307394006 Sema3d 0.002736656 0.78781102
Plau 0.000144508 0.898393979 Cdca7 0.002746019 0.638588898
Pno1 0.000175537 Q1.108917851 Gpbp1 0.002763384 0.606273759
1810055E12Rik 0.000185123 Q1.211232778 Adamts1 0.002773951 0.920852928
Uap1 0.000185349 Q1.397032621 Mettl1 0.002779502 Q0.696047218
Lrch2 0.000193094 0.89374528 2010003O02Rik 0.00278764 Q0.72021946
Enpp1 0.000193738 0.91516716 D13Ertd608e 0.002841484 Q0.703509474
Zdhhc2 0.000202895 Q1.033982934 Stard5 0.002846852 0.626408274
Ubxn2a 0.000205648 Q1.93552093 Fam107a 0.002851129 0.670444996
Ube2w 0.000206028 Q1.016143921 Lhfpl2 0.002869439 0.641930757
Gzme 0.000218115 1.728697861 Sall1 0.002881167 Q0.641365883
Pkdcc 0.000235341 0.976024437 Adcy9 0.002883211 Q0.646212959
229
Tgfbi 0.000235721 2.432722606 Spire1 0.002905422 Q0.671742014
Serpinb8 0.000236422 Q0.892405159 Slc37a3 0.00291557 Q0.881818225
Gzme 0.000245797 1.213091255 Ndrg4 0.002927438 Q0.607961889
Ptgds 0.000257894 0.915802085 Hmgcr 0.002976248 Q0.688581361
Slain1 0.000258932 Q0.864212256 Sprr1b 0.003018385 0.833404305
Tor1b 0.000272519 Q0.85966816 Krt80 0.003018871 0.723031504
Hnmt 0.000272607 0.990894098 Lactb2 0.003036363 Q0.613108731
Cxxc4 0.000277449 Q0.827243541 Cep97 0.003047418 0.610562712
Cxcl16 0.000281491 1.329128217 AI467606 0.003063955 0.842655771
Slc24a3 0.000285904 1.04927184 Fam57a 0.003076916 Q0.651060824
Fbln1 0.000289824 1.944486384 Krt39 0.003096599 1.210944376
Plekha7 0.000293592 Q1.08035233 Hpdl 0.003097405 Q0.586945416
Eif4e3 0.000305286 Q0.799969177 Fmn1 0.003099178 1.245452029
LOC100048050 0.000312838 1.510576777 Cyp4a10 0.003107953 Q0.915239301
Cpt1a 0.000318386 Q1.06928744 1436240_at 0.003109123 0.597759426
Adamts4 0.000327324 0.820603936 Suv420h1 0.003113982 Q0.656433231
Sfmbt2 0.000333262 Q1.036548793 Smpd3 0.003166642 Q0.724985306
Nipa1 0.000343719 Q0.794493839 Rhob 0.003169701 Q0.591417425
Camk2d 0.000377908 Q1.260358184 2310057J16Rik 0.00317018 Q0.989643753
Sult4a1 0.00038701 Q0.853113356 Has2 0.003181107 0.874945939
Zdhhc2 0.000388686 Q0.925556158 Tspan17 0.003191299 Q0.817715937
Arhgap29 0.000394635 0.753213937 Athl1 0.003193568 Q0.648430875
Pja1 0.000401214 Q0.767175476 Zfhx4 0.003197246 0.749487626
Sod2 0.000404688 Q0.837673732 Ephx2 0.003210472 Q0.684959306
Dsp 0.000407098 Q0.751876163 Eif4e3 0.003216935 Q0.663110312
Ubxn2a 0.000413005 Q0.965959667 Metrnl 0.00321999 1.456363807
Ggh 0.000416947 Q0.954220703 Spata6 0.003222242 Q0.634014329
Cdc42ep3 0.000425647 1.26131205 Uap1 0.003243502 Q0.599655866
Tanc2 0.000428004 1.157550031 Pgpep1 0.003261603 0.736779744
Serpine2 0.000431931 1.349082382 Tbc1d16 0.003262343 0.662670059
Ndst1 0.000441671 Q0.790198948 Il1rn 0.00328888 0.765477963
Vsig1 0.000442809 Q1.456836034 Adk 0.003290401 0.863637351
Ly6e 0.000442959 2.340338496 Gm1157 0.003292821 Q1.037569456
2410076I21Rik 0.000449637 0.787459016 S100a3 0.003340096 Q0.748867406
Cdc2l6 0.00045074 Q1.508232133 Slc9a3r2 0.003341955 Q0.83881258
Lamb1Q1 0.000451749 1.17073545 Mmp3 0.003351317 1.032870846
Hspb8 0.00045521 Q0.924313309 Sult1c2 0.003395405 0.833270127
Dnajc5 0.000459038 Q0.750030372 Gdf15 0.003406838 2.319866057
A930035D04Rik 0.000472892 Q0.916035222 Zdhhc6 0.003413213 Q0.735314581
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Bmp2 0.000481307 Q0.914708689 Fam71f1 0.003417808 0.597405284
Hnrnpa3 0.000484357 0.738080121 Cldn1 0.003418355 1.334778266
Krtap16Q7 0.000499333 Q0.840030483 D730040F13Rik 0.003434316 Q0.657039962
Zdhhc2 0.000500021 Q0.756281451 Tln1 0.003455799 Q0.753093218
Tanc2 0.000507302 1.327487172 Myo5b 0.003468442 Q0.594849499
Kif23 0.000508846 Q0.929172366 Fst 0.003499528 1.297545537
Cpne8 0.000515687 0.961393908 Prss23 0.003511766 1.363822334
Cpt1a 0.00051947 Q1.319330216 Tom1l1 0.003541248 Q0.600576648
B4galt6 0.000530262 Q0.74804846 Chfr 0.003564194 Q0.818534345
Aebp1 0.000530874 0.751007381 Ccbe1 0.003572192 1.067156342
Tpcn1 0.000534639 Q1.093585369 Cpsf6 0.003606607 0.827469476
Prl6a1 0.000545961 1.134763655 Rps6ka6 0.003677601 0.980977038
Fam43a 0.000552051 0.721591372 Rbpms2 0.003693628 0.66468463
Rab27b 0.000561191 Q0.793890464 Clmn 0.00371989 Q0.596699734
Glt8d1 0.000562084 Q0.819438728 Id2 0.003720923 Q1.187599805
Kazald1 0.000571528 Q0.81445701 BC016423 0.003722627 0.596626571
Dnajc5 0.000573002 Q0.770015247 Itgb6 0.003734725 Q0.900977262
Fgf1 0.0005815 Q0.763496089 Ppl 0.003739264 Q1.151328866
Dsp 0.000589639 Q0.707657417 Kif1b 0.003761936 Q0.661465698
Ptprd 0.000600743 0.69479981 Stc2 0.003819068 1.672313729
Gfra1 0.000611461 0.932708065 Tmem179b 0.003836678 Q0.673865409
Epb4.1l1 0.000617977 Q1.009455234 Gusb 0.003845331 0.71018386
LOC100048050 0.000618302 1.528132882 Lyrm2 0.003847246 Q0.834024091
Nup50 0.000619507 Q0.712909922 Cep97 0.003863294 0.625539176
Abcb7 0.00062169 Q0.713172899 Ndufaf1 0.003867201 Q0.796370982
Slc15a4 0.000627969 Q0.769417161 Nudt19 0.003872934 Q0.798582358
Tubb4 0.000628561 Q0.853091152 1441020_at 0.003874182 0.635962493
Gnb4 0.000628739 Q0.794626052 Id2 0.003874369 Q1.211432958
Gata5 0.000638358 Q0.707068056 Tmtc2 0.003909816 0.974676814
Lrrfip1 0.000641478 Q0.751479748 Amot 0.003924561 Q0.869329599
Ecscr 0.000650762 1.755329747 Pear1 0.003929477 Q0.789815381
Plod2 0.000653801 Q0.732403504 Gm16367 0.003948616 Q0.710751714
D4Ertd22e 0.000656892 Q0.786955765 Rgs3 0.003957554 0.70064593
Mfsd6 0.000660258 Q0.952576887 Mest 0.003965405 0.780497753
Prkaa2 0.000665939 Q1.239663201 Rnf157 0.003967367 0.654215347
LOC639910 0.000667632 Q0.946096466 Igsf9 0.003973862 0.749251878
Tgfbi 0.000670379 1.986956398 Hltf 0.003974471 0.84665315
Flrt2 0.00068395 0.767922281 H2afz 0.004012187 Q0.58885814
Serpinb8 0.000686434 Q0.794526646 Lbh 0.004020555 0.725499543
231
Satb1 0.000688306 2.126210827 March2 0.004025173 Q0.585214774
B4galt6 0.000694966 Q0.703995706 Col1a1 0.004108703 0.710404915
Dctd 0.000705637 0.844990613 Trpt1 0.004111949 Q0.585804457
Unc119 0.000708597 0.737088544 C76336 0.004114743 Q0.908872103
C1galt1 0.000711502 0.901050835 Fam171a1 0.004117391 Q0.610020099
Tm4sf1 0.000722311 1.833066055 Tgfa 0.004131855 Q0.7583242
Arrdc4 0.00073047 0.864959032 Lpar2 0.004138072 0.822360831
1600021P15Rik 0.000731694 Q0.988247795 EG628475 0.004143728 Q0.756922855
Cdc2l6 0.000745553 Q0.945297279 Fndc4 0.004171172 0.952767546
Mtap4 0.000746506 Q0.953982527 Gja1 0.004187191 0.691949349
Pax8 0.000747102 0.791061267 Churc1 0.004189274 Q0.598606281
Tomm22 0.000748676 Q0.75407341 Gda 0.004193156 0.895138024
Tcf4 0.000749703 0.950342423 Oxct1 0.004200482 0.676369259
Ccnc 0.000751712 Q1.091947263 Nsbp1 0.004216033 Q0.9631205
Il18rap 0.000755237 1.110989678 Cldn2 0.00422295 Q0.599372628
Tspan2 0.000763194 0.823272404 Hipk3 0.00422589 Q0.67116717
Fam65b 0.000764592 Q0.820728254 Cdc26 0.004235394 Q0.769368366
Cdca7l 0.000766815 0.715442007 Slc6a6 0.004240301 Q0.812236392
Avpr1a 0.000776655 0.765794262 Gm14226 0.004253985 Q1.080773942
Sema6a 0.000777131 1.311924262 Lilrb4 0.004259722 1.530690933
Enpp2 0.000777721 2.072589649 Aqp9 0.004273167 0.775469669
Mpp7 0.000779598 Q0.733020774 Ccdc47 0.004285701 0.721848567
Vegfc 0.00077984 0.763817576 Tmem9b 0.004295504 Q0.764093001
Rb1 0.000788477 Q0.729810168 Ddx26b 0.004302591 0.7181883
Evc2 0.000791109 0.665675092 Tmem9b 0.004316337 Q0.609473416
Alg14 0.00082697 Q1.660480034 B4galnt4 0.004331409 0.701997302
Celsr1 0.0008495 0.713041834 9030025P20Rik 0.004354905 Q0.67796281
Slc9a3r2 0.000856241 Q0.99464123 Tor1aip2 0.00437073 Q0.647925401
Anxa4 0.0008586 Q0.674168306 Bbs4 0.004382594 Q0.802197169
Lrrc8a 0.000864924 Q0.801752352 Cpne8 0.00439809 0.839913857
Crip2 0.00086891 Q1.315816099 Als2cr12 0.004438836 0.763678937
Cxcl16 0.000872106 0.748746608 1500003O03Rik 0.004439212 Q0.624291879
Ifitm1 0.000873457 1.366565507 Cttnbp2 0.004447476 1.540655614
Dnajc5 0.000883076 Q0.755696168 Ccnc 0.004448667 Q0.668396802
Ogg1 0.000884096 Q0.715638391 Adam12 0.004453543 0.927438658
Chfr 0.000893155 Q1.124291176 S100g 0.004490665 1.537318257
Vcan 0.000902955 0.815642225 Prdx3 0.004493067 Q0.625485094
Orm1 0.000908582 1.15723001 Plce1 0.004501079 Q0.671011402
Ly6e 0.000912903 1.388800574 Lnpep 0.004526912 Q0.619288296
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Krt14 0.000913932 0.681479786 Nicn1 0.004540724 Q0.592376523
Glt8d1 0.000916887 Q0.807648208 Tnfaip1 0.004543775 Q0.722686191
Cpt1a 0.00094163 Q1.046024127 Dok1 0.004546766 0.82042274
Ano1 0.00094195 Q0.71618039 Cdc42ep3 0.004561712 0.936901219
Sytl2 0.000944993 Q0.744073822 Tmem69 0.004651925 Q0.759619203
Chml 0.000945396 Q0.716788746 Ddx26b 0.004677127 0.672887455
Ptger4 0.000959148 0.973715479 Ccdc68 0.004678017 Q0.623281785
Rab27b 0.000966924 Q1.098534567 2310005N03Rik 0.00468583 Q1.484375898
Sema4a 0.000974266 1.113849616 Enpp1 0.004689716 0.717067714
Ahnak2 0.000981767 Q0.661147291 Sema3b 0.004713403 0.636689122
Spa17 0.000991928 Q1.470909362 Zdhhc3 0.004727269 Q0.781158033
Htra1 0.000998495 1.288632361 Rnf11 0.004728855 Q0.611606453
Prss23 0.001019158 1.318452404 Klf6 0.004729363 Q0.61287183
Ank2 0.001031298 1.516568098 Ccl9 0.004740001 1.473055745
2810022L02Rik 0.001034596 Q1.069171058 Pde7a 0.004753294 0.742251548
Skp2 0.001046376 0.760906037 Ndrg3 0.004762166 Q0.705574158
Gtf2b 0.001052163 Q0.748248981 Cars2 0.004765604 Q0.625158968
Tinagl1 0.001057266 Q0.947175225 Tcf4 0.004772639 0.826453996
2610002J02Rik 0.001072638 Q0.646086179 Grasp 0.004817902 0.824364434
Zfpm1 0.001086201 Q0.673449658 Pde7a 0.004822081 0.705983839
1500003O03Rik 0.001090246 Q0.648346372 Cdh1 0.004832479 Q0.805352699
Rab27b 0.001094988 Q0.742339669 Ptprf 0.004835692 Q0.880288406
Rab3gap2 0.001103693 Q0.620077358 Jag1 0.004855883 0.82447283
Satb1 0.001111253 2.146846888 Bmp7 0.004871938 Q0.793876593
Megf9 0.001112211 Q0.99976632 Sertad4 0.004881019 1.199148249
Aplp1 0.001131337 Q1.336740824 Edn1 0.004890304 1.047249779
Tspan2 0.001133831 0.670025782 Osmr 0.004910909 0.634226854
Zfp618 0.00115386 0.73585893 4932441K18Rik 0.004918897 0.587691815
Stc2 0.001178737 1.180840161 Cachd1 0.004931001 Q0.718242963
F2rl1 0.001187387 0.798507096 Bbs10 0.004932327 Q0.839255079
Pde7a 0.001189456 0.853495983 Slc37a3 0.004947824 Q0.730342649
Arhgef16 0.001195155 Q0.658444838 Kcnab1 0.004955651 Q0.668750035
1600029D21Rik 0.001195898 1.233002961 Vcl 0.004958123 0.60850883
Qsox2 0.00120096 Q0.650671615 Slco2a1 0.004969889 Q0.61204628
Adcy9 0.001203247 Q0.74149866 2810410D24Rik 0.005004148 Q0.640332353
Lpl 0.001218325 1.109337689 Renbp 0.005024122 0.678220295
Cd276 0.001224574 0.699645924 Micalcl 0.005035739 Q0.618487316
Cep290 0.001228892 Q0.828117697 Tcf4 0.005056212 0.832527615
Sytl2 0.001228893 Q0.876867375 Grasp 0.005152902 1.188151169
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Lmna 0.001228965 Q0.665163284 A630095E13Rik 0.005195836 0.878692585
S100a13 0.001231299 Q1.088122583 Adora2b 0.005214136 0.708232254
Ifi204 0.001232211 Q0.809598051 Fam19a5 0.005215129 Q0.881604816
Rab28 0.001236985 Q1.062217563 6720475J19Rik 0.005224547 0.952917606
Car8 0.001240084 1.803000883 Wasl 0.00523539 0.641257048
B230120H23Rik 0.001242771 0.716060251 Jag1 0.005243397 0.64423835
Pkdcc 0.001243073 0.99770131 St3gal5 0.005243929 Q0.683748385
Gja1 0.001252941 0.899967973 Nbl1 0.005258454 Q0.593857485
Nfic 0.001255649 Q0.67773405 Igsf11 0.005274541 Q0.742715019
D16H22S680E 0.001257756 Q0.785768857 Ela1 0.005315403 0.623065944
Flywch2 0.00125856 0.868425869 Mylk 0.005340125 0.857035294
Adamts6 0.001261445 1.04304323 Ngef 0.005350864 0.716281413
Csnk1a1 0.001281757 Q0.617043272 Nbeal2 0.005359723 Q0.614795087
Slc27a1 0.001287696 0.691482654 A230067G21Rik 0.005368959 Q0.591187066
Ktelc1 0.001312578 0.706351899 Parp3 0.005398508 Q0.646879201
Pdzrn3 0.001313139 0.864179566 Ptplad2 0.00544809 0.639728076
Npc1 0.001315801 Q0.768084508 5730410E15Rik 0.005471505 0.705164341
Gja1 0.001317548 0.815952903 Ccnyl1 0.005526123 Q0.602362479
Mcpt8 0.001318603 1.432686544 Mfsd6 0.005526964 Q0.673366317
Akt3 0.001322057 Q0.667794778 Rbpj 0.005576877 0.959160671
Dmrt2 0.001334632 Q0.631332278 Rhox5 0.00561405 1.667155822
Anxa10 0.001334872 Q0.917630286 Fut10 0.005615972 0.634041131
Casp12 0.001354926 1.064271491 Faah 0.005662243 Q0.609753333
Kif23 0.001367347 Q0.733829366 Atl3 0.005728075 Q0.917466379
Maf 0.001370739 0.627384024 Serpinb1a 0.005755068 0.966003947
Slc25a12 0.001381082 Q0.668043867 Maf 0.005786715 0.706309932
Fst 0.001381959 2.164641799 1810032O08Rik 0.005822576 0.588783492
Gstt1 0.001396486 1.128958226 Epb4.1l5 0.005827623 Q0.613637985
1110007A13Rik 0.001397025 Q0.765563981 2010011I20Rik 0.005892763 Q0.774185635
Gm9971 0.001411885 Q0.612527585 Car2 0.005901111 0.688075037
Kif1b 0.001415802 Q0.610963744 Malat1 0.005919577 Q0.744111719
Aplp1 0.001418147 Q0.631992482 Ung 0.005933682 0.638463522
Vegfc 0.00141903 0.809319721 B230380D07Rik 0.005967118 Q0.74961381
Tcf4 0.001425156 1.065834841 Rabl4 0.005983069 Q0.66760294
E430016P22Rik 0.001432043 0.908168894 1190007F08Rik 0.006000901 Q0.64535038
Lyrm2 0.001433856 Q1.218567249 5330431N19Rik 0.006068229 Q0.703712553
Gjb4 0.00143487 Q0.651959318 Hoxa1 0.006164709 Q1.28909575
Nfic 0.00144847 Q1.077814818 Gabarapl2 0.006168816 Q0.601301836
Tgfbi 0.001452591 2.083734424 Abhd2 0.006247226 Q0.749958174
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6030426L16Rik 0.001453339 Q0.937498442 Kbtbd7 0.006307958 Q1.00393646
Gja1 0.001462264 0.831213957 Tcf4 0.006322314 0.866832731
Ppp1r7 0.001465692 Q1.25487732 Nid1 0.006334857 0.678737528
Ano1 0.001480204 Q0.636865246 Cdkn2d 0.006387225 Q0.832964627
H60a 0.001499201 1.573678416 Tgif2 0.006405291 0.762525825
Smap1 0.001525737 Q0.596148213 Ptgds 0.00642541 1.129059934
Greb1 0.00153139 1.015254213 Cybasc3 0.006438208 Q0.66865316
Pcnx 0.001536248 Q0.586721122 Mctp1 0.006493057 0.704028206
1810048J11Rik 0.00153722 Q0.680938079 Ccbe1 0.006497449 1.156955636
Fam19a5 0.001540936 Q0.589000873 Cdyl2 0.006550749 Q1.027711301
Tomm22 0.001545759 Q0.718785569 2610034B18Rik 0.006616051 Q0.626275369
Hist2h2aa1 0.001547579 Q0.613903782 Rshl2a 0.006640076 1.082073283
Klf6 0.001554328 Q0.77001268 Traf3ip1 0.006655917 Q0.809717598
Abhd2 0.001554507 Q0.672339411 Prkar2a 0.006735434 Q0.700063142
Abhd2 0.001559487 Q0.65838517 9130219A07Rik 0.006778388 Q0.700840576
Wdr90 0.001561199 Q0.59204578 Ralgps1 0.006790885 Q0.616706501
Slco2a1 0.001580312 Q0.666408337 Dll1 0.006798618 1.19034083
Klf4 0.001594087 Q0.605786332 Eif5a2 0.006832626 Q0.647458244
Nras 0.001594308 Q0.586234907 LOC100046012 0.006836442 0.60095445
Smad6 0.001595912 Q0.682124161 Mreg 0.006864439 0.642418158
Cltb 0.001599812 Q0.632888132 Chrna1 0.00687285 Q1.129281869
Efna5 0.001605106 0.585551826 Tlcd2 0.006888723 1.132391361
Srgap3 0.001626443 0.72685787 Osbpl2 0.006901172 Q0.693548201
Mcart6 0.001633225 Q0.633697731 Tcstv1 0.006956239 Q0.899163299
Gm13043 0.001647176 Q0.610205428 Itm2a 0.006963889 1.711218168
Ror1 0.00165188 Q2.169639027 Mfsd4 0.006994472 Q0.68474979
4930504B16Rik 0.001660563 0.631686269 Ddr2 0.007061434 0.814425004
Suds3 0.001662515 Q0.758481423 Oxct1 0.007071156 0.645728665
Casp12 0.001669105 0.996259045 Unc13b 0.007075966 Q0.596016313
Mylk 0.001686029 0.80125245 Pik3r5 0.007076805 0.596500587
Lad1 0.001686291 Q0.672811107 Ppnr 0.007111736 Q0.58871335
Tex264 0.001686492 Q0.651448511 LysA 0.00711733 Q0.688109964
4631416L12Rik 0.001694661 Q0.837324781 Flt3l 0.007124815 Q0.596787395
Ifna7 0.00171645 Q0.779899969 Flt1 0.007149789 Q0.73333226
Abcb7 0.001723168 Q0.94101719 Serpinb7 0.007194049 Q1.019517682
2010011I20Rik 0.001725308 Q0.742339977 Tst 0.007203125 Q0.832501806
Xdh 0.00175243 1.118397988 Mrps6 0.007247694 0.591810801
Nol7 0.001759719 Q0.624680547 Wdr78 0.007265546 Q0.720338799
Slc33a1 0.00176062 Q0.762009371 Rps24 0.007268758 1.154906103
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Gnb4 0.001771923 Q0.611845963 Snx24 0.007328167 0.713283814
Tspan7 0.001778696 0.860456227 Slc39a4 0.007347198 1.730183414
B4galnt2 0.001781799 0.70471415 2310009A05Rik 0.007362112 Q0.716023729
Ado 0.00178241 Q0.589077207 Ablim3 0.007367664 Q1.474274234
Klf6 0.001787759 Q0.696443823 Slc25a16 0.007396142 Q0.599039084
Mtm1 0.00179735 0.670452894 S100a1 0.007471308 Q0.67730295
Cxxc4 0.001800005 Q0.804025029 Sh3kbp1 0.007473351 0.679375923
Id4 0.001812886 Q0.653357498 Mpped2 0.007499244 Q0.70019001
Slco2a1 0.001819738 Q0.811785881 Rangap1 0.00754191 0.678241266
Rnf11 0.001827166 Q0.588679225 Rnf157 0.007566952 0.91022584
Gpr161 0.001829287 0.611641084 Rbpj 0.007580781 0.585798883
Sh3bp2 0.001850542 0.684218795 Mlph 0.007586609 Q1.020780111
Tmem65 0.001855729 Q0.603219797 Ccnc 0.007654383 Q0.593283649
Vegfc 0.001859962 0.805760347 5133401H06Rik 0.007701805 Q1.072684608
Bmp7 0.001861009 Q0.683730227 Havcr2 0.007843037 1.54679209
Kras 0.001878822 Q0.640713665 Ptprf 0.007863623 Q0.936179187
F13a1 0.001889884 2.671442527 Slc43a3 0.007878318 1.80075045
Tmem86a 0.001893484 0.992222932 Slc4a7 0.00788119 0.733950487
Ckb 0.001898274 Q0.809266723 St3gal1 0.007912608 0.818984451
Lhfpl2 0.001898309 0.745981826 Isyna1 0.007958061 0.991279272
Atp10a 0.001907485 Q0.625268396 Mmd 0.008028152 0.603653596
Trfr2 0.001912894 0.662932109 Nphp3 0.008032451 Q0.617213869
Mpped2 0.001913574 Q0.621277247 Slc36a1 0.008035479 Q0.597480663
Sec16b 0.001915339 1.3704358 Il1rn 0.00812388 0.76819484
Enpp2 0.001923853 0.700178823 Zdhhc2 0.008178043 Q0.864465773
2010300C02Rik 0.001937402 1.34617287 4933407K13Rik 0.008179036 0.747300979
9030622O22Rik 0.001939794 Q0.74449225 Hnf4g 0.008207643 0.687810762
Klf6 0.001951907 Q0.824362282 Tmem218 0.008239935 Q0.799594439
Mapre2 0.001951968 Q0.586599061 Dnajb14 0.008252578 Q0.603785832
Gabarapl2 0.001963173 Q0.713404755 Zfhx4 0.008260313 0.707143135
Klhl22 0.00196454 0.595332938 Asrgl1 0.008324136 0.605742829
D8Ertd82e 0.001971591 0.686988552 Mki67 0.00843237 Q0.791671778
Pabpc4 0.001975151 Q0.653687764 Ctnnal1 0.008461623 0.623586104
Hoxb8 0.001984113 1.47929964 A630038E17Rik 0.008493903 0.614595679
Ndst1 0.002008746 Q0.704798641 Phtf1 0.008673962 0.604339711
Ripk3 0.002011709 0.874948097 Spry3 0.008681241 0.660361783
Neto2 0.002023777 0.773071356 Cdkl2 0.0086939 Q0.647276147
Slc9a3r2 0.002030875 Q0.75392176 Fam117a 0.008714481 0.739142171
Tmbim4 0.002049613 Q0.70273702 Enpp4 0.008765466 Q0.693871716
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2010107G23Rik 0.00206265 Q0.598826433 Atp8a1 0.008766505 0.697023214
Ube2w 0.002063697 Q0.76560239 Nbr1 0.00879876 Q0.676697483
Leprot 0.002064864 Q0.656933473 Ccl9 0.008878713 1.213162161
1810044D09Rik 0.00206568 Q0.775906383 Btbd11 0.008885198 1.040213397
Vav3 0.002073646 0.714780465 Itgb8 0.008902296 1.288206616
Fgfr4 0.002081706 1.021058271 Mtmr9 0.008914516 Q0.910948016
Trim24 0.002086905 0.631543707 Yif1a 0.009030848 Q0.623328555
Tor3a 0.002088831 Q0.814523243 Spo0B 0.009034428 Q0.717814606
Mtap4 0.002096772 Q0.624212975 Nme5 0.009048164 Q0.796723111
Nat8l 0.002107018 1.106153044 Av336852 0.009072036 Q0.731475696
Rab28 0.002108387 Q0.911863545 Rasl11b 0.00908389 0.690455179
Smap1 0.002122533 Q0.644882977 2700023E23Rik 0.009151307 0.659867411
Ppp3ca 0.002123854 0.638465421 Nudt18 0.009160089 Q0.617133928
Htra1 0.002133383 1.142136004 Pcyt1b 0.009190708 0.851080568
Kat2a 0.002147061 0.586243811 Gm5909 0.00919109 0.590944286
Syk 0.002150994 1.063855581 Atoh8 0.009310657 Q0.992028861
4930562D19Rik 0.002188115 Q0.641327358 Itgb7 0.009338489 0.778809068
2210008F06Rik 0.002200967 Q0.6229643 Esco2 0.009357422 Q0.664167809
Slc7a4 0.00221159 Q0.75902829 Fkrp 0.009434719 Q0.598399547
Vcan 0.002244263 0.669919613 Ildr2 0.009477763 Q1.071173029
2810022L02Rik 0.002245143 Q1.233421552 Lbh 0.009481658 0.627587606
Rab11fip5 0.002276501 0.726797859 Sept6 0.009486128 0.665448444
Gusb 0.002278325 0.739788187 Tpm3 0.009496658 Q0.630672198
Tspan15 0.002285516 Q0.699401569 Rbm26 0.009509285 0.607537203
Hspb11 0.002287859 Q0.600448992 EG434402 0.009536923 Q0.611955808
Pla1a 0.002292985 0.690349514 Slco4a1 0.009587095 0.72795444
Smpd3 0.002340221 Q0.592351869 Tmem168 0.009603835 Q0.712682555
Plekha5 0.002348979 0.612589025 Ugp2 0.00961702 Q0.805818694
Vat1l 0.002357099 Q1.559152399 Nucks1 0.009691974 Q0.761569059
Slfn2 0.002390086 1.184898546 Mapk11 0.009733833 Q0.625831409
Gda 0.002396194 0.935013244 Slc7a2 0.009910713 0.704317457
AU020206 0.002403585 0.595745529 Apob 0.009986501 Q0.587603738
Yif1a 0.002442222 Q0.682509116 Scrn3 0.009990957 Q0.85441688
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